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Mü he , de  10.5.2017                                  …………..………………... 
           (Lisa-Maria Zink) 
 
 
 
DANKSAGUNG 
Zuerst möchte ich von Herzen Sandra Hake danken. Nie könnte ich mir eine bessere Chefin 
wünschen! Sie hat mich immer auf ganzer Linie unterstützt, ob es nun wissenschaftliche 
Durststrecken gab oder ich Unterstützung im Privaten brauchte, Du warst immer da! Du 
schaffst es mit deiner motivierenden Art einfach immer einen wieder mitzureißen. Danke für 
die beste wissenschaftliche Betreuung, tolle Teams, lustige Proseccorunden und sehr viel 
Menschlichkeit! 
Ich danke auch Prof. Dr. Peter Becker, der die beste Arbeitsatmosphäre schafft, die man sich 
wünschen kann. Das gesamte ABI macht es einem leicht jeden Tag gerne in die Arbeit zu 
kommen und an jeder Ecke Hilfe und Unterstützung zu finden. Außerdem möchte ich 
meinen TAC Mitgliedern Axel Imhof, Sandro Baldi und Gunnar Schotta für die Unterstützung 
und den wissenschaftlichen Input danken!  
Natürlich möchte ich mich auch bei meinen Kollaborationspartnern bedanken: Erwan 
Delbarre und Philippe Collas, Eva Keilhauer und Matthias Mann, sowie Marek Bartkuhn. 
Großen Dank auch an die Praktikanten und Masterstudenten Lucia, Janina und Schmiri. Es 
war mir ein Fest! 
Meine liebsten Kollegen & Freunde! Das alte Northlab plus Sarah hat mir jeden Tag den 
Gang in die Arbeit versüßt. Ich hatte den größten Spaß mit euch! Seba, der mich in die große 
weite Welt der Wissenschaft u dieses H3.Ys eingeführt hat, Nils, der immer nur „Artefakt!  
gerufen hat, Corinna, die Schatzmeisterin, Nina, die zwar nur verhältnismäßig kurz bei uns 
war, dafür immer noch die liebste  Freundin ist und natürlich die Leftovers! Ohne euch, 
Sarah, Maria und Eylisa wäre es sicher nur eine halb so schöne Zeit geworden. Wir hatten so 
viel Spaß & Salat, ihr habt mit mir Freud und Leid geteilt. Natürlich danke ich auch euch, 
liebe Hake-Girls! Ramona, die sich immer aufopfernd um alles und jeden kümmert, Stephi, 
die schuhverrückte Reiswaffeltante und natürlich Martina, deren Tiramisu ich wohl nie 
vergessen werde. Ich war sehr gerne euer Sonnenschein!  
Selbstverständlich danke ich auch meiner Familie. Meiner Mama, meinem Papa, Bruder, 
Oma und Opa, sowie Tanten und Onkeln. Mama, Papa, ihr habt mich immer unterstützt und 
mich spüren lassen wie stolz ihr auf mich seid. Oma & Opa, ich könnte mir keine besseren 
Großeltern wünschen. Ihr wart immer für mich da. Opa, was wären meine Präsentationen 
ohne dich?  
Der allergrößte Herzensdank geht an meinen Kopf- und Seelenverwandten Götz. Für allzeit 
bereitwilliges Unterstützen in jeglichen Lebenslagen, ständiges Zuhören, fürs Beruhigen, für 
unzählige Illustrator lessons, für romantische Dates an der Ecke. Du bist der Hummer! 
 
 
 i 
TABLE OF CONTENTS 
SUMMARY ....................................................................................................................... 1 
ZUSAMMENFASSUNG ...................................................................................................... 2 
1 INTRODUCTION .......................................................................................................... 4 
1.1 CHROMATIN STRUCTURE ............................................................................................... 4 
1.2 COMPLEXITY OF CHROMATIN .......................................................................................... 7 
1.2.1 HISTONE POSTTRANSLATIONAL MODIFICATIONS ..................................................................... 9 
1.2.2 HISTONE VARIANTS .......................................................................................................... 11 
1.2.3 HISTONE VARIANT H3.3 ................................................................................................... 15 
1.2.4 HISTONE VARIANT H3.Y ................................................................................................... 19 
1.2.5 H3 SPECIFIC CHROMATIN REMODELER & HISTONE CHAPERONES ............................................ 21 
1.2.6 NUCLEOSOME-FREE H3.Y INTERACTOME/CHAPERONES......................................................... 27 
1.3 OBJECTIVES .............................................................................................................. 29 
2 MATERIALS AND METHODS ...................................................................................... 30 
2.1 MATERIALS .............................................................................................................. 30 
2.1.1 TECHNICAL DEVICES ......................................................................................................... 30 
2.1.2 CHEMICALS AND CONSUMABLES ........................................................................................ 31 
2.1.3 KITS, ENZYMES & MARKERS .............................................................................................. 33 
2.1.4 ANTIBODIES .................................................................................................................... 34 
2.1.5 PLASMIDS ....................................................................................................................... 35 
2.1.6 OLIGONUCLEOTIDES ......................................................................................................... 35 
2.1.7 BACTERIAL STRAINS & CELL LINES ...................................................................................... 36 
2.1.8 SOFTWARE ..................................................................................................................... 38 
2.1.9 STANDARD BUFFERS & SOLUTIONS ..................................................................................... 38 
2.2 MOLECULAR BIOLOGICAL METHODS ................................................................................ 39 
2.2.1 MUTAGENESIS OF H3.Y CONSTRUCTS ................................................................................. 39 
2.2.2 CLONING OF H3.Y MUTANT CONSTRUCTS INTO DESTINATION VECTOR PIRESNEO-EGFP ............ 40 
2.3 BIOCHEMICAL METHODS .............................................................................................. 41 
2.3.1 SDS POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) ................................................. 41 
2.3.2 COOMASSIE STAINING OF POLYACRYLAMIDE GELS................................................................. 41 
2.3.3 IMMUNOBLOTTING .......................................................................................................... 41 
 ii 
2.3.4 MONONUCLEOSOME PREPARATION ................................................................................... 42 
2.3.5 PURIFICATION OF MNASE DIGESTED DNA ........................................................................... 42 
2.3.6 MONONUCLEOSOME-IMMUNOPRECIPITATION (MNASE-IP) ................................................... 43 
2.3.7 MNASE-IP FOLLOWED BY QUANTITATIVE MS (MNASE-IP-QMS) ........................................... 43 
2.3.8 CHROMATIN IMMUNOPRECIPITATION (CHIP) OF CROSSLINKED & SONICATED HK CELLS ............. 45 
2.3.9 ILLUMINA SEQUENCING .................................................................................................... 47 
2.4 CELL BIOLOGICAL METHODS .......................................................................................... 47 
2.4.1 MAINTENANCE OF HUMAN HK & MESENCHYMAL STEM CELL LINES ........................................ 47 
2.4.2 GENERATION OF STABLE EGFP-H3.Y MUTANT HK CELL LINES ............................................... 48 
2.4.3 TRANSFECTION OF HUMAN MESENCHYMAL STEM CELLS ........................................................ 48 
2.4.4 IMMUNOFLUORESCENCE (IF) OF HK CELLS & MESENCHYMAL STEM CELLS ............................... 48 
2.4.5 FLOW CYTOMETRY ANALYSIS OF TRANSFECTED HUMAN CELL LINES ......................................... 50 
2.4.6 PREPARATION OF CHROMATIN-FREE EXTRACTS ..................................................................... 50 
2.4.7 IMMUNOPRECIPITATION OF EGFP-H3 VARIANTS IN CHROMATIN-FREE EXTRACTS ...................... 51 
2.5 BIOINFORMATICS ....................................................................................................... 52 
2.5.1 MNASE-IP-QMS ANALYSIS ............................................................................................... 52 
2.5.2 CHIP-SEQ ANALYSIS ......................................................................................................... 52 
3 RESULTS ................................................................................................................... 54 
3.1 H3.Y ONLY INTERACTS WITH THE HIRA COMPLEX BUT NOT DAXX/ATRX .................................... 54 
3.2 H3.Y NUCLEOSOMES ARE DEPLETED FROM H3K9ME3 ENRICHED SIMPLE REPEAT SITES ................. 57 
3.3 CHROMATIN INTERACTOME OF H3.Y-CONTAINING NUCLEOSOMES ......................................... 61 
3.4 RESIDUES IN THE H3.Y CORE & C-TERMINUS ARE NECESSARY FOR DAXX INTERACTION ................. 67 
3.4.1 MUTATION OF THE SINGLE Q59E RESIDUE IN H3.Y IS NOT SUFFICIENT FOR DAXX BINDING ........ 67 
3.4.2 REPLACING CORE RESIDUES IN H3.Y DOES NOT ENABLE DAXX INTERACTION ............................ 70 
3.4.3 H3.3 & H3.Y TAIL SWAP MUTANT CONSISTING OF N-TERMINAL H3.Y & H3.3 CORE/ C-TERMINUS 
ALLOWS STABLE DAXX INTERACTION .............................................................................................. 72 
3.5 H3.3-DAXX INTERACTION: A DEFINED COMBINATION OF AMINO ACIDS MATTERS ....................... 76 
3.6 DAXX BINDING TO H3.Y MUTANTS INFLUENCES CHROMATIN INCORPORATION SITES ................... 81 
4 DISCUSSION ............................................................................................................. 86 
4.1 H3.Y ONLY INTERACTS WITH THE HIRA COMPLEX & LOCALIZES TO EUCHROMATIC SITES ................ 87 
4.2 H3.Y NUCLEOSOMES ARE ENRICHED IN TRANSCRIPTION-ASSOCIATED INTERACTION PARTNERS ....... 90 
4.3 A COMBINATION OF CORE & C-TERMINAL H3.3 RESIDUES DETERMINES DAXX INTERACTION .......... 94 
 iii 
REFERENCES .................................................................................................................... 102 
ABBREVIATIONS ........................................................................................................... 124 
APPENDIX ......................................................................................................................... I 
CURRICULUM VITAE .........................................................................................................V 
 
 
 1 
SUMMARY 
The nucleosome is the basic subunit of chromatin, the packaging of DNA in the nucleus in an 
eukaryotic cell. Nucleosomes consist of DNA that is wrapped around a histone octamer. This 
octamer in turn contains 2 copies of each histone: H2A, H2B, H3 and H4. One mechanism 
how DNA-related processes such as transcription or DNA repair can be regulated involves 
the exchange of canonical histones with so-called histone variants. The incorporation of the 
variant counterparts is carried out by histone chaperone complexes. Various chaperones 
interact with the respective variants and determine their deposition into distinct genomic 
sites. Thus histone chaperones contribute to the regulation and plasticity of the chromatin 
landscape by introducing a variety of histones. To date eight different human histone H3 
variants are described with H3.3 being the best-studied H3 variant. H3.Y on the other hand is 
a relatively new variant and so far knowledge about its function in chromatin remained 
limited. Comparing H3 variant amino acid sequences, H3.Y shows the highest similarity to 
H3.3, and especially shares the same so-called chaperone recognition site with H3.3. The 
chaperone recognition site is a four-amino acid stretch that determines the interaction of H3 
variants with distinct chaperones complexes. Whereas H3.3 interacts with two distinct 
chaperone complexes, namely DAXX/ATRX and HIRA, our group surprisingly only identified 
the HIRA complex as a binding partner of H3.Y. In my PhD thesis, I initially confirmed that 
H3.Y indeed does not interact with DAXX/ATRX. In order to identify the amino acids in H3.Y 
that prevent DAXX binding I generated multiple H3.3/H3.Y mutants that exhibit amino acid 
exchanges of H3.Y with H3.3 residues. I could show that apart from the chaperone 
recognition site a combination of H3.3 core and C-terminal residues contributes to the 
specific recognition and/or binding of the histone chaperone DAXX to its substrate. 
DAXX/ATRX is responsible for the deposition of H3.3 to heterochromatic genomic sites while 
the HIRA complex mediates H3.3 incorporation into euchromatic regions. Since H3.Y does 
only interact with the HIRA complex I speculated about its incorporation into open, 
euchromatic sites. Indeed, I could show by ChIP-seq that H3.Y localizes only to 
H3K4me3-positive euchromatic regions and is excluded from DAXX dependent 
H3K9me3-positive and simple repeat sites. Correspondingly, H3.Y nucleosomes are enriched 
with the transcription-associated FACT complex and depleted of the repressive H3K9me3 
mark.  
In conclusion I could demonstrate that a combination of core and C-terminal residues 
prevents H3.Y s interaction with the histone chaperone DAXX, explaining its exclusive 
localization to euchromatic sites and absence from heterochromatic sites. 
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ZUSAMMENFASSUNG 
Das Nukleosom ist die grundlegende Einheit von Chromatin, der Verpackung der DNA in 
einer eukaryotischen Zelle. Nukleosomen bestehen aus DNA, die um ein Histonoktamer 
gewickelt ist; dieses Oktamer widerum besteht aus 2 Kopien jedes der Histone H2A, H2B, H3 
und H4. Ein Mechanismus wie DNA bezogene Prozesse wie Transkription oder DNA 
Reparatur reguliert werden können, beinhaltet den Austausch der kanonischen Histone mit 
sogenannten Histonvarianten. Der Einbau dieser Varianten wird von Histon-Chaperon-
Komplexen bewerkstelligt. Verschiedene Chaperone interagieren mit den entsprechenden 
Varianten und bestimmen deren Einbau an unterschiedliche genomische Stellen. Histon-
Chaperone tragen somit, indem sie eine Vielzahl an Histonen an bestimmten genomischen 
Stellen einfügen, zur Regulation und Plastizität der Chromatinlandschaft bei. Bis heute sind 
acht verschiedene humane Histon H3 Varianten im Menschen beschrieben, von denen H3.3 
die am besten untersuchte Variante darstellt. H3.Y widerum ist eine relativ neue Variante 
und bisher ist das Wissen um ihre Funktion im Chromatin begrenzt. Vergleicht man die 
Aminosäuresequenzen der H3 Varianten, zeigt H3.Y die größte Ähnlichkeit zu H3.3 und weist 
insbesondere die selbe sogenannte Chaperonerkennungssequenz, ein vier Aminosäuren 
langer Abschnitt, der die Interaktion von H3 Varianten mit verschiedenen 
Chaperonkomplexen bestimmt, wie H3.3 auf. Während H3.3 mit zwei unterschiedlichen 
Chaperonkomplexen interagiert, und zwar DAXX/ATRX und HIRA, hat unsere Gruppe 
überraschenderweise nur den HIRA-Komplex als Bindungspartner von H3.Y identifiziert. In 
meiner Dissertation habe ich zunächst bestätigt, dass H3.Y tatsächlich nicht mit DAXX/ATRX 
interagiert. Um herauszufinden welche Aminosäuren in H3.Y die Bindung an DAXX 
verhindern, habe ich diverse H3.3/H3.Y-Mutanten generiert, die Aminosäureaustausche von 
H3.Y mit H3.3 Resten aufweisen. Ich konnte zeigen, dass abgesehen von der 
Chaperonerkennungssequenz auch eine Kombination von H3.3-Resten in der Mitte und am 
C-terminus der Sequenz zur Erkennung und/oder Bindung von DAXX an sein Substrat 
beitragen. 
DAXX/ATRX ist verantwortlich für den Einbau von H3.3 an heterochromatische genomische 
Stellen, während HIRA die Inkorporation in euchromatische Regionen vermittelt. Da H3.Y 
nur mit dem HIRA-Komplex interagiert, habe ich über dessen Einbau in offene, 
euchromatische Stellen spekuliert. Tatsächlich konnte ich durch ChIP-seq zeigen, dass H3.Y 
nur an H3K4me3 positiven euchromatischen Regionen lokalisiert und von DAXX abhängigen 
H3K9me3 positiven und simple repeat Stellen ausgeschlossen ist. Entsprechend sind H3.Y-
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Nuklesomen angereichert mit dem transkriptionsassoziierten FACT-Komplex und 
abgereichert mit der repressiven Modifizierung H3K9me3. 
Zusammengefasst konnte ich zeigen, dass eine Kombination aus innenliegenden und C-
terminalen Resten die Interaktion von H3.Y und dem Histonchaperon DAXX verhindert, was 
die ausschließliche Lokalisierung in euchromatischen Regionen und den Ausschluss von 
heterochromatischen Stellen erklärt.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
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1 INTRODUCTION 
1.1 CHROMATIN STRUCTURE 
The development from a single zygote to a multicellular organism includes the 
differentiation into various cell types, each containing the same DNA sequence. Nuclear 
transfer experiments in mice revealed that the contribution of both the paternal and 
maternal genomes plays a role to successfully develop an embryo (1, 2). It was concluded 
that the DNA alone does not provide sufficient information to allow the completion of 
mouse embryogenesis (3-5). Moreover, since the sequencing of the human genome in 2001 
(6, 7) it became apparent that unraveling the genetic code of the DNA can not account for 
every process. Thus, it is crucial to understand how the genetic information is interpreted in 
different cell types. Here, chromatin comes into play. In eukaryotes, the DNA is not present 
as a naked molecule in the cell but exists as a nucleoprotein complex, so-called chromatin. 
The basic repeating subunit of chromatin is the nucleosome (8, 9), comprised of a 
nucleosome core particle (NCP) and the linker DNA. The NCP is a disc-shaped complex of 
145-147 bp of DNA that are 1.65 times wrapped around a histone octamer in a left-handed 
manner (10) (Figure 1). This octamer consists of two copies of each histone H2A, H2B, H3 
and H4. Histones, in turn are basic proteins that are composed of a N-terminal tail and a 
globular domain containing the histone fold domain, the region where nucleosomal histones 
interact with each other and the DNA (10, 11). 
 
Figure 1: Crystal structure of a nucleosome, looking down the DNA superhelix. Histone H2A is 
depicted in yellow, H2B in red, H3 in blue and H4 in green, respectively. The interaction of the two 
H3-H4 dimers by the formation of a H3-H3 -4-helix bundle is highlighted. Adapted and reprinted with 
permission from Annual Reviews (12). 
 INTRODUCTION 
 5 
Although lacking sequence similarity, the histone fold domains (HFD) of the four different 
histones all share a structural motif: they compose of three alpha-helices α  – α  connected 
by two unstructured loops, L1 and L2. Two histone H3-H4 dimers interact with each other 
via a 4-helix bundle of the HFD of H3 and H3  to form a tetramer (see Figure 1). In the 
presence of DNA or under high salt conditions this (H3-H4)2-tetramer associates with the 
two H2A-H2B dimers by the formation of a 4-helix bundle and additionally by the interaction 
of the H2A docking domain and H3 (12). NCPs are connected by the linker DNA and arranged 
in an array, thereby making up the primary so-called beads on a string  structure (Figure 2) 
with a diameter of ca. 10 nm (13-16).  
 
Figure 2: Primary, secondary and tertiary structures of chromatin. Chromatin is thought to be 
organized in these three structural states. First, an array of nucleosomes defines the primary 
structure, with nucleosomes consisting of either canonical histones (in light blue and yellow) or 
variant histones (in green and purple, see chapter 1.2.2). The 30 nm fiber describes the secondary 
structure whereas long-range interactions between different 30 nm fibers determine the tertiary 
structure. Secondary and tertiary structures are influenced by the presence of architectural proteins 
like the linker histone H1 and heterochromatin binding protein 1 (HP1) (see section 1.2) Adapted and 
reprinted with permission from Nature Publishing Group (13). 
 
Chromatin secondary structure results from short-range interactions between neighboring 
nucleosomes (17) resulting in a predicted and in in vitro experiments observed 30nm fiber 
(15). Two competing models for this higher order structure of chromatin exist: first the 
solenoid model and second the zigzag model (Figure 3). The solenoid model proposes that 
nucleosomes are arranged linearly along a helical turn that is composed of 6 nucleosomes 
(18-20). It was suggested to be the most stable structure. Yet, later studies revealed a zigzag 
conformation of the 30 nm fiber where nucleosomes interact with every second neighbor 
(15, 21, 22). The zigzag model was additionally supported by the crystallization of a 
tetranucleosome that revealed a zigzag conformation (22).  
 INTRODUCTION 
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Figure 3: Two models of a 30 nm fiber. (A) Solenoid model of the 30 nm fiber. Nucleosomes are 
arranged in a helical turn. (B) Alternatively, the Zigzag model exists to describe the conformation of 
the 30 nm fiber. Here nucleosomes are arranged in a zigzag shape. See text for details. Adapted and 
reprinted with permission from John Wiley and sons (23). 
 
However, the existence of a 30 nm fiber in vivo is under debate (24-27). Rhodes et al. 
observed that different linker lengths give rise to different conformations of higher order 
chromatin structures (28). 30 nm fibers have been demonstrated by different in vitro 
approaches, most of them with uniform linker length and precise nucleosome positioning. In 
vivo, however, variable linker length, DNA sequences and heterogeneous histone octamers 
exist that influence the folding of higher order structures (29, 30). Indeed, the existence of a 
heteromorphic 30 nm fiber with a mixed conformation of both models was observed (31). 
Still, recent studies suggest instead of a 30 nm fiber rather the folding into a polymer melt 
(32) where nucleosome arrays are disordered and in a interdigitated state.   
In general, chromatin tends to localize in different compartments according to its functional 
state (14, 33). Two major functional states of chromatin have been described: on the one 
hand the repressed heterochromatin and on the other hand the active euchromatin (34). It 
is believed that differential chromatin compaction between eu- and heterochromatin 
accounts for the distinct accessibilities to the DNA template and thus its repressed or active 
transcriptional state.  
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1.2 COMPLEXITY OF CHROMATIN  
As mentioned in 1.1 two major states of chromatin exist: eu- and heterochromatin. 
Heterochromatin can be subdivided further into facultative and constitutive, determining its 
either temporary (facultative) or permanent (constitutive) transcriptional repression (35).  
Not only during transcription but also during other DNA-related processes such as 
replication or DNA repair, access to the DNA has to be granted. The balance between 
maximal compaction of DNA during mitosis and accessibility of DNA is highly complex and 
regulated by DNA methylation, long noncoding RNAs, architectural proteins, chaperones, 
ATP-dependent chromatin remodelers and thus nucleosome positioning, posttranslational 
modifications (PTM) of histones or the incorporation of histone variants (36-47).  
DNA methylation is one way to regulate chromatin. It occurs mainly at cytosines (5mC), 
especially at CpG dinucleotides, and was initially associated with gene silencing (48). 
However, more recent studies suggest that depending on the position in the gene, DNA 
methylation can also function in gene activation (49). Whereas methylation around the 
transcriptional start site (TSS) accounts for transcriptional repression, methylation of the 
gene body, in contrast, activates transcription (50). Moreover, additional biological functions 
such as the recruitment of transcription factors (TF) (51), nucleosome positioning (52, 53) 
and splicing (54) have been linked to 5mC. It has also been demonstrated that methylation is 
important for genomic stability since it is required for silencing of transposable elements 
(55), imprinting (56) and chromosomal stability (57). Sequential oxidation of 5mC generates 
the demethylation intermediates 5-hydroxymethylcytosine (5hmC), which can be further 
converted into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), respectively (58). 5hmC 
has been found at enhancers, promoters and gene bodies of active genes and is therefore 
considered as an active mark (59). 5fC alters in contrast to the other modified cytosines the 
conformation of the DNA double helix structure and might thus influence the binding of 
diverse proteins (60). Its function is so far unknown but it has been detected at active and 
poised enhancers in mouse embryonic stem cells (mESCs) (61). A recent study suggested 
that 5caC serves to decelerate the transcription machinery, thereby fine tuning 
transcriptional elongation (62). 
In addition to cytosine, the methylation of adenine in mouse embryonic stem cells was 
described in 2016, resulting in silenced LINE transposons and neighboring enhancers and 
promoters (63). It is becoming obvious that DNA methylation is highly complex and has 
differential outcomes regarding the circumstances: localization of the methylation mark in 
the transcriptional unit (TSS versus gene body) or elsewhere in the genome (centromeric 
 INTRODUCTION 
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and pericentromeric localization) as well as methylation timing during development results 
in different effects (56). 
In addition to DNA methylation chromatin can also be regulated by long noncoding RNAs 
(lncRNAs). These are defined as non-protein coding transcripts longer than 200 
nucleotides  (nt) (64) and are often expressed tissue- and developmental stage-specific (65). 
They can influence chromatin regulation by either recruiting chromatin modifying enzymes 
such as DNA methyltransferases or histone modifying enzymes to establish DNA methylation 
and histone posttranslational modifications, or control nucleosome positioning (47).  
A third way to regulate chromatin structure is achieved by the presence of architectural 
proteins. These proteins have the property to bind chromatin and thus modulate higher-
order chromatin structures (13, 66) (see also Figure 1). Shaping the 3-dimensional 
organization of the genome functions through binding of the linker histone H1 that stabilizes 
higher-order structures (18, 67) as well as through Polycomb group proteins that are 
responsible for the establishment of facultative heterochromatin (16). Furthermore, CCCTC-
binding factor (CTCF) has been demonstrated to mediate long-range interactions in the 
genome and by that e.g. enables enhancer-promoter-interactions (68, 69). Several 
architectural proteins have been identified, but introduction and discussion of these go 
beyond the scope of this thesis. For more details see (68, 70, 71).  
Diverse biological processes such as transcription, replication or DNA repair require access 
to the DNA. Normally DNA is occluded in nucleosomes, thereby providing hurdles for these 
processes and regulating them. One way to gain access happens via ATP-dependent 
chromatin remodeling (36). Chromatin remodelers are multiprotein complexes that modify 
chromatin structure by sliding or evicting nucleosomes or exchanging histones with their 
variants (see 1.2.2) (39). They can be grouped in four families depending on the domain 
structure surrounding their ATPase domain: SWI/SNF (switch/sucrose non-fermentable), 
CHD (chromodomain helicase DNA-binding protein), ISWI (imitation switch) or INO80 
(inositol-requiring 80). All these enzymatic subunits pair with a variety of different proteins 
thereby building diverse chromatin remodeling complexes with distinct characteristics. 
SWI/SNF remodelers are capable of sliding and/or evicting nucleosomes, ISWI remodelers 
are involved in nucleosome spacing, chromatin assembly and gene silencing by compacting 
chromatin in higher order structures. Depending on the associated proteins and the 
complex, ISWI can also be involved in transcriptional activation highlighting the diverse 
nature of the different complexes (72). Similarly, CHD remodelers are also associated with 
diverse functions ranging from transcriptional repression to activation and nucleosome 
 INTRODUCTION 
 9 
sliding (73, 74). INO80 remodelers exhibit helicase activities and regulate the exchange of 
H2A/H2A.Z-H2B dimers. Moreover they can evict and slide nucleosomes and are involved in 
DNA repair (75-79).  
In the further sections other ways of chromatin regulation will be discussed in detail.  
 
 
1.2.1 Histone Posttranslational Modifications 
As mentioned earlier, not only the DNA but also histones can be modified in various ways to 
influence chromatin packaging and accessibility. Among the posttranslational modifications 
are at least: acetylation, methylation, phosphorylation, deimination, glycosylation, ADP-
ribosylation, ubiquitination, SUMOylation, propionylation, formylation and crotonylation 
(80-82). Histone PTMs are established by writers , enzymes that set the respective 
modification and can be removed by so-called erasers  (83). There are two ways how PTMs 
affect chromatin: they can either directly modulate chromatin structure or recruit other 
readers  thereby indirectly mediating changes in chromatin structure through other 
effector chromatin proteins (40, 80).  PTMs can occur on the N-terminal tail of the histones, 
or on the other hand on the histone core. So far, studies mainly focused on modifications of 
the histone tails; however, more and more data reveal the functions of core histone 
modifications (84).  Here, I will discuss the best-studied PTMs, especially on H3 as the thesis 
focuses on this histone type. 
Acetylation, in general, appears on lysines and causes a charge neutralization of this 
positively charged amino acid, thereby weakening the interaction of the histone and the 
negatively charged DNA (80). This is believed to induce changes in chromatin structure and 
facilitate access to the DNA. In general, this modification is set by so-called histone 
acetyltransferases (HATs) or alternatively called lysine acetyltransferases (KATs) and 
associated with transcriptional activity (85). Removing acetylation by histone deacetylase 
(HDACs) is thought to stabilize chromatin, therefore HDACs are generally associated with 
gene silencing (86). Histone acetylation occurs on the N-terminal tail as well as on core 
residues of the histones (40, 84): histone H3 lysine 4 acetylation (H3K4ac), H3K9ac, H3K14ac, 
H3K18ac, H3K23ac, H3K27ac, and H3K36ac all correlate with transcriptional activation (40, 
87-92). Additionally, H3K14ac and H3K18ac facilitate DNA repair (93, 94), illustrating the 
complexity of PTMs depending on the chromatin context. This modification also occurs on 
histone core residues, e.g. H3K56, H3K64, H3K115, and H3K122 were demonstrated to be 
acetylated (95, 96). Both, H3K56ac and H3K64ac mark active chromatin and are believed to 
 INTRODUCTION 
 10 
destabilize the nucleosome (97). H3K115 and H3K122 are located at the dyad axis of the 
nucleosome where the strongest contacts between histone and DNA occur. Acetylation 
might enable nucleosome disassembly (98). Both residues have been shown to be 
acetylated, although functional studies for H3K115ac are missing so far. H3K122ac is 
enriched around the TSS and involved in transcriptional activation in agreement with its 
ability to facilitate nucleosome eviction (99, 100). 
In addition to acetylation, histones can also be methylated at lysine (mono-, di- and 
trimethylation) and arginine residues (mono- and dimethylation; symmetric or asymmetric). 
H3 lysine 4 di- or trimethylation are both associated with euchromatin (101, 102), whereas 
H3K9me3 and H3K27me3 mark transcriptionally silent regions (103, 104). Additionally, 
enriched H3K9me3 is found in imprinted regions (105), while H3K27me3 is involved in X-
inactivation in mammals (106). Trimethylation of H3K36 is involved in transcriptional 
elongation (107). H3R42 is located at the DNA entry/exit site of the nucleosome and 
methylation at this position might disrupt the histone-DNA binding. Dimethylation of R42 
has been demonstrated in vivo in human and mouse cells and results in enhanced 
transcription in in vitro transcription assays (108). Moreover, H3K56 and H3K64 are not only 
acetylated but also methylated. Trimethylation of the two residues is a heterochromatic 
mark, localized at pericentromeric repeats and might play a role in compaction of chromatin 
(40, 109). Both, H3K56me3 and H3K64me3, partly overlap with H3K9me3, again supporting 
their function in heterochromatin (109, 110). Finally, H3K79 can be mono-, di- and 
trimethylated. This residue is located on the solvent-exposed site of the nucleosome and 
therefore easily accessible. All H3K79 methylation states have been linked to transcription 
and accordingly H3K79 hypomethylation correlates with heterochromatic loci in yeast (111-
114). 
Last but not least, serine, threonine and tyrosine residues can be phosphorylated. Among 
the best-studied phosphorylated H3 residues are H3S10 and H3S28. Both have opposing 
roles and are either associated with transcriptional activation of immediate early genes or 
on the other hand involved in chromosome condensation during mitosis (115-118).  
It is getting more and more clear that depending on the chromatin context, spatiotemporal 
dynamics and the crosstalk between PTMs different outcomes derive from the same histone 
modification. Indeed, the histone code hypothesis  was brought forward years ago where it 
is postulated that the combination of PTMs on one or different tails of the histones 
establishes a histone code that affects different biological processes by recruiting different 
reader proteins (119). This hypothesis is still highly debated since only a limited number of 
 INTRODUCTION 
 11 
combinations occurs in vivo (120). Nonetheless, it is clear that several combinations of PTMs 
have been demonstrated to result in different biological outcomes: the repressive 
H3K27me3 and the active mark H3K4me3 occur together at bivalent genes in mESCs to 
enable transcriptional activation while keeping the genes in a generally repressed state 
(121). The antagonistic modifications do not necessarily have to be on one tail, but can also 
appear on the two copies of H3 in one nucleosome with one H3 tail carrying H3K27me3 and 
the other one carrying H3K4me3 (122). 
Apart from that, it has also been demonstrated that in some cases specific modifications are 
prerequisites to establishing additional marks. Trimethylation of H3 lysine 27 in Drosophila 
melanogaster is dependent on phosphorylated H3S28. Mutating H3 serine 28 to alanine that 
can not be phosphorylated anymore results in a global reduction of H3K27 methylation 
(123). Moreover, the methylation of H3K4 and H3K79 are both dependent on ubiquitinated 
H2BK123 (124). 
All in all, it becomes obvious that different PTMs and combinations thereof depend on 
developmental or cell cycle stages, modification timing, genome localization, and histone 
residues, thereby establishing another complex layer to the regulation of chromatin 
structure.  
 
 
1.2.2 Histone Variants 
To complicate the regulation of chromatin even more, the canonical core histones H2A, H2B 
and H3 exist in a variety of variants. So far no H4 variants have been discovered in humans 
and higher eukaryotes (125). Canonical histones and histone variants differ in some general 
aspects. Multiple gene copies of canonical variants are organized in gene clusters that are 
transcribed only during S-phase thereby ensuring the high histone demand for packaging 
when doubling the amount of DNA. In contrast, histone variant genes are present in only 
one or two copies outside of histone gene clusters and are expressed throughout the cell 
cycle, except CENP-A whose expression peaks in Gap 2 (G2) phase (126). Whereas genes of 
histone variants often contain introns that can give rise to splice isoforms, again providing 
more complexity, canonical histones lack introns. Similarly, mRNAs of canonical histones lack 
a poly A tail and instead contain a stem-loop structure at the 3 end that is suggested to 
regulate histone supply according to the cell s needs (127). The differences in protein 
sequence between histone variants and their canonical counterparts can be minimal but 
also tremendous, ranging from single amino acid substitutions to the exchange of whole 
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domains. Generally speaking, the exchange of canonical histones with their variants in 
chromatin can have two different effects: first, the incorporation of variants can result in 
changes in nucleosome structure and stability or second, the chromatin landscape can be 
affected by the recruitment of alternative readers and/or different PTMs that in turn recruit 
other readers.  
 
1.2.2.1 Histone H2A family 
So far, the H2A family consists of most variant members. Besides H2A eight variants exist in 
humans: H2A.Z.1, H2A.Z.2.1, H2A.Z.2.2, H2A.X, macroH2A1.1, macroH2A1.2, macroH2A2, 
and H2A Barr body deficient (H2A.Bbd). Generally, H2A variants differ mostly in their C-
terminus reaching from differences in sequence to alternative length of C-termini (128).  
H2A.Z is probably the best-characterized variant. It is highly conserved from yeast to humans 
and has been shown to be essential in Tetrahymena, D. melanogaster, frog, and mouse 
(128).  
Although H2A and H2A.Z differ considerably in their primary sequence, the overall 
nucleosome structure between the two is remarkably similar. However, these minimal 
changes in nucleosome structure account for H2A.Z s decreased stability. Especially the 
combination of H2A.Z and the histone H3 variant H3.3 in one nucleosome leads to a 
significant reduction in stability. Accordingly, H2A.Z localizes around the TSS of genes and is 
implicated in transcription initiation but also localizes to enhancers and insulators (129-132).  
H2A.Z is also an important player in DNA repair. Initially, the rapid accumulation of H2A.Z 
after a DNA double strand break was thought to generate an open chromatin configuration, 
thereby allowing the repair machinery to gain access to the damaged site (133). However, 
more recent data support the view, that only after H2A.Z removal, an open chromatin state 
is established. The initial incorporation of H2A.Z together with the recruitment of 
heterochromatic factors like HP1 serves as a safety net to prevent transcription of the 
damaged site and keep the damaged DNA ends in close proximity (133, 134). 
Moreover, H2A.Z is implicated in genome organization. First, it was demonstrated to 
preserve chromatin boundaries and prevent heterochromatin spreading (135). Second, 
H2A.Z has been shown to be essential for genome integrity. After its depletion mouse and 
monkey cell lines exhibited chromosome segregation defects with chromatin bridges and 
lagging chromosomes (136). Third, H2A.Z seems to be implicated in centromere formation. 
With the onset of mitosis, the localization of H2A.Z changes from promoter regions to the 
centromere, arguing for a role in centromere structure (137, 138). 
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 MacroH2A is approximately three times larger than H2A and has a unique domain structure 
with an N-terminal histone-like domain, a linker domain and a non-histone macro domain, 
that is able to bind nicotinamide adenine dinucleotide (NAD) metabolites (139). MacroH2A is 
generally considered as a repressive variant (140) conferring gene silencing by three 
mechanisms. First, it was shown to inhibit chromatin remodeling (141), although this is in 
conflict with another study that demonstrated no differences in macroH2A remodeling 
(142). Second, binding of TF is inhibited by the presence of macroH2A in nucleosomes (143). 
Third, macroH2A reduces histone acetylation by directly inhibiting acetylation and by 
physically interacting with HDACs (139, 141). MacroH2A is not only implicated in 
transcriptional repression but is also found at the promoters of both, active and repressed 
genes and is implicated in the transcriptional activation of some target genes (144, 145).  
H2A.Bbd is an unusual, smaller histone and shows only 50% similarity to H2A (146). It is 
lacking the C-terminal tail and part of the docking domain thereby nucleosomes containing 
H2A.Bbd result in an altered nucleosome structure with more relaxed chromatin, that binds 
DNA less tightly (147, 148). Concomitant with this reduced stability, H2A.Bbd is associated 
with open chromatin such as sites of active transcription and DNA replication (149, 150). 
Depletion of H2A.Bbd results in changes in gene expression and altered splicing patterns, 
arguing for roles in transcription and mRNA splicing (150).  
H2A.X is the H2A variant with the most specialized function and defined by its unique C-
terminus with a so-called SQ(E/D)Φ otif Φ sta ds for a h dropho i  residue . It is referred 
to as the histone guardian of the genome  (151). Shortly after a double strand break (DSB) 
H2A.X gets phosphorylated at seri e 9 γH A.X . γH A.X a u ulates the  i  nuclear foci, 
which spread along the sites of the DSB, in mammals up to several Mb (152). H2A.X and 
espe iall  γH A.X are elie ed to ark the da aged sites i  the ge o e a d rather tha  
recruiting, are more likely responsible for preserving the repair machinery at the damaged 
spot. Several studies argue for a role in chromatin destabilization, thereby allowing the 
repair machinery to gain access to the DNA damage (128). 
 
1.2.2.2 Histone H2B family 
In humans H2B has two testis-specific variants, namely TH2B and H2BFWT. In mice, H2BE 
was identified as the newest variant and is expressed solely in olfactory neurons. Strikingly, 
its presence is correlated with the life span of olfactory neurons with elevated H2BE levels 
showing a decreased lifespan (153).  
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TH2B differs from canonical H2B in 19 amino acids (aa) with most of the replacements at the 
N-terminal tail, thus resulting in an overall similar nucleosome structure than an H2B-
containing nucleosome. It is expressed in testis and involved in histone-protamine exchange 
during spermatogenesis, but also in the oocyte where it contributes to the reprogramming 
of the paternal genome (154, 155).  
H2BFWT reveals despite its similarity of only 45% with H2B a very comparable nucleosome 
structure with the same stability. The biggest differences to H2B are located in the N-
terminal tail of H2BFWT. Boulard et al. suggested a function in telomere identity but 
evidence for this is still missing (156, 157). 
In general, it has been demonstrated that different combinations of H2A variants together 
with H2B variants result in different nucleosome structures and stabilities with a large set of 
variations accounting for the complex needs in various biological processes (158). 
 
1.2.2.3 Histone H3 Family 
In humans, the H3 family consists of the canonical histones H3.1 and H3.2 and the variants 
H3.3, H3.X, H3.Y, CENP-A (cenH3), H3.1t and H3.5. Some of these variants are universal and 
highly conserved, whereas others are tissue- or species-specific.  
CENP-A shares only ca. 45% similarity with its canonical counterparts, with the histone fold 
domain that shares 62% identity and the more divergent N-terminal tail (159). CENP-A is the 
most specialized histone variant: it defines a centromere (160). The presence of CENP-A at 
the centromere is necessary and sufficient for centromere formation but also for the 
assembly of a kinetochore (161). Although its function as a centromeric variant is highly 
conserved, its sequence is mildly conserved and rapidly evolving (162).  
 Due to its divergence in sequence, the CENP-A nucleosome structure differs from canonical 
nucleosomes. Whereas H3.1- or H3.2-containing nucleosomes wrap 145-147 bp of DNA, 
CENP-A nucleosomes wrap only 121 bp (163). Despite revealing more flexible DNA ends a 
CENP-A-containing nucleosomal array is more densely packed than H3-containing ones 
(164). Moreover, it has been shown that the CENP-A gene is essential. CENP-A knockout 
mice die 6.5 days after fertilization and reveal mitotic defects like micro- and macronuclei 
and nuclear bridges (165). 
CENP-A is crucial for proper centromere function. Misregulation in CENP-A expression and 
thus disturbed CENP-A levels can account for defects in chromosome segregation and result 
in aneuploidy, a hallmark of cancer. Hence, it is not surprising that elevated CENP-A levels 
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were detected in various cancer types such as lung, ovarian, colorectal or breast cancer and 
correlates in some cases with poor patient outcome (166). These elevated levels of CENP-A 
are suggested to establish neocentromeres at ectopic sites, thereby causing chromosome 
breaks, leading to genomic instability (167). 
H3.1t and H3.5 are testis-specific H3 variants (168, 169). So far only little is known about the 
function of H3.5. It is generally associated with euchromatin and in agreement with this 
excluded from the repressive chromatin regions revealing H3K9me3 and HP1 (169).  
The histone variants H3.3 and H3.Y will be discussed in greater detail in 1.2.3 and 1.2.4, 
respectively since they are the main focus of this thesis.  
 
 
1.2.3 Histone Variant H3.3 
H3.3 is evolutionary highly conserved from yeast to humans. In yeast, only one 
noncentromeric H3 variant exists and this resembles H3.3 (170). In humans, it is encoded by 
two genes, H3f3a and H3f3b, resulting in the same protein but with distinct untranslated 
regions (UTRs). These differences are responsible for discrete expression patterns, 
depending on the tissue, developmental stage and cell type (161, 171, 172). 
H3.3 differs in humans from the canonical H3.1 and H3.2 in five or four amino acids, 
respectively. One exchange lays in the N-terminal tail at position 31. Alanine in H3.1/H3.2 is 
replaced by a serine in H3.3 that can be posttranslationally modified, namely 
phosphorylated. This phosphorylation occurs in mESCs at both telomeres and pericentric 
satellite repeats. In differentiated cells, the phosphorylation at telomeres disappears and 
persists on pericentric heterochromatin. There, the mark is set during mitosis in late 
prometaphase and metaphase by the Aurora B and CHK-1 kinase (173-176). The other aa 
differences between H3.1/H3.2 and H3.3 are located in the HFD, more precisely, at position 
87, 89 and 90. Overall, these differences do not result in structural changes of the 
nucleosomes containing either H3.3 or H3.1 (177). In line with this, H3.3-containing 
mononucleosomes exhibit comparable stabilities than H3.1-containing ones (178, 179). 
However, these results are in conflict with in vivo data from Jin et al. who demonstrated 
reduced stability for H3.3-containing nucleosomes, especially in the combination with H2A.Z. 
Indeed, H3.3 und H2A.Z have been demonstrated to co-localize at the TSS of active 
promoters and other regulatory sites and displayed higher turn over rates in vivo (130, 180, 
181). Additional in vitro studies revealed H3.3 s effect on chromatin structure. Nucleosomal 
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arrays containing H3.3 showed reduced folding of higher-order chromatin structures 
whereas H2A.Z nucleosomal arrays were able to efficiently compact chromatin. Arrays 
containing both variants demonstrated intermediate folding states, suggesting that H3.3 is 
able to antagonize H2A.Z mediated compaction (178). Accordingly, H3.3 could counteract 
the binding of the linker histone H1 in D. melanogaster, supporting H3.3 s role in relaxed, 
open chromatin (182). All of this highly supports the idea of H3.3 as a destabilizing variant, 
that localizes to nucleosome-depleted regions of active promoters, enhancers and insulators 
and is able to generate an accessible chromatin environment where TFs can bind.  
Conflicting opinions exist about H3.3 s contribution to transcription. Whereas some studies 
unravel the positive effect of H3.3 on transcription (178, 183-185), others report that H3.3 
depletion does not cause any transcriptional changes, arguing that H3.3 has no effect on 
transcription (186-188). In D. melanogaster, depletion of both H3.3 genes results in 
transcriptional defects. To overcome the loss of H3.3, flies upregulate the expression of 
canonical H3. Similarly, exogenous expression of canonical H3 at one of the endogenous 
H3.3 loci can compensate the transcriptional defects caused by H3.3 loss (189). In contrast, 
the double knock out mouse does only show mild transcriptional abnormalities, suggesting 
only a minor function for H3.3 in transcription in the mouse. Unlike in D. melanogaster, no 
elevated level of canonical H3 was detected, thus the general loss of histones by depleting 
H3.3 is not compensated (187).  Inducible genes, however, reveal impaired transcriptions 
after H3.3 knockdown, arguing that H3.3 positively influences their expression (178, 184). In 
general, H3.3 is associated with active PTMs and marks of ongoing transcription like the 
presence of RNA Polymerase II (190). Recent studies suggest, that deposition of H3.3 at 
transcribed loci happens due to a gap-filling mechanism . H3.3 is expressed and available 
throughout the cell cycle and can therefore be deposited during transcription when 
nucleosomes get disrupted and gaps  in chromatin appear. This suggests that H3.3 can be 
deposited anywhere in the genome where nonnucleosomal DNA occurs and might therefore 
be important for genome integrity (191). 
As mentioned above, H3.3 differs only in a few aa from the canonical variants (see Figure 4). 
Although the exchanges in the HFD do not alter the nucleosome structure they are sufficient 
for the differential localization of the variants. Whereas H3.1 and H3.2 are deposited 
throughout the genome during replication H3.3 is deposited at distinct genomic regions. 
Mutating the canonical specific residues to the corresponding H3.3 residues in D. 
melanogaster abolishes replication-dependent deposition and allows incorporation 
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throughout the cell cycle, arguing that not the expression time but the sequence determines 
the differential deposition modes (192).  
On the one hand H3.3 gets deposited at euchromatic and nucleosome depleted sites like 
promoters and enhancers, at TF binding sites, at the gene body of actively transcribed genes, 
at transcriptional end sites of highly transcribed genes but also localizes to heterochromatic 
sites like pericentric heterochromatin, telomeres and retroviral elements (130, 175, 190, 
191, 193-200). Here H3.3 is associated with gene repression. In mESCs H3.3 is present at a 
subset of repetitive endogenous retroviral elements and there co-localizes with the 
repressive histone mark H3K9me3. Depletion of H3.3 results in loss of H3K9me3 and 
upregulation of certain nearby genes. Additionally, H3.3 has been shown to be essential for 
the establishment of the heterochromatic H3K9me3 mark at telomeres. Knockout of either 
H3f3a or H3f3b in mESCs resulted in reduced levels of the silencing modifications H3K9me3 
and H4K20me3, accompanied by increased transcription of the telomeric repeat-containing 
RNA TERRA (190, 197). The tumor suppressor ZMYND 11 was shown to simultaneously bind 
H3.3 and H3K36me3, a mark of active transcription. Thus, ZMYND11 localizes indeed to 
transcribed genes but there represses transcription, although in the presence of H3.3 (107). 
This goes in line with the H3.3 dependent recruitment of the Polycomb Repressive Complex 
2 (PRC2) that localizes to the promoters of bivalent genes and is required for the 
establishment of the heterochromatic PTM H3K27me3 (188). Altogether H3.3 s role in 
transcription is not clear. Various effects of H3.3 suggest that it could function as a 
transcriptional activator and repressor depending on the context.  
Apart from its role in transcription, H3.3 is also responsible for the formation of 
heterochromatin and maintaining chromatin integrity. In mouse embryos, H3.3 and H3.3K27 
are necessary for the initial establishment of heterochromatin. Expression of the H3.3 
mutant H3.3K27R leads to increased transcription of pericentric repeats, chromosome 
segregation defects and developmental arrest (201). Accordingly, mouse embryonic 
fibroblasts (MEFs) and mESCs derived from H3.3 double knockout mice reveal a more open 
chromatin at centromeres and telomeres, mitotic defects like anaphase bridges and lagging 
chromosomes but also increased telomeric sister chromatid exchanges, aneuploidy, and 
polyploidy, arguing for a role of H3.3 in genome stability (187). Similarly, in mESCs H3.3 has 
been demonstrated to be critical for telomeric integrity. Depletion of H3.3 leads to the 
accumulation of telomere dysfunctional induced foci (TIFs), a chromatin structure defined by 
the presence of DNA damage response factors indicating impaired genome integrity (202).  
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H3.3 knockout mice die early in embryonic development, however conflicting data exist 
about the survival of single H3f3a or H3f3b knockout mice (187, 203-206). Strikingly, H3.3 
depleted mice and flies exhibit reduced fertility, suggesting an essential role for H3.3 in 
germline development (187, 189, 203-206). Indeed, it has been shown that either both, 
H3f3a and H3f3b are critical for oocyte development or H3f3b alone is essential for 
spermatogenesis (204, 205). These findings are further supported by the fact, that both 
genes reveal highest expression in the testes, followed by the ovary, implying again a key 
function for H3.3 in germ cell development (187).  
All in all, rather than functioning in transcription, H3.3 might have an essential role in 
maintaining genomic integrity and chromosome stability.  
Often histone genes are up- or down-regulated in cancer. Also H3.3 was reported to be 
upregulated in esophagus and lung cancer (207, 208). Furthermore, mutations in H3.3 were 
the first mutations detected in histones linked to a disease. In 2012, Wu et al. and 
Schwartzentruber et al. unveiled a somatic heterozygous mutation in H3f3a, resulting in an 
H3.3K27M or H3.3G34R/V mutant in pediatric glioblastoma (209, 210). Additionally, the 
recurrent mutations H3.3K36M and H3.3G34L/W were found in juvenile bone cancer 
patients (211). Several studies uncovered the mechanism how these mutations affect 
chromatin. Normally H3K27 is methylated by the PRC2 complex, resulting in H3K27me3, an 
important mark for gene silencing. However, cells expressing the K27M mutant exhibit 
overall lower levels of H3K27me3. Noticeably, although the mutant H3.3 contributes only a 
minor fraction to the total histone pool, the overall levels of H3K27me2 and H3K27me3 
were dramatically diminished, suggesting that K27M acts as a gain-of-function mutation. The 
authors could show that the enzymatic activity of the PRC2 subunit EZH2 was inhibited by 
K27M (212, 213). Moreover, K27M binds PRC2 more tightly than the wildtype equivalent, so 
that it sequesters PRC2 and it can no longer distribute the repressive K27me3 mark (214). A 
cell line derived from a tumor tissue isolated from a glioblastoma patient harboring the 
H3.3K27M mutation was analyzed by deep sequencing. In addition to globally loosening 
H3K27me3, this patient cell line also revealed the differential distribution of the remaining 
mark. First, the chromatin regions still carrying H3K27me3 were broader in comparison to 
human neural stem cells (NSCs) that were used as a control. Secondly, 63% of the remaining 
peaks were unique, meaning they did not appear in NSCs. This led i.e. to silencing of the 
tumor suppressor p16INK4A as shown by transcriptome analysis. Moreover, these unique 
peaks, as well as most of the remaining H3K27me3 peaks, almost completely overlap with 
EZH2 peaks, supporting again the idea of H3K27M sequestering PRC2 (213). The oncogenic 
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potential of H3.3K27M arises probably not only from a general loss of methylation and 
thereby the activation of potential oncogenes but also from the mislocalization of the 
remaining H3K27me3 so that tumor suppressor genes get repressed. 
A similar scenario can be observed in cells harboring the K36M mutation that occurs in 
cancers arising from mesenchymal tissues like chondroblastomas. Lysine 36 on H3 lies in the 
gene body of active genes and is associated with transcriptional elongation.  Complementary 
to K27M inhibiting EZH2 in the PRC2 complex, also the K36M mutation inhibits the catalytic 
subunits of H3K36 methyltransferases. This inhibition results in reduced H3K36me2 and 
H3K36me3 levels (215, 216). However, in this case, loss of H3K36 methylation is 
accompanied by an increase in H3K27me3 at intergenic and a reduction at gene-associated 
sites. Together with the reallocation of the repressive PRC1 complex that binds to 
H3K27me3, this results in changes in the transcriptome (215, 217).  
How G34 mutations contribute to tumorigenesis is unknown. G34 itself is not 
posttranslationally modified. Yet it lies in close proximity to lysine 36 and is therefore 
assumed to influence its accessibility for PTMs. Indeed, a study revealed that H3K36me3 is 
reduced in H3.3G34R expressing human HEK293T cells, suggesting that it can modulate 
histone posttranslationally modifications (212). Alternatively, G34 mutations could interfere 
with the binding of specific H3K36me3 readers and thereby contribute to cancer 
development.  
 
 
1.2.4 Histone Variant H3.Y  
H3.Y is one of the most recently discovered histone H3 variants. In contrast to the 
evolutionary conserved H3.3, it is a younger histone variant only present in primates. 
Alignment of H3.Y with the canonical variants and H3.3 reveals its highest similarity to H3.3, 
although it shares overall only 80% with H3.3 (Figure 4). Some of the residues prone to 
posttranslational modification are exchanged in H3.Y such as S10, S28, K14, S31 and K79. 
Interestingly, acetylation of lysine 18, 23 and 27 was detected on histone H3.Y (218). 
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Figure 4: Alignment of human H3 variants. Identical aa are shown in dark gray, similar ones in light 
gray and aa differences are highlighted with white boxes. The secondary structure of the histones is 
illustrated with αN, α , α  a d α . The canonical variants H3.1 and H3.2 differ only in 4 and 5 aa from 
H3.3. In contrast, H3.Y shares only 80% similarity with its most similar partner H3.3. The part where 
H3.3 and the canonical variants differ the most (aa 87-90) is in H3.Y identical to H3.3 (red boxes). 
Alignment was created using ClustalW Alignment (MacVector 13.5.1). 
 
H3.Y transcripts were detected in some human cell lines but also in primary cells from 
different human normal and cancer tissues such as lung, bone, breast and ovary tumor 
tissues as well as in brain and testes. Noticeably, nutritional starvation in combination with 
overgrowth led to an increase in H3.Y levels in U2OS cells. This osteosarcoma cell line 
showed minimal H3.Y expression under normal conditions but upregulated its expression 
during stress. H3.Y is detected in the nucleus, outside of DAPI dense regions, suggesting 
euchromatic localization and function. Depletion of H3.Y causes transcriptome changes with 
293 genes being up- and 974 genes being downregulated, arguing again for a role of H3.Y in 
euchromatin and gene activation. Moreover, depletion of H3.Y results in diminished cell 
growth. Classification of downregulated genes uncovered genes belonging to cell cycle 
control suggesting that this leads to the cell cycle arrest and reduced cell growth (218). 
In 2016, the structure of a H3.Y-containing nucleosome was resolved (219). The overall 
structure was similar to a H3.3-containing nucleosome, however some differences were 
observed. Residues at the DNA entry/exit site are exchanged in H3.Y suggesting different 
contacts between the DNA and H3.Y. Indeed, H3.Y nucleosomes had more flexible DNA 
ends, resulting in a more relaxed chromatin configuration than H3.3-containing 
nucleosomes. Furthermore, the linker histone H1 that is responsible for chromatin 
compaction (220) bound less efficiently to H3.Y than H3.3 nucleosomes. Kujirai et al. showed 
that lysine 42 in H3.Y contributes to the reduced binding of H1. These features of H3.Y are 
also conserved in heterotypic nucleosomes containing H3.3 and H3.Y: both, DNA end 
flexibility, as well as binding of H1, are reduced in heterotypic nucleosomes. Finally, the 
authors stably expressed H3.Y in the cervical carcinoma cell line HeLa and demonstrated its 
presence at the TSS of actively transcribed genes.  Altogether, H3.Y s flexible DNA ends as 
well as reduced H1 binding might contribute to an open chromatin conformation and 
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provide better access for the transcription machinery, thereby maintaining active 
transcription (219).  
 
 
1.2.5 H3 Specific Chromatin Remodeler & Histone Chaperones 
α-thalassaemia/mental retardation X-linked protein (ATRX) is a SWI/SNF remodeler 
implicated in the deposition of H3.3 to heterochromatic sites such as telomeres, pericentric 
heterochromatin, and retrotransposons (221, 222). Together with H3.3, ATRX contributes to 
the establishment and maintenance of H3K9me3 at these regions and transcriptional 
silencing (190, 197, 223, 224). Moreover, ATRX is implicated in the establishment of a 
functional telomere and its maintenance (175, 225). Loss of ATRX in human and mouse cell 
lines is associated with telomere dysfunction, impaired DNA DSB repair and mitotic defects 
such as chromosome congression defects or chromosome decondensation, leading to 
genomic instability (225-227). Inactivating mutations and loss of ATRX are associated with a 
variety of diseases in humans. Initially, ATRX was identified in male patients suffering from 
mental retardation, α-thalassaemia and facial and genital abnormalities (228). Moreover, 
ATRX mutations were found in pancreatic neuroendocrine tumors (panNETs) and in 
glioblastoma where ATRX is often mutated in addition to H3.3 (209, 229-231). Interestingly, 
tumors associated with ATRX mutations often exhibit an alternative pathway to ensure the 
maintenance of their telomeres (209, 230). Instead of reactivating telomerase, 10-15% of 
cancers accomplish immortality by a mechanism based on homologous recombination, so-
called alternative lengthening of telomeres (ALT) (232). The high correlation of ATRX 
mutations and ALT prevalence supports ATRX  known function in telomere maintenance. 
ATRX loss results in telomere malfunction potentially by impaired deposition of H3.3. This 
might result in telomere destabilization and lead to the ALT phenotype, emphasizing again 
the important role of H3.3 and proteins implicated in its deposition for genome integrity.  
Histone chaperones are a very diverse group of proteins defined as histone-binders that 
influence chromatin dynamics in an ATP-independent manner  (43). Their functions range 
from nuclear import, providing histone stability, nucleosome assembly, and disassembly to 
ensuring the right localization in chromatin.  From their synthesis to chromatin incorporation 
histones are permanently bound by histone chaperones. Interestingly, histone chaperones 
mostly bind either H3-H4 or H2A-H2B (one exception is FACT (facilitates chromatin 
transcription) (233) and NAP1 (nucleosome assembly protein 1) (234, 235)). In the following, 
I will elaborate on the diversity of H3-H4 chaperones.  
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Anti-silencing function 1 (ASF1) is the most conserved chaperone and has been shown to be 
able to handle the canonical variants as well as the replacement variant H3.3. In humans, 
two paralogues with non-redundant functions exist: ASF1A and ASF1B. The different 
isoforms determine the interaction with different downstream chaperones. First, ASF1 is 
involved in nuclear import of H3-H4 into the nucleus thereby associating with Importin 4, 
nuclear autoantigenic sperm protein (NASP), retinoblastoma (Rb)-associated protein 46 
(RbAp46) and 48 (RbAp48) and histone acetyltransferase 1 (HAT1) (44, 236, 237). After 
nuclear import, ASF1 functions as a histone donor to downstream chaperones that mediate 
nucleosome assembly. In complex with ASF1, H3 residues that allow the discrimination 
between the variants are solvent exposed, meaning different downstream chaperones are 
able to distinguish between the variants (238). H3.1 and H3.2 are handed over to chromatin 
assembly factor 1 (CAF1), H3.3 to histone regulatory homolog A (HIRA) and death domain-
associated protein DAXX. Evidence exists that HIRA preferentially associates with ASF1A, 
whereas CAF1 is primarily associated with ASF1B (239-242). Moreover, the binding of CAF1 
and HIRA is mutually exclusive, explaining the different deposition modes for the distinct 
variants (241). All three, CAF1, DAXX and HIRA promote deposition of newly synthesized H3 
histones. CAF1 is responsible for the deposition during replication, while HIRA and DAXX 
mediate H3.3 deposition in a replication-independent manner. ASF1 is not only implicated in 
de novo nucleosome assembly but also aids in the disruption of H3-H4 tetramers and 
histone eviction at promoters and in coding regions (238, 243-245). A model for the function 
of ASF1 at the replication fork suggests, that ASF1 associates with the replicative helicase 
MCM2 during unwinding of the DNA and aids to disrupt tetramers (246). Behind the 
replication fork, it assists in depositing new histone dimers by handing them over to the 
CAF1 chaperone complex. This model illustrates the dual function of ASF1 in the deposition 
of newly synthesized histones and parental tetramer disruption. Thus, ASF1 is implicated in 
the proper distribution of parental histones on newly synthesized and parental DNA strands, 
thereby ensuring the proper inheritance of epigenetic information.  
Only a few aa differ between the canonical H3 variants and H3.3, however, they are 
sufficient to cause differential binding to distinct chaperone complexes. Amino acids 87-90 
are therefore referred to as chaperone recognition site and determine the association with 
either replication-coupled deposition pathways, as it is the case for the canonical variants or 
replication-independent deposition (247, 248).  
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1.2.5.1 Replication-dependent Deposition of Histone H3 
CAF1 is a trimeric complex consisting of the subunits p150, p60, and p48 (also called 
RbAp48, see above) and is responsible for the deposition of H3.1-H4 and H3.2-H4 during 
replication and DNA repair (249, 250). The p150 subunit determines CAF1 s association with 
the replication machinery since it directly binds proliferating cell nuclear antigen (PCNA), a 
protein involved in replication processibility (251). Additionally, CAF1 co-localizes with 
replication foci in HeLa cells, supporting its role in replication-coupled histone deposition 
(252). ASF1 directly binds to the p60 subunit, which can be phosphorylated thereby 
regulating CAF1 localization and activity during the cell cycle and upon DNA damage (253, 
254). Only a fraction of total RbAp48 in the cell is present in the CAF1 complex. It is 
additionally part of histone acetyl- and deacetyltransferase complexes and part of the 
remodeling complexes NuRD and NURF (42, 255). Depletion of CAF1 or introduction of a 
dominant negative p150 version in human cells causes tremendously diminished 
nucleosome assembly, S-phase arrest, DNA replication defects, DNA DSB and even induces 
cell death in proliferating cells. Thus, CAF1 is essential for chromatin assembly and might 
also be critical for cell viability (256-258). 
Additionally, another chaperone is involved in replication-dependent H3-H4 deposition, 
namely the FACT complex. It was initially identified as a protein required during transcription 
and was recently discovered to be involved in H3-H4 deposition during DNA replication in 
yeast. The FACT complex consists of the two subunits Spt16 (suppressor of Ty16, also called 
FACT140) and SSRP1 (structure specific recognition protein 1, also called FACT80) (259, 260). 
Introducing a mutant Spt16 allele into a yeast strain that allows discrimination between 
FACT functions in transcription and replication revealed its role in replication-coupled 
nucleosome assembly. The authors suggest a model where FACT cooperates with other 
chaperones in the deposition of newly synthesized histones (260). It remains to be seen if 
FACT chaperone function in DNA replication is conserved in humans.  
 
1.2.5.2 H3.3 Chaperones 
H3.3 gets deposited replication-independently by two different chaperone complexes, 
namely the HIRA and DAXX/ATRX complexes. HIRA is responsible for H3.3 deposition in the 
gene body of actively transcribed genes, regulatory regions like promoters and enhancers 
and DNA repair sites whereas DAXX/ATRX deposits H3.3 at heterochromatic simple repeat 
sites often marked by the presence of H3K9me3 (190, 191, 198, 261, 262).  
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The HIRA complex consists of HIRA, Ubinuclein 1 (UBN1), calcineurin binding protein 1 
(CABIN1) and ASF1A (240, 263). HIRA directly binds ASF1A, which does not seem to be a 
permanent complex member but rather is only transiently bound. This idea is further 
supported by the fact that H3.3-H4 are still efficiently deposited after ASF1 depletion (264). 
Recent structural studies revealed that H3.3 specificity is derived from UBN1. It contacts 
H3.3 around the chaperone recognition site. Especially G90 was identified as the aa that 
determines UBN1 s specificity for H3.3. The mutant H3.3G90M harboring H3.1 s methionine 
instead of glycine at position 90 lost binding to UBN1. In contrast H3.1M90G gained binding, 
arguing that H3.3G90 mediates the specificity for UBN1 and therefore HIRA (265).  
HIRA is recruited to chromatin target sites in multiple ways. The interaction of HIRA with 
transcriptional regulators, RNA pol II and naked DNA could explain H3.3 s presence at 
regulatory regions and at actively transcribed genes where nucleosomes are displaced and 
naked DNA occurs (188, 191, 266). Recently, HIRA was shown to build a complex with H3.3 
and replication protein A (RPA), a single-stranded DNA binding complex that is involved in 
DNA replication, repair, and transcription. HIRA, H3.3 and RPA co-localize at gene regulatory 
regions. Depletion of RPA or HIRA resulted in dramatically reduced H3.3 deposition and 
association of HIRA at chromatin and altered transcription (262). These data are in conflict 
with another study. Goldberg et al. observed no changes in H3.3 occupancy at regulatory 
regions and telomeres after HIRA depletion but demonstrated that gene bodies of actively 
transcribed genes reveal reduced H3.3 occupancy (190). Moreover, depletion of HIRA leads 
to reduced CABIN1 expression and vice versa, depletion of CABIN1 results in reduced HIRA 
abundance. It seems like HIRA and CABIN1 stabilize each other in complex formation (263). 
Nonetheless, CABIN1 appears to have only a minor effect on H3.3-H4 deposition.  
The absence of HIRA and impaired H3.3 deposition is not rescued by CAF1 mediated H3.1 
deposition. In contrast, HIRA can compensate for CAF1 loss and deposits H3.3 at replication 
sites, probably by its DNA binding capability (191). This binding could also explain HIRA s role 
in DNA repair. Very early after DNA damage HIRA gets recruited to UV-C damaged regions 
and promotes deposition of H3.3-H4. This H3.3 deposition might serve as a mark for 
transcription restart after DNA repair (261). It is so far not clear, whether H3.3 deposition by 
HIRA serves only as a gap-filling mechanism in nucleosome depleted regions thereby 
ensuring genomic integrity or whether it directly regulates DNA-related processes as 
suggested by (262). 
Additionally, H3.3 deposition at heterochromatic sites is accomplished by the DAXX/ATRX 
complex (190, 198, 222, 223, 267, 268). Absence of DAXX did not result in a general loss of 
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H3.3, surprisingly partially due to CAF1 s binding to H3.3 (191, 267). On the other hand, 
DAXX loss affected deposition of H3.3 to pericentric repeats thereby leading to impaired 
transcription from these repeats, similar to ATRX depletion (267). This result is maybe 
counterintuitive since H3.3 was shown to be implicated in silencing in these regions and 
other studies mentioned above showed upregulation of TERRA after ATRX loss (190). 
Both DAXX and HIRA knockout mice die during embryonic development. Since DAXX has also 
crucial roles apart from its functions in nucleosome assembly, these phenotypes can not 
only be accredited to the loss of H3.3 deposition (269, 270).  
The histone-binding domain (HBD) of DAXX was crystallized together with an H3.3-H4 dimer 
(247, 248). The structure revealed that DAXX occupies an α-helical fold and wraps around an 
H3.3-H4 dimer (Figure 5). DAXX binding to H3.3-H4 is composed of hydrophobic and 
electrostatic interactions and hydrogen bonds.  
 
Figure 5: DAXX wraps around an H3.3-H4 dimer. The HBD of DAXX crystallized together with an H3.3-
H4 dimer. The crystal structure unveils the overall α-helical fold of DAXX. DAXX is shown in pink, H3.3 
in purple and H4 in green. Adapted and reprinted with permission from Nature Publishing Group 
(247). 
 
DAXX binding competes, such as many other chaperones do, with H3-H4 tetramerization 
and DNA binding. Moreover, it also competes with ASF1, suggesting that in contrast to HIRA 
or CAF1 DAXX is not found in one complex with ASF1. Indeed, pull down experiments in 
HeLa cells revealed that DAXX and ASF1 can not be immunoprecipitated together. Increasing 
the availability of free H3.3-H4 by depleting ASF1 resulted in an increased association of 
DAXX-H3.3-H4 ternary complexes. In turn, overexpression of ASF1 led to a diminished 
abundance of DAXX-H3.3-H4 complexes. DAXX contacts H3.3 at its unique residues A87, I89 
and G90. To analyze whether these aa indeed determine DAXX specificity for H3.3, single 
point mutants exhibiting exchanges with the corresponding H3.1 residues were investigated 
for DAXX binding. H3.3G90M demonstrated impaired DAXX binding by approximately 50%. 
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Surprisingly, H3.3G90M pulled down CAF1, suggesting that DAXX loss is partially 
compensated by CAF1. Conversely, H3.2M90G gained DAXX binding. A closer look identified 
an extensive hydrogen bond network in the vicinity of Gly90 including H3.3S57 and H3.3E59, 
whereas the crystal structure of DAXX-H3.3G90M showed a reduced number of hydrogen 
bonds. These data demonstrate the crucial role of glycine at position 90 in DAXX binding.  
The αN heli  of H .  is ofte  disordered i  other hapero e o ple es. In the DAXX-H3.3-H4 
complex, however, it is stabilized (247, 271). Depletion of aa 1-6 , i ludi g the αN heli , 
abolishes DAXX binding, highlighting its important role in DAXX binding. DeNizio et al. could 
also support this  sho i g that H .  αN e perie ed the highest i rease i  sta ilit  after 
DAXX binding. In fact, H3.3 changes its conformation from a disordered state in solution to a 
stable fold when in complex with DAXX. Surprisingly, also DAXX stability itself is highly 
coupled to H3.3-H4 binding. Both, the chaperone and its substrate achieve a stable 
conformation by their interaction. The high selectivity for H3.3 can be explained by the 
stabilized fold that DAXX only achieves when bound to its substrate H3.3 and not by binding 
to H3.2 (271).  
Another function of DAXX was detected in the H3.3 deposition pathway by Delbarre et al. 
(272). The authors reported a stepwise deposition pathway for H3.3 whereby Promyelocytic 
leukemia (PML) nuclear bodies (NBs) play a key role as an intermediate triage center for 
H3.3. PML-NBs are nuclear structures implicated in the storage and PTMs of diverse nuclear 
proteins (273). Depletion of DAXX results in an accumulation of soluble H3.3, arguing that 
DAXX is responsible for the recruitment of H3.3 to these structures prior to deposition. In 
addition to DAXX also ATRX, HIRA, and ASF1A localize to PML-NBs, thus they might function 
as a triage center for H3.3 to the distinct chaperones (272). Moreover, DAXX or PML loss 
leads to an impaired incorporation of H3.3 at periCEN. Conversely, overexpression of DAXX 
results in increased H3.3 levels at PML-NBs and pericentric repeats, arguing for a role for 
PML-NBs in heterochromatin composition (274). This hypothesis is further supported by a 
study in mESCs where the depletion of PML results in telomere dysfunction characterized by 
the increased presence of TIFs (275). Together, these data suggest a function for DAXX in the 
recruitment of H3.3 to PML-NBs. Thereby they might, on the one hand, serve as a meeting 
point for H3.3 and its chaperones and/or on the other hand stabilize heterochromatin 
integrity. 
In addition to H3.3 and ATRX, DAXX is also mutated or misregulated in a variety of cancers 
(166, 229, 231, 276, 277). In line with H3.3 and ATRX DAXX is also mutated in pediatric brain 
cancer. However, DAXX mutations are less frequently observed than H3.3 or ATRX mutations 
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(209). In panNETs and leiomyosarcoma DAXX mutations correlate with poor prognosis (278, 
279). As mentioned earlier, ATRX and also DAXX mutations are associated with the ALT 
pathway, an acquired mechanism to escape apoptosis or senescence (229, 230, 232, 277). 
Notably, DAXX mutations concerning its functions outside of H3.3 deposition pathway also 
have a high impact on tumorigenesis. In the case of H3.3 deposition, loss of DAXX function 
can result in diminished association with H3.3, thereby providing an accumulation of soluble 
H3.3 or a shift towards HIRA-mediated deposition. Simultaneously, H3.3 is missing at 
heterochromatic sites, impairing heterochromatin integrity and promoting genomic 
instability. 
 
 
1.2.6 Nucleosome-free H3.Y Interactome/Chaperones 
In order to gain further insight into the function of the new histone H3 variant H3.Y its 
chaperones responsible for the deposition into chromatin should be identified. H3.Y shows 
the highest similarity to H3.3 and importantly shares the same chaperone recognition site 
with H3.3 (aa 87-90, see Figure 4). Due to this similarity it was expected to pull down the 
same chaperone complexes that are responsible for H3.3 deposition. Clemens Bönisch, a 
former PhD student in our group, analyzed together with Hans Christian Eberl from the 
group of Matthias Mann the soluble pool of histone H3 variants concerning their 
predeposition interaction partners. HeLa Kyoto (HK) cells stably expressing eGFP-H3 variants 
were SILAC (stable isotope labeling of amino acids in cell culture) labeled. The nuclear 
fraction was isolated and ultracentrifuged to separate chromatin from the soluble part that 
was used for immunoprecipitation with GFP-trap magnetic beads to isolate eGFP-tagged H3 
variants and their associated binding partners. The associated proteins were identified by 
mass spectrometry (MS). In Figure 6 the interactome of soluble nuclear eGFP-H3 variants is 
depicted.  
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Figure 6: DAXX/ATRX only interacts with H3.3 but not H3.Y. HeLa Kyoto cells expressing eGFP-H3.2, -
H3.3 and -H3.Y were SILAC labeled and the soluble nuclear fraction of the H3 variants and their 
interaction partners were immunoprecipitated via magnetic GFP-trap_M beads. The known 
chaperone complexes are depicted in red, Ku proteins in green, MCM family members in blue and 
FACT complex members in purple. Black dots correspond to background binders. 
 
Unsurprisingly, eGFP-H3.2 could pull down chaperone complex members CAF1A, CAF1B and 
CAF1C in addition to ASF1A, verifying the applicability of the method. Interestingly, eGFP-
H3.2 also immunoprecipitated members of the MCM2-7 complex, namely MCM2, MCM4, 
MCM6 and MCM7. This highlights again the specificity of the approach since these proteins 
were already identified in a recent study addressing the H3.2 interactome (280).  
As expected, DAXX/ATRX and also the HIRA complex members HIRA, CABIN1 and ASF1A 
were identified in the eGFP-H3.3 pulldown as well as the FACT complex (FACT80 and 
FACT140). Additionally the Ku proteins Ku70 and Ku80 that are implicated in DNA repair and 
MCM2, MCM4, MCM6 and MCM7 were pulled down.  
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eGFP-H3.Y immunoprecipitated as well the FACT complex, Ku70 and Ku80, MCM2, MCM4, 
MCM6 and MCM7 and HIRA, CABIN1 and ASF1A. Surprisingly, although H3.3 and H3.Y share 
the same chaperone recognition site, eGFP-H3.Y could not immunoprecipitate the 
DAXX/ATRX complex, indicating that only H3.3 but not H3.Y interacts with DAXX/ATRX. 
Despite the fact that both chaperone complexes bind the same region in H3.3 that is 
identical in H3.Y only the HIRA complex but not DAXX/ATRX binds H3.Y. 
 
 
 
1.3 OBJECTIVES 
In this thesis I aimed to unravel the function of the novel H3 variant H3.Y. Therefore, I 
analyzed its localization in chromatin by ChIP-seq and identified its interactome by MS. 
Although H3.3 and H3.Y share the same chaperone recognition site, H3.Y only interacts with 
the HIRA complex. Since it is responsible for the deposition into euchromatic sites I 
evaluated the consequences of this interaction on H3.Y chromatin via ChIP-Seq. Secondly I 
dissected the H3.Y chromatin composition by label-free interaction proteomics of H3.Y-
containing mononucleosomes. Do H3.1, H3.3 and H3.Y interact with different proteins? 
What can we learn from the different interaction partners about H3.Y s function? 
Next, I set out to uncover what residues prevent DAXX-H3.Y interaction or what determines 
DAXX specificity for H3.3, respectively. Hence, I generated H3.Y mutants that exhibit 
exchanges with corresponding H3.3 residues. Performing immunoprecipitations of stable 
HeLa Kyoto cell lines expressing respective H3.Y mutants aims to reveal the residues that 
determine the DAXX-H3.3 specificity. Furthermore, these mutants that gain DAXX binding 
should be analyzed regarding their chromatin distribution.  
In conclusion, gaining novel insights into H3.Y deposition mechanisms and chromatin 
localization will allow uncovering unknown aspects of H3.Y function. 
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2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Technical Devices 
Description      Supplier 
-20°C freezer      Beko, Liebherr 
-80°C freezer      Thermo Scientific 
4°C fridge      Liebherr 
37°C incubator (bacteria)     Binder 
37°C (human cells)     New Brunswick 
2100 Bioanalyzer      BioRad 
Centrifuges      Beckmann Coulter Optima Max-XP 
    Eppendorf 5424R 
       Heraeus Biofuge pico 
       Roth Rotilabo-mini-centrifuge 
       Thermo Shandon Cytospin 4 
Thermo Scientific Multifuge X3R 
CASY Cell Counter     Innovatis 
Developer machine     AGFA Curix 
Dounce homogenizer     Kontes Glass Co 
Gel documentation system    BioRad ChemiDoc 
Hood       Binder 
Incubation shaker (37°C)     Infors, New Brunswick 
Microscopes      Leica SP5 II confocal scanning 
       Zeiss Axiovert 200M Epifluorescence 
       Olympus IX71 
Nucleofector      Lonza 
pH meter      inoLab 
Pipetboy      Neolab 
Pipettes       Gilson 
Protein gel chamber     Novex Mini cell 
Serva BlueVertical PRiME 
Qubit fluorometer     Invitrogen 
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Rotating wheel      Neolab 
Scales       Sartorius 
Sonicator      Covaris S220  
Spectrophotometer     Peqlab GFP-trap_M drop ND1000 
Thermomixer      Eppendorf 5436  
Thermomixer C 
Trans Blot SD semi-dry transfer cell    BioRad 
Vortex        Bachofer Genie2 
 
 
2.1.2 Chemicals and Consumables 
Description      Supplier 
1.5 ml reaction tubes     Greiner, Sarstedt 
2 ml reaction tubes     Greiner, Sarstedt 
1.5 ml low binding tubes (DNA and protein)   Sarstedt 
15 ml and 50 ml tubes     Sarstedt 
16% Formaldehyde Solution (methanol-free)  Thermo Scientific 
Acetic acid      Sigma-Aldrich 
Agarose       Bio & Sell 
Ampicillin      Roth 
AMPure XP beads     Beckman Coulter 
LB Agar       Serva 
BSA 98%      Sigma-Aldrich 
Chlorophorm      VWR 
Cell culture plates     Sarstedt 
Centrifuge tubes (ultracentrifugation)   Beckman Coulter 
Combitips plus   Eppendorf 
Complete Protease Inhibitor Cocktails Tablets  Roche 
Coomassie Brilliant Blue     Sigma-Aldrich 
Coverslips      Hecht-Assistant 
Cryovials      Roth 
DAPI        Invitrogen 
Developer      AGFA 
DMEM       Sigma-Aldrich 
DMSO       Sigma-Aldrich 
DNA oligonucleotides     Sigma-Aldrich, Eurofins MWG 
dNTP mix      NEB 
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DTT       Roth 
Dynabeads M-280 sheep anti-rabbit IgG   Invitrogen 
ECL Western Blotting detection reagents   Amersham 
EDTA       Sigma 
EGTA       Sigma 
Ethanol, absolute      Roth 
Ethidium bromide     Sigma 
FCS dialyzed      Sigma 
Filter paper Whatman 3MM    Whatman 
Filter tips      Biozym, Gilson 
Fixer       AGFA 
G418-sulfate      Sigma 
GFP-trap_M      Chromotek 
Glycerol       VWR 
Glycine       VWR 
HEPES        Serva 
IPTG       Roth 
Isoamyl alcohol      Merck 
KCl       VWR 
MaXtract High Density Column    Qiagen 
ß-mercaptoethanol     Sigma 
Methanol      Sigma 
MgCl2       VWR 
Microscope slides SuperFrost    Roth 
Mowiol 4-88      Polysciences 
Multiply StripPro ith 8 x 0.2 ml tubes    Sarstedt 
NaCl       VWR 
Na-deoxycholate      Sigma 
NP-40       Sigma 
Opti-MEM Reduced-Serum Medium    Invitrogen 
Penicillin / streptomycin      Sigma 
Pipette tips       Biozym, Greiner, Sarstedt 
Ponceau S solution      Sigma 
Protein gels precast      Invitrogen, Serva 
Protran Nitrocellulose Transfer Membrane    Whatman 
Proteinase K      life technologies 
Qubit assay tubes      Invitrogen 
Quick Start Bradford 1x Dye Reagent   Biorad 
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RNase A       life technologies 
SDS       Serva 
TFA       Sigma 
TSA       Sigma 
Tris       Invitrogen 
Triton X-100      Sigma 
Trypsin/EDTA (cell culture)     Sigma 
Trypsin (MS)      Promega 
Tween20      Sigma 
Vectashield mounting medium    Vector Laboratories 
X-ray films      Fujifilm 
X-treme Gene HP Transfection Reagent   Roche 
 
 
2.1.3 Kits, Enzymes & Markers 
Description      Supplier 
100 bp ladder      NEB 
1 kb ladder      NEB  
2-log DNA ladder      NEB 
DNA 1000 Kit      Agilent 
Gel extraction Kit      Qiagen 
Midiprep Kit      Qiagen, Macherey-Nagel 
Micronuclease nuclease     Sigma 
Microplex Libraray Preparation Kit     Diagenode 
MinElute PCR Purification Kit    Qiagen 
NucleoSpin
®
 Plasmid EasyPure Kit    Macherey-Nagel 
PCR purification Kit     Qiagen 
peqGOLD protein marker IV, V    Peqlab 
Phusion High Fidelity DNA polymerase   Biolabs 
Pfu Turbo Hotstart DNA Polymerase   Agilent 
Qubit dsDNA HS Assay Kit     Invitrogen 
Restriction endonucleases     NEB 
Taq DNA Polymerase     NEB 
 
 
 MATERIALS AND METHODS 
 34 
2.1.4 Antibodies 
2.1.4.1 Primary Antibodies 
Name (product #)  Supplier  Application  Dilution 
Ra it α-DAXX (25C12)  Cell Signalling  WB   1:1000 
(45335) 
Ra it α-DAXX (M-112)  Santa Cruz  WB   1:1000 
(SC-7152) 
Rabbit α-GFP   Abcam   ChIP   5 µg per IP 
(ab290) 
Mouse α-GFP   Roche   WB   1:10000 
(11814460001) 
Ra it α-H3K9me3  Diagenode  WB   1:1000 
(C15410056) 
mouse α-H3S10ph  Active motif  IF   1:800 
(ab39636) 
Mouse α-PAR   Gift from A. Ladurner, WB   1:5000  
LMU Munich 
Rabbit α-PML   Abcam   IF   1:100 
(ab53773) 
Mouse α-SUMO-1 (GMP-1) Invitrogen  WB   1:1000 
(332400) 
Mouse α-Ubiquitin  Merck Millipore  WB   1:5000 
(04-263) 
 
2.1.4.2 Secondary Antibodies 
Name    Supplier  Application  Dilution 
α-rabbit HRP   VWR   WB   1:10000 
α-mouse HRP   VWR   WB   1:10000 
α-rabbit Alexa555  Jackson Laboratories IF   1:1000 
α-rabbit Cy3 conjugated  Jackson Laboratories IF   1:200 
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2.1.5 Plasmids 
Name   Source   Description   Marker 
pUC57-   Genewiz   ordered constructs  Amp 
  -N3-Y      arrived in pUC57 
  -NY-3      vector; 
  -3-CY      subcloning 
  -Y-C3 
  -H3.Y core GERA 
  -H3.Y K53R core GERA 
  -H3.Y K53R core R122KM124I 
  -H3.Y K53R core C 
pIRESneo-eGFP  C. Bönisch  Expression of N-   Amp, Neo- 
      terminally GFP-tagged fusion mycin (Neo) 
      proteins in mammalian 
      cells 
pIRESneo-eGFP  S. Pünzeler  Expression of N-   Amp, Neo 
-H3.Y Q59E     terminally GFP-tagged  
H3.Y mutant protein  
in HeLa Kyoto cells 
pIRESneo-eGFP  this thesis  Expression of N-   Amp, Neo 
      terminally GFP-tagged  
H3.Y mutant proteins  
in HeLa Kyoto cells 
  -H3.Y core 
  -N3-Y       
  -NY-3       
  -3-CY       
  -Y-C3 
  -H3.Y core GERA 
  -H3.Y K53R core GERA 
  -H3.Y K53R core R122KM124I 
  -H3.Y K53R core C3 
  -H3.Y K42R K53R core C3 
  -H3.Y L46V K53R core C3 
  -H3.Y K53R L62I core C3 
  -H3.Y K42R L46V K53R core C3 
  -H3.Y K42R K53R L62I core C3 
  -H3.Y L46V K53R L62I core C3 
 
 
2.1.6 Oligonucleotides 
2.1.6.1 Oligonucleotides for Cloning 
Oligonucleotides were synthesized by Sigma-Aldrich or Eurofins MWG.  
Name    Sequence 5  – 3    Description 
gw_H3.3_fwd   GGGGACAAGTTTGTACAAAAAAGCAGGC Cloning of H3.3, 3-CY and N3-Y 
TTAACTGCCCGAACCAAGCAGAC     into pIRESneo-eGFP 
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Name    Sequence 5  – 3    Description 
gw_H3.3_rev  GGGGACCACTTTGTACAAGAAAGCTGGG Cloning of H3.3, NY-3 and Y-C3  
TCTTAAGCTCTCTCTCCCCGTATCC   into pIRESneo-eGFP 
gw_H3.Y_fwd   GGGGACAAGTTTGTACAAAAAAGCAGGC Cloning of H3.Y mutants 
TTAACTGCGCGCACCAAGCAGAC  into pIRESneo-eGFP 
gw_H3.Y_rev  GGGGACCACTTTGTACAAGAAAGCTGGGT Cloning of H3.Y mutants 
CTTAAGGACCCTCTCTGCGGAG   into pIRESneo-eGFP 
gw_H3.Y_GERA_rev GGGGACCACTTTGTACAAGAAAGCTGGGT Cloning of H3.Y GERA and 
CTTAAGCACGCTCTCCGC   H3.Y K53R GERA into  
     pIRESneo-eGFP 
 
2.1.6.2 Oligonucleotides for Mutagenesis 
Name     Sequence 5  – 3       
H3.Y DFKT_fwd   CGAGATCGCCCAGGATTTCAAAACCGACCTGCGCTTCC 
H3.Y DFKT_rev    GGAAGCGCAGGTCGGTTTTGAAATCCTGGGCGATCTCG  
H3.Y Q102G_fwd   GAGGCCTACCTGGTGGGTCTCTTTGAAGACACC 
H3.Y Q102G_rev   GGTGTCTTCAAAGAGACCCACCAGGTAGGCCTC  
H3.Y K42R_fwd     GATCAAGAAGCCTCACCGCTACAGGCCTGGCACCCTGGCGCTGCGGG 
H3.Y K42R_rev     CCCGCAGCGCCAGGGTGCCAGGCCTGTAGCGGTGAGGCTTCTTGATC  
H3.Y L46V_fwd    TACAAGCCTGGCACCGTGGCGCTGCGGGAAATC 
H3.Y L46V_rev   GATTTCCCGCAGCGCCACGGTGCCAGGCTTGTA 
H3.Y L62I_fwd   GAAGTCCACGGAGCTGCTCATTCGCAAGCTGCCCTTCCAG 
H3.Y L62I_rev   CTGGAAGGGCAGCTTGCGAATGAGCAGCTCCGTGGACTTC 
H3.Y K42R_L46V_fwd     GATCAAGAAGCCTCACCGCTACAGGCCTGGCACCGTGGCGCTGCGGG 
H3.Y K42R_L46V_rev  CCCGCAGCGCCACGGTGCCAGGCCTGTAGCGGTGAGGCTTCTTGATC 
 
 
2.1.7 Bacterial Strains & Cell Lines 
2.1.7.1 Human Cell Lines 
Cell line    Origin    Source 
HeLa Kyoto (HK)   cervical cancer   H. Leonhardt, LMU Munich 
Primary mesenchymal stem cells bone marrow   P. Collas, University of Oslo 
HeLa Kyoto cells were transfected with pIRESneo-eGFP plasmids. Stable human cell lines were derived 
from G418-sulfate selected cell populations.  
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Cell line    Plasmid     Source 
HK GFP    pIRESneo-eGFP    this thesis 
HK GFP-H3.Y Q59E  pIRESneo-eGFP-H3.Y Q59E  S. Pünzeler 
HK GFP-H3.Y core  pIRESneo-eGFP-H3.Y core   this thesis 
HK GFP-N3-Y   pIRESneo-eGFP-N3-Y   this thesis 
HK GFP-NY-3   pIRESneo-eGFP-NY-3   this thesis 
HK GFP-3-CY   pIRESneo-eGFP-eGFP-3-CY  this thesis 
HK GFP-Y-C3   pIRESneo-eGFP-Y-C3   this thesis 
HK GFP-N3-Y   pIRESneo-eGFP-N3-Y   this thesis 
HK GFP-H3.Y core GERA  pIRESneo-eGFP-H3.Y core GERA  this thesis 
HK GFP-H3.Y K53R core GERA pIRESneo-eGFP-H3.Y K53R core GERA this thesis 
HK GFP-H3.Y K53R core  pIRESneo-eGFP-H3.Y K53R core  this thesis 
R122KM124I   R122KM124I 
HK GFP-H3.Y K53R core C3 pIRESneo-eGFP-H3.Y K53R core C3  this thesis 
HK GFP-H3.Y K42R K53R core C3 pIRESneo-eGFP-H3.Y K42R K53R core C3 this thesis 
HK GFP-H3.Y L46V K53R core C3 pIRESneo-eGFP-H3.Y L46V K53R core C3 this thesis 
HK GFP-H3.Y K53R L62I core C3 pIRESneo-eGFP-H3.Y K53R L62I core C3 this thesis 
HK GFP-H3.Y K42R L46V K53R  pIRESneo-eGFP-H3.Y K42R L46V K53R this thesis 
core C3    core C3 
HK GFP-H3.Y K42R K53R L62I  pIRESneo-eGFP-H3.Y K42R K53R L62I this thesis 
core C3    core C3 
HK GFP-H3.Y L46V K53R L62I  pIRESneo-eGFP-H3.Y L46V K53R L62I this thesis 
core C3    core C3 
 
2.1.7.2 E. coli Strains 
Strain    Genotype      Supplier 
E.coli DH5a   fhuA  Δ argF-lacZ U  phoA gl V  Φ     NEB 
   Δ lacZ M  gyrA  recA  relA  e dA  thi-1 hsdR17  
E.coli Stellar  F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA,  Clontech 
   Φ d lacZΔ M , Δ lacZYA - argF  U , Δ rr -  
   hsdRMS - crBC , Δ crA, λ–  
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2.1.8 Software 
Application    Software 
Image Processing    Adobe Photoshop CS5 
     Adobe Illustrator CS5 
     Axio Vision (Zeiss) 
Primer Design    Primer3 (web-browser based) 
qMS     Perseus (1.3.10.0) 
     R Studio / R (3.0.2) 
Sequencing (ChIP)   BioViz Integrated Genome Browser 
     Broad Institute Integrative Genomics Viewer 
Sequence Alignment   ClustalW  
 
 
2.1.9 Standard Buffers & Solutions 
Ampicillin stock solution    100 mg/ml Ampicillin (1000x) 
Blocking solution     5% milk powder (w/v)  
PBS + 0.1 % Tween20 
Coomassie staining solution    10% acetic acid (v/v) 
      50% methanol 
      0.1% Coomassie Brilliant Blue (w/v) 
Coomassie destaining solution   10% acetic acid 
      30% methanol 
Ethdidium bromide stock solution   10 mg/ml Ethidium bromide (20000x) 
5x Laemmli loading buffer    314 mM Tris 
(adjust pH to 6.8 with HCl)    50% glycerol 
      5% SDS 
      5% beta-Mercaptoethanol (v/v)  
      0.01% Bromphenol blue 
Laemmli running buffer    25 mM Tris 
      192 mM glycine 
      0.1% SDS (w/v) 
LB Agar plates     1.5% LB Agar 
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LB medium     1.0% Tryptone (w/v) 
      0.5% yeast extract (w/v) 
      1.0% NaCl (w/v) 
Phosphate buffered saline (PBS)   140 mM NaCl 
      2.7 mM KCl  
      10 mM Na2HPO4 
      1.8 mM KH2PO4 
TBE      45 mM Tris 
      45 mM Boric acid 
      1 mM EDTA 
Transfer Buffer (SDS gel electrophoresis)  48 mM Tris 
      39 mM glycine 
      0.0375% SDS (w/v) 
      20% methanol (v/v) 
TE      10 mM Tris 
      1 mM EDTA 
 
 
 
2.2 MOLECULAR BIOLOGICAL METHODS 
2.2.1 Mutagenesis of H3.Y Constructs 
pIRESneo-eGFP-H3.Y plasmids were used for site-directed mutagenesis. Primer pairs carrying the 
desired mutation were used for PCR amplification with the following conditions (Table 1 and Table 2):  
Table 1: Composition of reagents for site-directed mutagenesis. 
Template (50 ng/µl) 1 µl 
10x Pfu reaction buffer 2 µl 
dNTPs 2 µl 
Primer fwd (10 µM) 2 µl 
Primer rev (10 µM) 2 µl 
Pfu Turbo Hotstart DNA Polymerase 0.5 µl 
H2O 11.5 µl 
Total volume 20 µl 
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Table 2: Conditions for site-directed mutagenesis of H3.Y 
  Temperature Time Cycles 
Initial denaturation 95°C 30 s 1 
Denaturation  95°C 30 s 
20-25 Annealing 55°C 1 min 
Elongation 68°C 6 min 
 
After PCR, 10 µl of the PCR product were subjected to DpnI digest in order to eliminate the parental 
template DNA not carrying the mutation. Next, the DpnI digested DNA was transformed into 
competent E. coli cells. Finally, the isolated DNA of several clones was analyzed by sequencing 
(Eurofins MWG) and the obtained DNA sequence was investigated by the ClustalW sequence 
alignment program in order to determine whether it contains the desired mutation(s).  
 
 
2.2.2 Cloning of H3.Y Mutant Constructs into Destination Vector pIRESneo-eGFP  
Plasmids that were ordered at Genewiz containing H3.Y mutants arrived in the pUC57 vector. In order 
to clone the constructs into pIRESneo-eGFP, the vector used for expression in HK cells, the DNA was 
amplified with primers containing attL overhangs for gateway cloning (see Table 3 and Table 4). 
Table 3: Reagents used for PCR to clone H3.Y mutants into destination vector pIRESneo-eGFP. 
pUC57 H3.Y mutant (1ng/µl) 1 µl 
5x HF buffer 10 µl 
dNTPs 1 µl 
Primer fwd (10 µM) 0.5 µl 
Primer rev (10 µM) 0.5 µl 
Polymerase (Phusion) 0.5 µl 
H2O 36.5 µl 
Total volume 50 µl 
 
Table 4: PCR conditions for amplification of H3.Y mutant constructs. 
  Temperature Time Cycles 
Initial denaturation 95°C 30 s 1 
Denaturation  95°C 30 s 
30 Annealing 55°C 1 min 
Elongation 72°C 1 min 
Final elongation 72°C 7 min 1 
 
Obtained PCR products were PCR purified and subjected to Gateway Cloning according to the 
manufacturer s protocol. Briefly, 50-150 ng of the purified PCR product was mixed with 150 ng of 
pIRESneo-eGFP vector and filled up to 8 µl with TE buffer. 2 µl of LR Clonase II enzyme mix was added 
to this mixture and incubated at 25°C for 1 hour. Afterwards, 1 µl of Proteinase K was added and 
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incubated at 37°C for 10 min. Finally, 2 µl of the final mix were transformed into competent E. coli 
cells. DNA of the received bacterial clones was isolated with the NucleoSpin Plasmid EasyPure Kit and 
analyzed with the help of the ClustalW sequence alignment program.  
 
 
 
2.3 BIOCHEMICAL METHODS 
2.3.1 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Proteins were separated with precast gels from Serva or Invitrogen by SDS-polyacrylamide gel 
electrophoresis. PeqGOLD protein marker IV and V were used to determine the size of the respective 
proteins. Before loading samples were boiled 5 min at 95°C in 5x Laemmli buffer and then run for 
approximately 2 hours at 150 V. Afterwards the gel was either used for Coomassie staining or 
subsequent immunoblotting. 
 
 
2.3.2 Coomassie Staining of Polyacrylamide Gels 
In order to visualize proteins separated by SDS-PAGE, the polyacrylamide gel was stained for 1 hour in 
Coomassie staining solution. Subsequently, the gel was destained in destaining solution until the 
proteins bands became apparent. After washing the destained gel with water, it was scanned in the 
transparency mode, 300 dpi, 16 bit HDR gray scale.  
 
 
2.3.3 Immunoblotting 
Polyacrylamide gels were blotted onto a nitrocellulose membrane with a semidry blotting device. The 
polyacrylamide gel, a nitrocellulose membrane and Whatman papers were equilibrated for 5 min in 
transfer buffer prior to the formation of a blotting sandwich in the following order: 2 Whatmann 
paper, membrane, gel, two additional Whatman paper. The sandwich was blotted for 1 hour at 250-
300 mA. Subsequently, the membrane was blocked for at least 1 hour in blocking solution. Primary 
antibody was diluted in blocking solution (see 2.1.4.1 for details) and incubated over night at 4°C, 
followed by three washing steps à 10 min with PBS-T the next day. After washing the membrane was 
incubated with the secondary antibody diluted in blocking solution (see 2.1.4.2 for details) and 
incubated for 1 hour at room temperature (RT). Afterwards, the membrane was again washed three 
times with PBS-T. Next, respective proteins were detected by incubation with ECL detection reagent 
for 2-10 min. Exposure of X-ray films for a time ranging from 10 sec to 20 min was followed by the 
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development of the film with the help of a developing machine. X-ray films were scanned and saved 
with the settings mentioned in 2.3.2. 
 
 
2.3.4 Mononucleosome Preparation 
The implemented protocol was initially developed by (149). HK cells were harvested, counted with 
the CASY counter and aliquots of 4x10
7
 cells were separated into 15 ml falcon tubes. All following 
steps were done on ice. The cells were washed with PBS and subsequently lysed for 10 min with 5 ml 
PBS + 0.3% Triton X-100 + complete protease inhibitors (CPI) at 4°C. Nuclei were pelleted by 
centrifugation for 5 min at 2000 rpm and washed in 5 ml PBS + CPI. Nuclei were resuspended in 500 µl 
EX100 buffer, CaCl2 was added to a final concentration of 2 mM and the mixture was transferred to a 
low-binding reaction tube. 1.5 U micrococcal nuclease (MNase) was added to the reaction mix and 
incubated for 20 min at 26°C. Adding EGTA to a final concentration of 10 mM stopped the reaction. 
Afterwards, the samples were centrifuged for 30 min at 21130 rcf; the supernatant (S1) was used for 
subsequent analysis. First, 25 µl of S1 were boiled for 5 min at 95°C in Laemmli loading buffer to serve 
as input for immunoprecipitations (2.3.6). Second, 25 µl of S1 were subjected to DNA extraction (see 
2.3.5). 
EX100 buffer:  10 mM Hepes pH 7.6 
  100 mM NaCl 
  1.5 mM MgCl2 
  0.5 mM EGTA 
  10% Glycerol 
  10 mM β-Glycerol phosphate 
prior to use: 1 mM DTT 
  1 x CPI 
 
 
2.3.5 Purification of MNase Digested DNA 
In order to determine the MNase digestion degree, DNA was extracted from the S1 fraction obtained 
after MNase digestion (see 2.3.4). Initially, nucleic acids were isolated by 
phenol/chloroform/isoamylalcohol extraction, followed by the DNA precipitation by ethanol. First, 
175 µl 5 mM Tris-HCl were added to 25 µl S1, then 200 µl phenol and 200 µl 
chloroform/isoamylalcohol (ratio 24:1) were added, the mixture was vortexed and transferred to 
maXtract tubes. Aqueous and organic phase were separated by centrifugation at 7 000 rcf. The 
aqueous phase containing nucleic acids was used for subsequent DNA precipitation: after addition of 
glycogen to reach a final concentration of 200 µg/ml, sodium acetate (final concentration 0.3 M) and 
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500 µl 100% ethanol the DNA was precipitated for at least 20 min at -20°C. Centrifugation for 20 min 
at 20000 rcf at 4°C pelleted the DNA. The pellet was washed twice with 500 µl 70% ethanol and dried 
at RT for 10 min. After drying, the DNA pellet was resuspended in 30 µl double distilled water 
(ddH2O). The DNA concentration was analyzed by the Nanodrop ND1000 spectrophotometer 
(Peqlab). 500 ng DNA were analyzed regarding the digestion degree on a 2% agarose gel.  
 
 
2.3.6 Mononucleosome-Immunoprecipitation (MNase-IP) 
Mononucleosomes from HK cells were prepared as described in 2.3.4 and then subjected to 
immunoprecipitation. All following steps were done on ice or at 4°C. 4 x 10
7
 cells were used for 
immunoprecipitation with 25 µl slurry GFP-trap magnetic beads (GFP-trap_M, Chromotek). First, 25 µl 
of GFP-trap_M beads were equilibrated in EX100 buffer. Next, the S1 fraction containing the 
mononucleosomes was added to the GFP-trap_M and incubated for 2.5 hours at 4°C. The mixture was 
then magnetically separated and the supernatant kept as nonbound . The beads were washed twice 
in 1 ml wash buffer 1 for 5 min and twice in 1 ml wash buffer 2. After washing beads were 
magnetically separated, the supernatant was removed and the beads were boiled in 25 µl 1x Laemmli 
loading buffer. The obtained immunoprecipitated fractions (IP) were analyzed by immunoblotting. 
Wash buffer 1:  10 mM Tris pH 7.5 
  150 mM NaCl 
  0.1% NP-40 
prior to use: 1 mM DTT 
  1 x CPI 
Wash buffer 2:  10 mM Tris pH 7.5 
  150 mM NaCl 
prior to use: 1 mM DTT 
  1 x CPI 
 
 
2.3.7 MNase-IP followed by Quantitative MS (MNase-IP-qMS) 
Mononucleosomes were generated and immunoprecipitated as described in 2.3.4 and 2.3.6 with the 
following variations: instead of 4 x 10
7
 cells only 3.5 x 10
7
 cells were used for immunoprecipitations. 
IPs were done in technical triplicates (3 x 3.5 x 10
7
 cells). The S1 fractions of the three replicates were 
combined after MNase digestion and 50 µl S1 was kept as input for DNA extraction. The rest of the 
combined samples was equally distributed and subjected to three IP reactions with GFP-trap_M 
magnetic beads. IP and washing were done as described before (2.3.6).  
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2.3.7.1 On-bead Tryptic Digest 
Immunoprecipitated proteins were subjected to an on-bead tryptic digestion. To do so, wash buffer 2 
was removed after washing and the beads were incubated for 20 min at 25°C in buffer E1 (mild 
shaking) followed by magnetic separation. The supernatant was then transferred to a new low-
binding tube before adding 2-chloracetamide (CAA) to reach a final concentration of 5 mM. The 
remaining beads were resuspended in buffer E2, incubated for 5 min (mild shaking) before adding 
trypsin (final concentration 5 µg/ml). The resulting reaction was then incubated for 1 hour at 25°C 
while shaking. After magnetic separation both supernatants were combined and incubated overnight 
at RT. The next morning 1 µl concentrated trifluoracetic acid (TFA) was added to the reaction to stop 
the tryptic digest. The beads were boiled in Laemmli buffer to check whether protein elution from the 
beads was completed by SDS-PAGE and Coomassie staining.   
 
2.3.7.2 StageTips 
StageTips were supplied by our collaboration partner Eva Keilhauer from the group of Matthias Mann 
(MPI of Biochemistry) (281). After activation of the tips with 100 µl methanol, they were centrifuged 
for 1 min at 1500 rcf followed by two washing steps with 100 µl 0.5% acetic acid. The trypsin digested 
samples (see 2.3.7.1) were split in two halves (50 µl each) and loaded on the tips to serve as working 
and backup sets. The tips were washed with 50 µl 0.5% acetic acid and dried by centrifugation. Finally, 
they were stored at 4°C until LC-MS/MS analysis.  
 
2.3.7.3 LC-MS/MS Analysis 
Our collaboration partner Eva Keilhauer eluted the peptides from the StageTips according to the 
standard protocol (281) and analyzed them by reversed-phase liquid chromatography on an EASY-nLC 
1000 system (Thermo Fisher Scientific, Odense, Denmark) coupled to a Q-Exactive mass spectrometer 
(Thermo Fisher Scientific) with the help of a nanoelectrospray source (Thermo Fisher Scientific). High-
performance liquid chromatography (HPLC) columns with 20 cm length and an inner diameter of 
75 µm were in-house packed with ReproSil-Pur 120 C18-AQ .9  parti les Dr. Mais h G H . 
Peptides were analyzed using a linear gradient (buffer A++: 0.1% FA, buffer B++: 80% ACN, 0.1% FA) 
with a flowrate of 250 µL/min and a retention time of 140 min at 50°C in a column oven 
(Sonation GmbH).  The mobile phase was directly applied to the mass spectrometer. The spray 
voltage was adjusted to 2.4 kV and the capillary temperature to 250°C. Data acquisition was 
performed in data-dependent mode . Precursor ion scan acquired data at 70.000 resolution with an 
AGC target of 3E06 and an injection time of 20 ms. Top10 ion spectra were selected for fragmentation 
with an isolation window of 2 m/z and fragmented by HCD (higher energy collisional dissociation) 
with a normalized collision energy of 25. MS2 spectra were acquired at 17.500 resolution with an AGC 
target value of 1E05 ions and 120 ms injection time. Dynamic exclusion was enabled at 20 sec time 
window.    
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2.3.7.4 Raw Data Analysis 
Raw data analysis was performed by our collaboration partner Eva Keilhauer: RAW data files were 
searched against the UniProtKB human proteome database (Swissprot May 2013) and a database 
containing frequently detected contaminants, using the MaxQuant software (282) (vers. 1.3.9.20). 
Two missed cleavages and a protein false discovery rate of 1 % were set as analysis parameters. 
Carbamidomethylation of cysteine residues was defined as fixed modification and methionine 
oxidation and N-terminal acetylation as variable modifications. Label-free quantification (LFQ) was set 
to a minimum ratio count of 1 and Raw files of the same baits were analyzed using the 
match-between-runs option. 
 
 
2.3.8 Chromatin Immunoprecipitation (ChIP) of Crosslinked & Sonicated HK Cells 
2.3.8.1 Fixation of HK Cells 
HK cells were harvested, counted and cross-linked for 10 min at RT in 12.5 ml DMEM + 
1% formaldehyde (methanol free (Thermo Fisher Scientific) at a density of 2 x 10
6
 cells/ml (results in 
2.5 x 10
7
 cells per fixation reaction). The reaction was stopped by adding glycine to a final 
concentration of 0.125 M. After incubating the mixture 5 min at RT, the cells were pelleted by a 5 min 
centrifugation step at 1600 rcf. Now the cells were washed twice with 10 ml PBS + 10% fetal calf 
serum (FCS) and flash frozen in liquid nitrogen. The fixed cells were stored at -80°C.  
 
2.3.8.2 Chromatin Shearing 
The cross-linked HK cells were thawed on ice and resuspended in 5 ml lysis buffer 1 (LB 1). All the 
following steps were conducted on ice or at 4 °C. The samples were rotated for 10 min and 
centrifuged for 5 min at 1350 rcf. Afterwards the cell pellets were resuspended and incubated for 
10 min in LB 2 before pelleting the nuclei by a 5 min centrifugation at 1350 rcf. Now 1 ml buffer B was 
added and the samples were sheared for 35 min using a Covaris S220 (PP 120; DF 20, CB 200) in 1 ml 
12x12 tubes with AFA fiber) to obtain chromatin fragments of 150 bp in average. After chromatin 
shearing, the samples were transferred into low binding tubes and centrifuged for 1 min at 20000 rcf. 
The soluble chromatin containing supernatant was again transferred into a new low binding tube and 
diluted to 2.5 x 10
6
 cells/ml by the addition of 9 ml buffer A. This mixture was now divided into 1 ml 
aliquots and subjected to immunoprecipitation (see 2.3.8.3). 
Lysis buffer 1 (LB 1):  50 mM Hepes KOH, pH 7.5 
   140 mM NaCl 
   1 mM EDTA 
   10% glycerol 
0.5% NP-40 
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0.25% Triton X-100 
prior to use:  1 x CPI 
Lysis buffer 2 (LB 2):  10 mM Tris-HCl, pH 8.0 
   200 mM NaCl 
   1 mM EDTA 
   0.5 mM EGTA 
prior to use:  1 x CPI 
Buffer B:   50 mM Tris-HCl, pH 8.0 
   10 mM EDTA 
   0.5% SDS 
prior to use:  1 x CPI 
Buffer A:   10 mM Tris-HCl, pH 7.5 
   1 mM EDTA 
   0.5 mM EGTA 
   1% Triton x-200 
0.1% SDS  
0.1% Na-deoxycholate 
140 mM NaCl 
prior to use:  1 x CPI 
 
2.3.8.3 Chromatin Immunoprecipitation of Sheared Chromatin 
First 30 µl of Dynabeads M-280 sheep anti rabbit IgG were washed twice in 500 µl PBS + 0.1% 
Tween20 in low binding tubes. After washing, 5 µg GFP antibody was coupled to the beads for at least 
2 hours in 500 µl PBS + 0.1% Tween20 while rotating at 4°C. Additionally, one mock sample was 
prepared without the addition of antibody. The beads were then washed twice with PBS + 0.1% 
Tween20 and 1 ml of sheared chromatin (see 2.3.8.2) was added to the pre-coupled beads. Now the 
beads were incubated over night at 4°C while rotating at 7 rpm. The next day 50 µl supernatant of the 
mock sample was saved as input and the beads were washed four times with 900 µl buffer A and one 
time buffer C, each time rotating the samples for 10 min. Subsequently 100 µl elution buffer was 
added to the beads and incubated at 65°C over night to elute and reverse crosslink the 
immunoprecipitated material. The following day the supernatant was transferred into a new tube and 
100 µl TE and 4 µl RNase A (10 mg/ml DNase-free) was added and the reactions were incubated at 
37°C for 1 hour. Afterwards 4 µl Proteinase K (10 mg/ml DNase-free) was added and the samples 
were incubated for 2 hours at 56°C. Finally, the DNA was purified with the MinElute PCR purification 
Kit (Qiagen). The DNA was eluted in 30 µl elution buffer and DNA size was analyzed on a 1000 DNA 
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BioAnalyzer chip (Agilent). Additionally the DNA concentration was measured with the Qubit Assay 
(life technologies). 
Buffer C:   10 mM Tris-HCl, pH 8.0 
10 mM EDTA 
Elution buffer:    50 mM Tris-HCl, pH 8.0 
 10 mM EDTA 
   1% SDS 
 
2.3.8.4 Library Preparation 
Illumina sequencing libraries were prepared according to the manufacturer s protocol (MicroPlex 
Library Preparation kit v2, Diagenode) with the following variations. 10 ng of purified DNA was 
subjected to library preparation. The number of amplification cycles was adjusted until a 
concentration of 5 ng/µl of the library was obtained. After library purification, the DNA was eluted in 
20 µl 0.1 x TE and analyzed on a 1000 DNA BioAnalyzer chip (Agilent). 10 µl of the purified library DNA 
were sent for Illumina sequencing. 
 
 
2.3.9 Illumina Sequencing  
Next-generation sequencing was performed at the Laboratory of Functional Genome Analysis 
(LAFUGA) in the Gene Center (Munich) by Dr. Stefan Krebs. Libraries were sequenced on an Illumina 
HiSeq 2000 using V3 clustering and sequencing reagents (50 bp read length, single end) according to 
the manufacturer s instructions.  
 
 
 
2.4 CELL BIOLOGICAL METHODS 
2.4.1 Maintenance of Human HK & Mesenchymal Stem Cell Lines 
HK wildtype cells were cultivated in Dulbecco s modified Eagle medium (DMEM) plus 10% FCS and 1% 
penicillin/streptomycin (P/S) at 37°C and 5% CO2. Transfected HK cells and stable HK cell lines were 
kept in DMEM plus FCS, P/S and G418-sulfate at a concentration of 600 µg/ml. Normally, cells were 
kept in 10 cm dishes with 10 ml growth medium until they reached confluency. In this case, old 
medium was removed, cells were washed with sterile PBS to remove the remaining medium and 
incubated for 5 min at 37°C with 1 ml Trypsin/EDTA (diluted 1:10 in PBS). Subsequently, cells were 
detached by resuspending them in 9 ml medium. 1 ml of this cell suspension was then further 
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cultivated (corresponds to the usual splitting ratio of 1:10) and the rest was either discarded or 
transferred to 15 cm dishes to expand the cells for further experiments. For storage, cells were frozen 
at regular intervals. To do so, trypsinized cells were resuspended in FCS + 10% DMSO. Usually, 1 x10
7
 
cells were resuspended in 3 ml FCS + 10% DMSO and separated into three 1 ml aliquots, transferred 
to cryovials and frozen at -80°C. For long term storage, cells were relocated to liquid nitrogen. In the 
case of thawing, the frozen cells were put into a 37°C waterbath for quick melting, transferred to a 
10 cm dish and 9 ml DMEM + FCS + P/S was added.  
Mesenchymal stem cells were cultured by our collaboration partner Erwan Delbarre (University of 
Oslo) in GlutaMAX
 
(Gibco) containing 20% FCS (272). Cells were passaged 1:3 and passages 5-15 used 
for transfection (see 2.4.3 and (272)).  
 
 
2.4.2 Generation of Stable eGFP-H3.Y Mutant HK Cell Lines 
To establish HK cell lines stably expressing eGFP-tagged histone proteins, 4 x 10
5
 cells were seeded 
into 6-well plates. The following day, the cells should have reached a confluency of approximately 
90%. 1 µg plasmid DNA was mixed with 100 µl Opti-MEM before adding 3 µl X-tremeGENE 
transfection reagent. Additionally, one negative control HK sample that was not transfected was set 
up. All plasmids were transfected in triplicates. The reaction mixture was incubated for 15 – 30 min at 
RT and then drop-wise added to the cells. The plates were mildly shaken to distribute the transfection 
mix into the cell medium. Cells were then incubated for 48 hours before analyzing the transfection 
efficiency by flow cytometry (see 2.4.5) and transferring them to cell plates of 10 cm diameter. 12-24 
hours after the transfer cells were subjected to selection medium containing 600 µg/ml G418-sulfate 
until the non-transfected control cells were dead. The transfected surviving cells were again analyzed 
by flow cytometry when they reached again a confluency of at least ca. 50%. Stable cell lines 
containing 50-100% green cells (except the eGFP-Y-C3 cell line, see Figure 24) were used for further 
experiments.  
 
 
2.4.3 Transfection of Human Mesenchymal Stem Cells 
Cells were transfected by our collaboration partner Erwan Delbarre as described in (272). 
 
 
2.4.4 Immunofluorescence (IF) of HK Cells & Mesenchymal Stem Cells 
2.4.4.1 IF Staining 
1 x 10
5 
 HK cells were seeded onto a round coverslip with a diameter of 12mm in a 24-well plate. The 
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next day, cells were washed with 400 µl PBS and fixed for 15 min at RT with 400 µl 1% formaldehyde 
in PBS. After fixation, cells were washed with 400 µl PBS + 0.1% Triton X-100 (PBS-Tr). Now, cells were 
blocked in 400 µl PBS-Tr+ 1% BSA (PBS-Tr-B) for at least 20 min at RT before incubating them for at 
least 30 min at RT with the primary antibody in 100 – 200 µl PBS-Tr-B while slowly shaking. The cells 
were then washed three times with 400 µl PBS-Tr for 5 min each and incubated with the secondary 
antibody in 100 – 200 µl PBS-Tr-B for 30 min. Again, the cells were washed three times with 400 µl 
PBS-Tr. Afterwards, the DNA was stained with 200 µl DAPI (200 ng/ml) in PBS for 5 min. Subsequently, 
cells were washed once with 400 µl PBS, the coverslips were dipped into ddH2O and mounted using 
Vectashield mounting medium (Vector laboratories).  
Mesenchymal stem cells were prepared for immunofluorescence by our collaboration partner Erwan 
Delbarre according to (272). 
 
2.4.4.2 Preparation of Metaphase Chromosome Spreads 
A 10 cm cell culture plate 100 % confluent with HK cells expressing eGFP-tagged H3 variants were 
transferred onto a 15 cm cell culture dish and incubated over night with DMEM + Nocodazole 
(200 ng/ml). The following day metaphase-arrested cells were harvested by mitotic shake off and 
diluted to a concentration of 800.000 cells/ml. For lysis 3 volumes of prewarmed RBS buffer was 
added and incubated for 15 min at 37°C. After 15 min cells were transferred on ice and the slides 
were prepared for cytospinning. 100 µl cell suspension were spread on microscope slides by the 
Shandon cytospin 4 for 10 min at 2000 rpm with low acceleration. After centrifugation cells were 
fixed for 10 min with 50 µl 2% formaldehyde in PBS. Now the cells were washed twice for 5 min with 
KCM + 0.1% Triton X-100. Metaphase chromosomes were then extracted with KCM + 0.1% Tween + 
0.5% Triton X-100 (20 min incubation) and washed with KCM + 0.1% Tween20. Now, DNA was stained 
with DAPI (400 ng/ml) for 5 min. Afterwards slides were washed with PBS and mounted with 
Vectashield mounting medium (Vector laboratories). Chromosome spreads were analyzed by confocal 
imaging (see 2.4.4.3).  
RBS buffer:  10 mM Tris-HCl, pH 7.5 
10 mM NaCl 
5 mM MgCl2 
KCM buffer:  120 mM KCl 
   20 mM NaCl 
   10 mM Tris pH 8.0 
   0.5 mM EDTA 
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2.4.4.3 IF Microscopy 
Fixed HK cells on coverslips were analyzed with the Zeiss Axiovert 200 epifluorescence microscope 
LSM200 and pictures were taken with a CDD camera (AxioCamMR, Zeiss). Images were edited in 
Adobe Photoshop CS5 and Adobe Illustrator CS5.  
Mesenchymal stem cells were analyzed by our collaborator Erwan Delbarre (272). 
Metaphase chromosome spreads were analyzed and recorded on the confocal microscope Leica SP5 
II. For the Confocal images the Argon laser (488 nm) for GFP and the UV-diode (405 nm) for DAPI was 
used. Further settings are summarized below:  
Laserlines    Argon (488 nm, 15%); UV-diode (405 nm, 100%) 
Acousto-optical tunable filters (AOTF) 488 nm: 25%; 405 nm: 10% 
Photomultiplier tubes (PMTs)  PMT1: DAPI 415-470 nm; PMT2: GFP: 498 – 570 nm 
Frame averaging    4 frames per channel 
Objective    PL APO CS 63x 1.3 Gly 21°C UV  
Pinhole     default 
Scanning speed    400 Hz 
Image depth     16 bit 
Image size    1024 x 1024 pixel 
Zoom     6x 
Pixel size    40 x 40 nm 
 
 
2.4.5 Flow Cytometry Analysis of Transfected Human Cell Lines 
Flow cytometry analysis was performed with the FACSCanto machine (BDI Biosciences), the FACS Diva 
software and FlowJo (8.8.7). HK cells were harvested and 200 – 1000 µl of the cell suspension were 
subjected to flow cytometry analysis. First, forward (FSC) and sideward scatter (SSC) were applied to 
gate for living single cells. GFP fluorescence was then visualized by a histogram.  
 
 
2.4.6 Preparation of Chromatin-free Extracts 
HK cells were seeded onto 5 cell culture plates (or 10 in the case of Y-C3) with a diameter of 15 cm to 
reach a confluence of approximately 90-100%. Cells were harvested, centrifuged 5 min at 400 rcf, 
washed twice with PBS and incubated on ice for 10 min in five volumes buffer A. All following steps 
were carried out on ice or at 4°C. After incubation, cells were centrifuged for 5 min. Due to the 
osmotic uptake of liquid, cell volume increased. Now the cells were resuspended in 2 volumes of 
buffer A + 0.2% NP-40 + CPI and transferred to a Dounce homogenizer. Cells were lysed with 30 – 40 
strokes with a type B pestle and centrifuged for 15 min at 3550 rcf. The supernatant contains the 
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cytoplasmic extract and was removed; the nuclear pellet was washed twice with 10 volumes PBS, 
transferred into a 1.5 ml reaction tube suitable for ultracentrifugation and incubated in 500 µl buffer 
C for 1 hour. The nuclear suspension was then ultracentrifuged for 1 hour at 186 000 rcf. The 
supernatant contains the chromatin-free extract and was flash frozen in liquid nitrogen and stored at 
-80°C. Small aliquots from 1-10 µl were used for the determination of the total protein concentration 
by Bradford protein assay according to manufacturer s protocol (Biorad).  
Buffer A:   10 mM Hepes KOH, pH 7.9 
1.5 mM MgCl2 
10 mM KCl 
Buffer C:  420 mM NaCl 
20 mM Hepes KOH pH 7.9 
20% glycerol 
2 mM MgCl2 
0.2 mM EDTA 
prior to use:   0.1% NP-40 
CPI 
0.5mM DTT 
 
 
2.4.7 Immunoprecipitation of eGFP-H3 Variants in Chromatin-Free Extracts 
400 – 1500 µg of total protein of nuclear extracts according to the eGFP expression determined by 
flow cytometry analysis (see 2.4.5) was subjected to immunoprecipitation. Nuclear extracts were 
diluted with buffer C to obtain the same concentration of all extracts utilized in the experiment and 
with dilution buffer to reach a final NaCl concentration of 210 mM. After GFP-trap_M equilibration 
(three times with equilibration buffer), diluted nuclear extracts were added to the beads and 
incubated for 2 hours at 4°C.  After the incubation, beads were magnetically separated from the 
supernatant (referred to as nonbound and stored for further immunoblot analysis) and washed 5 
times with wash buffer. Finally, samples were boiled 10 min in 20 µl 2x SDS loading buffer and 
subjected to immunoblot analysis (see 2.3.1 and 2.3.3). 20 µg chromatin-free extracts were boiled in 
SDS loading buffer and used as input. 
Dilution buffer:   50 mM Tris HCl, pH 7.5 
prior to use:   CPI 
   0.01% NP-40 
0.5 mM DTT 
Equilibration buffer: mix dilution buffer and buffer C (see 2.4.6) in a 1:1 ratio 
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Wash buffer:   50 mM Tris HCl, pH 7.5 
   150 mM NaCl 
prior to use:  CPI 
   0.01% NP-40 
   0.5 mM DTT 
 
 
 
2.5 BIOINFORMATICS 
2.5.1 MNase-IP-qMS Analysis 
MNase-IP-qMS analysis was performed by our collaborator Eva Keilhauer. Protein intensities obtained 
by the software suite MaxQuant of 3 biological replicates were extracted, merged by protein name 
and analyzed in Perseus (283, 284) (vers. 1.5.3.0). Proteins detected in a single replicate were 
eliminated as well as hits to the reverse database, contaminants, proteins with one or less razor. 
Unique peptides and single peptide identifications present in at least 1 triplicate were included. LFQ 
intensities were normalized to the peptide count and log2-transformed. Missing values in the data 
matrix were assigned to values representing a normal distribution close to the detection limit of the 
mass spectrometer. Protein abundances in the 12 histone pulldowns were averaged, and the 
significance of their fold-changes (FC) to the 3 eGFP control was assessed by a two-sample t-test. 
Protein identifications were identified as true if their enrichment to the negative control was at least 
two-fold. Subsequent t-tests were performed using the filtered databases comparing H3.2 vs. H3.1, 
H3.3 vs. H3.1, H3.Y vs. H3.1, and H3.Y vs. H3.3. Significant outliers were dissected by permutation-
based FDR. Number of permutations was set to 250 and S0, FDR parameters were modified for each 
experiment. Respective p-values were plotted against their t-test differences in volcano plots using R 
(vers. 2.15.3). Also, the average ratios of interactor to bait intensities were calculated and displayed 
by a heatmap. Therefore, the log-FC of averaged LFQ intensities from triplicates of histone H3 
mononucleosome pull-downs were plotted using Perseus and displayed by a color scale. 
 
 
2.5.2 ChIP-seq Analysis 
ChIP-seq analysis was executed by our collaborator Marek Bartkuhn (JLU Gießen).  
First, quality control of FASTQ files was done without additional trimming or filtering using fastqc 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Additional publicly available ChIP-seq 
data were downloaded from NCBI s Gene Expression Omnibus (GEO). Raw reads were downloaded as 
SRA archives and were extracted into FASTQ files using the fastq-dump program of the NCBI SRA 
Toolkit (https://trace.ncbi.nlm.nih.gov/Traces/sra/).  
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Publicly available data used in this study:  H3K9me3 ChIP-seq data from HeLa cells (sample 
GSM2308949 from GSE86811) and H3K4me3 ChIP-seq coverage data from HeLa cells (ENCODE data 
downloaded trough the UCSC genome browser portal 
(http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeBroadHistone/wgEncodeB
roadHistoneHelas3H3k4me3StdSig.bigWig)).  
Reads were aligned with Bowtie 2 (285) as previously described (286). Parameter settings were 
bowtie2-align -p 6 -D 15 -R 2 -N 0 -L 32 -i S,1,0.75 -M 10000. Repeat information was downloaded 
through the hg19 table browser of the UCSC genome browser. Peaks were called using MACS version 
2 (287) with default settings. If not indicated differently, all downstream analyses were done in 
R/BioConductor (288). Neighboring peaks were stitched together when lying within 2 kb. When 
available, the overlap between two replicates was then selected as the actual set of binding sites for 
downstream analysis. Hg19 RefSeq annotations were downloaded from Illumina s iGenome 
repository. In order to identify H3.3 sites bound differentially for H3.Y, extended reads (200 bp) were 
counted across these intervals. DESeq2 was used for normalization of read counts as well as for 
inference of regions with relevant binding differences between H3.3 and H3.Y (289). DESeq2-
normalized read counts were further normalized for peak width and then used in order to visualize 
differential binding efficiencies between individual H3.Y-mutants. Observed differences were 
statistically tested with Wilcoxon-signed-rank test. De novo discovery of enriched motifs within sites 
with reduced H3.Y binding was done with MEME-ChIP (290). Coverage vectors were produced using 
deepTools bamCoverage function. Similarly, deepTools was used for the representation of ChIP-seq 
coverage across peak intervals as heat maps (291). Bigwig files were used for visualization via the 
R/BioC-package Gviz (292).  
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3 RESULTS 
3.1 H3.Y ONLY INTERACTS WITH THE HIRA COMPLEX BUT NOT 
DAXX/ATRX 
Although sharing the same chaperone recognition site (see alignment Figure 4), only H3.3, 
but not H3.Y, was able to interact with DAXX (Figure 6). As the results obtained in the SILAC 
approach previously performed by Hans Christian Eberl (group of Matthias Mann, MPI 
Munich) and Clemens Boenisch (former PhD student in the Hake group) were surprising in 
regard to DAXX interaction, they should first be confirmed. To verify this result soluble 
nuclear proteins were extracted from HeLa Kyoto cell lines stably expressing eGFP as a 
negative control or eGFP-tagged H3.1, H3.3 or H3.Y. eGFP-tagged proteins were precipitated 
with GFP trap_M beads and the interaction with DAXX was analyzed by immunoblot (Figure 
7). The SILAC results could be confirmed: whereas H3.3 was able to bind DAXX, H3.Y was 
not. 
 
 
Figure 7: DAXX interacts with H3.3 but not H3.Y. Soluble nuclear proteins were isolated from stable 
HeLa Kyoto cell lines expressing eGFP-H3 variants in addition to eGFP as a negative control. 
Respective Input was subjected to immunoprecipitations (IP) and analyzed by immunoblotting with a 
DAXX antibody. Anti-GFP antibody served to control for successful precipitation. nb = nonbound 
fraction. 
 
Interestingly, I observed a higher molecular weight of DAXX when bound to H3.3 (Figure 7). 
DAXX is known to be differentially modified. First, the attachment of SUMO (small ubiquitin-
like modifier) is reported to have an effect on DAXX localization, the regulation of 
transcription mediated by DAXX and its recruitment to PML nuclear bodies (293-295). 
Second, DAXX has been shown to be hyperphosphorylated (293, 296-298) with distinct 
outcomes for the diverse roles of DAXX. To complicate the situation a crosstalk between 
different modifications of DAXX exists: phosphorylation of DAXX modulates its function by 
enhancing the association with SUMO and this, in turn, increases DAXX-PML interaction and 
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its localization to PML-NBs (293). Third, DAXX was also reported to be ubiquitinated, 
marking DAXX for proteasomal degradation (299, 300). Finally, poly (ADP-ribose) polymerase 
1 (PARP1) is an enzyme catalyzing poly ADP-ribosylation (301). Since an interaction of DAXX 
and PARP1 was detected in an interactome screen in HeLa cells (302), I speculated whether 
this interaction could result in the poly ADP-ribosylation of DAXX.  
I was wondering whether the higher molecular mass reflects any of these modifications, 
hence I tested this by using specific antibodies against several modifications. GFP-tagged H3 
variants were immunoprecipitated with the GFP-trap_M beads, the IP was split into two 
halves and subjected to immunoblotting with a DAXX antibody on the one hand and the 
modification specific antibodies on the other hand. This way I could directly compare the 
heights of the two bands and conclude whether immunoprecipitated DAXX is modified in 
the H3.3-bound fraction (Figure 8).  
 
 
 
Figure 8: DAXX is neither sumoylated (SUMO), polyadenoribosylated (PAR), nor ubiquitinated. 
Stable HeLa Kyoto cell lines expressing GFP-tagged H3 variants were employed for isolation of soluble 
nuclear proteins (Input). These were subjected to immunoprecipitation (IP) via the GFP-tag of H3 
variants and immunoblotting using DAXX- and indicated modification-specific antibodies. The IP was 
split into two halves to directly compare the DAXX band and the potential band of the different 
modification antibodies. On the left, H3.1 immunoprecipitations were used as a negative control. Nb 
= non-bound fraction after immunoprecipitation. 
 
H3.3-bound DAXX did not seem to be sumoylated, polyadenoribosylated or ubiquitinated. 
Bands for these modifications occurred in H3 variant pulldowns but they were neither H3.3-
specific nor did they show the same molecular weight than DAXX. Additionally, a potential 
hyperphosphorylation of DAXX was analyzed by treating the immunoprecipitated material 
ith -phosphatase. Unfortunately, this did not show a clear result. It is therefore still 
possible, that phosphorylation corresponds to the shift in the DAXX band.  
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As mentioned earlier, the intermediate localization of H3.3 to PML-NBs prior to deposition 
into chromatin is DAXX-dependent (272). Since H3.Y does not interact with DAXX, no 
localization of H3.Y to PML-NBs is expected. In order to further confirm our obtained results, 
a collaborative work with Erwan Delbarre from the group of Philippe Collas at the University 
of Oslo was set up. Mesenchymal stem cells were transiently transfected with H3.3-GFP or 
eGFP-H3.Y and PML body localization was analyzed 24h after transfection (Figure 9).  
 
Figure 9: eGFP-H3.Y does not localize to PML nuclear bodies. (A) Human primary mesenchymal stem 
cells were transiently transfected with H3.3-GFP or eGFP-H3.Y, respectively and analyzed for PML 
body recruitment. DNA is stained with DAPI (left panel), GFP-tagged H3 variants are shown in green 
(second left panel) and PML-NBs are visualized with a commercially available antibody (red, second 
right panel). Scale bar is 5 µm. (B) >100 cells were quantified regarding H3.3 s or H3.Y s localization to 
PML-NBs (gray) or not (black). 
 
While H3.3-GFP was recruited to PML-NBs, H3.Y was depleted from PML structures and only 
localized to chromatin, again confirming that H3.Y does not interact with DAXX and is 
therefore not found in PML-NBs. 
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3.2 H3.Y NUCLEOSOMES ARE DEPLETED FROM H3K9ME3 ENRICHED 
SIMPLE REPEAT SITES 
The HIRA chaperone complex was described to be responsible for the deposition at open 
chromatin sites like transcribed genes and sites of DNA repair (190, 191, 261, 266). 
DAXX/ATRX on the other hand deposits H3.3 at heterochromatic sites like telomeres and 
pericentric heterochromatin (190, 198, 222, 267, 268). Since H3.Y only interacts with the 
HIRA complex but not with DAXX/ATRX I was wondering whether this impacts H3.Y 
localization in chromatin. In order to investigate the chromatin localization of H3.3- and 
H3.Y-containing nucleosomes, stably expressing eGFP (as a negative control), eGFP-H3.3, 
and -H3.Y HeLa Kyoto cell lines were employed for a genome-wide chromatin 
immunoprecipitation combined with high-throughput sequencing (ChIP-seq) analysis of two 
independent biological replicates. To do so, cells were fixed with formaldehyde and 
chromatin mechanically sheared into 150 bp fragments on average. Using a GFP-antibody, 
fragments were immunoprecipitated. Input DNA and immunoprecipitated DNA were 
purified and subjected to sequencing libraries preparation. Illumina sequencing was carried 
out by the LAFUGA lab at the Gene Center Munich and bioinformatic analyses performed by 
Marek Bartkuhn (JLU Giessen).  
To first test the feasibility of our method we analyzed the co-localization of H3.3 and H3.Y 
with H3K4me3. H3K4me3 serves as a mark for euchromatin and is found at the promoters of 
active genes (303, 304). Since H3.3 and H3.Y are both deposited by the HIRA complex we 
were wondering whether this interaction is also reflected by the presence at open 
chromatin and thus co-localization with H3K4me3. Indeed, both, H3.3 and H3.Y were 
enriched at genic regions, especially at the TSS and underrepresented at intergenic regions 
(Figure 10A). Moreover, H3.3 and H3.Y shared the majority of peaks (Figure 10B). 
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Figure 10: Both H3.3 and H3.Y mainly localize to genic, euchromatic H3K4me3-positive sites in the 
human genome. (A) Annotation of H3.3, H3.Y and HK4me3 to different genomic regions compared to 
the total human genome obtained by ChIP-seq. Data for H3K4me3 downloaded from ENCODE. (B) 
Venn diagram illustrating the overlap of H3.3, H3.Y and H3K4me3 peaks. Depicted are the numbers of 
peaks. Most peaks overlap, indicating H3.3 s and H3.Y s presence at euchromatic sites.  
 
Correspondingly to the presence of the active PTM H3K4me3, H3K9me3 as a 
heterochromatic mark was absent from H3.3 and H3.Y enriched sites (Figure 11). These 
results, so far, suggested that most of H3.3 is incorporated by the HIRA complex. To identify 
DAXX/ATRX deposition sites we were searching for regions where only H3.3 but not H3.Y is 
localized and called them H3.Y-reduced sites  (Figure 11B).  
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Figure 11: H3.Y and most of H3.3 are depleted from H3K9me3-positive sites. (A) ChIP-seq density 
heatmap of peaks identified in H3.3 replicate 1, correlated to H3.3 replicate 2, both H3.Y replicates 
and H3K9me3 (H3K9me3 data from (305)). Color intensity represents normalized and globally scaled 
tag counts. (B) Snapshot from Genome browser of a representative region on chromosome 16 
depicting eGFP (gray) as a negative control, H3.3 (blue) and H3.Y (green) in two replicates, H3K4me3 
(black) and H3K9me3 (ruby). Annotated gene features are shown above. Blue boxes illustrate 
assigned peaks by MACS 2 peak calling method. H3.Y-reduced site  refers to sites in the genome 
where only H3.3 but not H3.Y is present, whereas shared site  describes sites where both, H3.3 and 
H3.Y, are enriched.  
 
In total we found 359 (at fold change <2 and adjusted p-value <0.05) of these H3.Y-reduced 
sites that were overlapping with H3K9me3 (Figure 12).  
 
Figure 12: H3.Y-reduced sites are enriched with H3K9me3. (A) ChIP-seq density heat map of H3.3 
H3.Y-reduced sites (replicate 1 and 2), H3.Y (in both replicates) correlated to H3K9me3. Color 
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intensity represents normalized and globally scaled tag counts. (B) Boxplot illustrating H3K9me3 
enrichment at H3.Y-reduced sites or all H3.3 sites. RPK = reads per kilobase. 
 
Recent studies in mESCs demonstrated a correlation between DAXX/ATRX-dependent 
incorporation of H3.3 and H3K9me3 at repetitive elements like telomeres or endogenous 
retroviral elements (197, 198, 222). In humans, however, a connection between DAXX/ATRX 
and repetitive sequences is so far unknown. To investigate whether H3.Y-reduced sites 
reflect potential DAXX/ATRX deposition sites that are enriched in repetitive sequences also 
in humans we screened the 359 identified H3.Y-reduced sites for de novo DNA motifs. In 
addition, an enrichment profile for repeat types that overlapped with H3.Y-reduced sites 
was established. Here repeat sequences were ranked according to the observed/expected 
ratio. Different de novo motifs, as well as simple repeat sequences, were identified (Figure 
13).  
 
Figure 13: De novo motif search revealed new H3.3 binding sites. (A) H3.Y-reduced sites were 
analyzed with the MEME tool (http://meme-suite.org/tools/meme) and (B) checked for repeat 
sequences included in the UCSC RepeatMasker from hg19 (log2 fold change < 2 and adjusted p-value 
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< 0.05). Repeats were ranked according to the observed/expected ratio. Simple repeats are 
highlighted in red. 
 
Notably, guanosines and thymidines and GT repeats were enriched in both, the newly 
identified motifs and in the top hits of the repeats. Among the top 20 repeats were 12 
simple repeats (Figure 13B, marked in red). 
All in all, we could show that H3.3 and H3.Y were mainly found in euchromatic sites, likely as 
a result of HIRA-mediated deposition. H3.Y-reduced H3.3 incorporation sites were enriched 
in simple repeat sequences and might accordingly represent DAXX/ATRX deposition sites.  
 
 
 
3.3 CHROMATIN INTERACTOME OF H3.Y-CONTAINING NUCLEOSOMES 
Since H3.Y indeed associated with active chromatin and was depleted from 
heterochromatic, repetitive sequences, I wondered whether this feature is also reflected by 
differential interaction partners of H3.3- or H3.Y-containing mononucleosomes. Considering 
H3.Y s localization to H3K4me3-positive, likely euchromatic sites (see Figure 10), it is 
tempting to speculate that H3.Y is enriched in interaction partners that are associated with 
active chromatin and depleted in interaction partners, that are linked to repressive 
chromatin states. To test this hypothesis, nuclei from different stable HeLa Kyoto cells lines 
expressing eGFP-tagged H3.1, H3.2, H3.3, H3.Y and eGFP as a negative control were isolated, 
and chromatin was digested with MNase in triplicates (see Figure 14). 
 
Figure 14: Schematic overview of isolation of mononucleosomes. Nuclei isolated from different HeLa 
Kyoto cell lines stably expressing eGFP-tagged H3.1, H3.2, H3.3 or H3.Y and eGFP as a negative control 
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were isolated and subjected to MNase digestion. The resulting mononucleosomes were 
immunoprecipitated using GFP-trap_M beads. The immunoprecipitated material was then analyzed 
by label-free quantitative mass spectrometry. 
 
Chromatin that was digested to almost 100% mononucleosome purity (Figure 15A) was used 
for immunoprecipitation. Mononucleosomes containing eGFP-tagged H3 variants and bound 
complexes were precipitated with GFP trap_M beads and afterwards subjected to on-bead-
tryptic digestion. Our collaborator Eva Keilhauer, a PhD student from the group of Matthias 
Mann, analyzed the samples by label-free quantitative mass spectrometry: Precipitated 
peptides were identified and quantified using MaxQuant software version 1.3.9.20 (306, 
307). Further analysis was performed with Perseus software, version 1.5.3.0. First, specific 
H3 variant binders were determined by comparing H3 variant pulldowns to GFP pulldowns 
(see Figure A.1 in appendix). Next, two sample t-tests comparing eGFP-H3.1 with eGFP-H3.2, 
eGFP-H3.3 or eGFP-H3.Y, as well as comparing eGFP-H3.3 with eGFP-H3.Y provided p-values 
and t-test differences which were subsequently plotted against each other in volcano plots 
using R 2.15.3. This way the nucleosome interactome of the different H3 variants could be 
compared and the distinct binding partners were analyzed (Figure 15B-E). First, the 
interacting proteins of the canonical variant H3.1 on the left were plotted against the 
interacting proteins of H3.2 on the right (Figure 15B). Only minor differences in the 
interactome could be detected.  
Comparison of the eGFP-H3.1 and the -H3.3 interactome, revealed more differences (Figure 
15C): whereas the canonical variant H3.1 on the left showed enrichment of known 
chaperone complex members CAF1A and CAF1B, H3.3 on the right was enriched in DAXX 
and H3.3, suggesting homotypic nucleosomes, that contain only H3.3 and no other H3 
variant. 
The biggest difference in enriched interacting proteins, however, was observed between 
eGFP-H3.1 and -H3.Y (Figure 15D). The H3.1 nucleosome interactome (Figure 15D, left) 
contained members of the CAF1 complex, CAF1A and -B (shown in light green) and of the 
PRC1 complex (displayed in orange) like Chromobox protein homolog 8 (CBX8), E3 ubiquitin-
protein ligase RING2 (RNF2) and RING1, Polyhomeotic-like protein 2 and 3 (PHC2 and PHC3) 
and Polycomb Ring Finger BMI1. In addition, H3.1 nucleosomes were enriched in SUV39H 
(suppressor of variegation 3-9) proteins (shown in pink), which are responsible for setting 
the trimethylation on lysine 9 of histone H3 (308, 309), a well-established mark for 
heterochromatin. Moreover, H3.1 nucleosomes also pulled down all HP1 proteins, 
Chromobox protein homolog 1, 3 and 5 (CBX1, 3 and 5, shown in blue), which are known to 
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recognize trimethylated H3K9 and are implicated in further repression of chromatin (310, 
311). While H3.1-containing nucleosomes precipitated members of heterochromatin-
associated complexes, H3.Y (Figure 15D, right) was enriched in FACT complex members that 
have been implicated in chromatin recovery during transcription (312) and DAXX.  
While H3.3 and H3.Y shared most of their deposition sites (Figure 10), they revealed 
differences in their associated proteins (Figure 15E). H3.3 nucleosomes specifically 
interacted with CAF1B (light green), members of the PRC1 complex (PHC3 and BMI1 in 
orange) and all HP1 proteins CBX1, 3 and 5 (shown in blue), whereas H3.Y nucleosomes 
(Figure 15E, right) were associated with FACT complex members FACT140 and FACT80 
(Figure 15E, left, petrol blue).  
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Figure 15: Nucleosome interactome of different H3 variants. Chromatin from different HeLa Kyoto 
cell lines stably expressing eGFP or eGFP-tagged H3 variants was successfully digested to 
mononucleosomes. (A) The agarose gel indicates a DNA size of 150 bp that reflects the corresponding 
DNA size of mononucleosomes. (B-E) Volcano plots visualize the specific enrichment of different H3 
variant interactors. After performing two sample t-tests, obtained p-values and t-test differences 
were plotted against each other in volcano plots using R. Permutation-based FDR cutoff was applied 
to identify specifically enriched candidate proteins, indicated with colored dots in green and blue, 
respectively. Interesting candidates were written in enlarged, colored letters. PRC1 complex members 
are shown in orange, CAF1 complex members in light green, SUV39H members in pink, CBX1 proteins 
in blue, DAXX in red, H3.3 in mint green and FACT complex members in petrol blue.  
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In conclusion, all H3 variant-containing nucleosomes except H3.Y demonstrated an 
enrichment in heterochromatic proteins such as members of the PRC1 complex, SUV39H 
proteins and HP1. In contrast, H3.Y mononucleosomes were enriched in the transcription 
associated FACT complex.  
To illustrate the enrichment of interesting candidate proteins, a heatmap was created using 
Perseus showing log2-fold changes of various interaction partners immunoprecipitated with 
H3 variant mononucleosomes (Figure 16A). Since SUV39H1 and 2 are responsible for the 
trimethylation of lysine 9 on histone H3 (308, 309) I wondered whether the depletion on 
H3.Y nucleosomes is also reflected by reduced levels of H3K9me3. To test this hypothesis, I 
isolated chromatin from HeLa Kyoto cells stably expressing eGFP and eGFP-H3.1, -H3.3 
and -H3.Y and performed an MNase digest. Resulting eGFP-H3 variant-containing 
mononucleosomes were immunoprecipitated with GFP-trap_M, followed by 
immunoblotting using a commercially available H3K9me3 antibody (Figure 16B).  
 
 
 
Figure 16: Enrichment of heterochromatic proteins on H3 variant-containing nucleosomes is also 
reflected by distinct H3K9me3 levels. (A) Heatmap visualizing enrichment of different candidate 
proteins for distinct H3 variant-containing nucleosomes (see Figure 15B-E). H3.1- and H3.2-containing 
nucleosomes are highly enriched in CAF1A and B. Besides, both the canonical variants H3.1 and H3.2 
and the replacement variant H3.3 are associated with heterochromatic proteins. In contrast, H3.Y 
nucleosomes are enriched in the FACT complex and DAXX. (B) Depletion of SUV39H on H3.Y 
nucleosomes is also reflected in reduced H3K9me3 levels, as seen by immunoblot. 
 
Indeed, a depletion of H3K9me3 could be noticed on immunoprecipitated H3.Y 
nucleosomes, whereas eGFP-H3.1 and -H3.3 revealed similar levels of trimethylated H3K9, 
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again confirming H3.Y s localization to euchromatic HIRA dependent sites (see also Figure 10 
and 11).  
 
 
 
3.4 RESIDUES IN THE H3.Y CORE & C-TERMINUS ARE NECESSARY FOR 
DAXX INTERACTION  
3.4.1 Mutation of the Single Q59E Residue in H3.Y is not Sufficient for DAXX Binding 
Since the structure of the HBD of DAXX together with an H3.3-H4 dimer has been crystalized 
(247, 313), we were able to further examine the interaction of DAXX HBD and H3.3. 
Glutamic acid in H3.3 at position 59 is directly binding DAXX arginine 251 and participates in 
a hydrogen bond network together with H3.3 serine 57 and DAXX tyrosine 222, glutamic 
acid 225, and Lysine 229 (247). As Q59 is replaced in H3.Y by glutamine (see Figure 4) I 
speculated whether this replacement could be responsible for the missing interaction of 
H3.Y and DAXX. To check this hypothesis Sebastian Pünzeler, a former PhD student from our 
lab, generated a stable mutant eGFP-H3.Y cell line called eGFP-H3.Y Q59E where he 
exchanged H3.YQ59 with the corresponding H3.3E59. eGFP expression was determined in 
G418-sulfate selected cells by flow cytometry analysis (Figure 17A). To confirm the nuclear 
localization of the H3.Y Q59E mutant and to exclude the possibility of a localization or 
incorporation defect into chromatin, I analyzed these HeLa Kyoto cells expressing eGFP-H3.Y 
Q59E by immunofluorescence. The cells showed nuclear localization in interphase cells as 
well as localization to condensed chromatin indicated by co-localization with H3S10 
phosphorylation signal (Figure 17B). Phosphorylation of H3 serine 10 is a posttranslational 
modification that occurs during mitosis and indicates condensed chromatin (116, 118). Since 
most chromatin components that are not stably associated, dissociate from condensed 
chromatin during mitosis co-staining with H3S10 phosphorylation serves as an indicator for 
stable chromatin incorporation.  
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Figure 17: All H3 variant cell lines reveal stable GFP expression and are stably incorporated into 
chromatin. (A) Flow cytometry analysis of stable HeLa Kyoto cell lines expressing eGFP (gray 
histogram) or eGFP-H3.1 (light green), -H3.3 (turquoise), -H3.Y (blue) and -H3.Y Q59E (purple). eGFP 
serves as positive control. GFP intensity was detected in the FITC-A channel and plotted in a 
histogram. (B) Immunofluorescence imaging of stable H3 variant cell lines. HeLa Kyoto cells stably 
expressing eGFP-H3 variants and mutant -H3.Y Q59E were fixed; DNA was stained with DAPI (blue, 
left panel), H3 variants are shown in green (GFP, second left panel) and H3S10 phosphorylation was 
probed using a commercially available antibody to visualize mitotic cells (red, second right panel). The 
overlay is depicted on the right. Scale bar: 5 µm.  
 
In addition, all variants including eGFP-H3.Y Q59E were visible on metaphase chromosome 
spreads (Figure 18), suggesting that they are stable parts of the nucleosome core.  
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Figure 18: Chromosomal localization of eGFP-H3 variants. HeLa Kyoto cells stably expressing eGFP-
H3.1 (left), -H3.3 (second left), -H3.Y (second right) and mutant -H3.Y Q59E (right) were metaphase-
arrested and chromosomes spread on microscope slides. The distinct H3 variants appear in different 
patterns along the chromosome. DNA was stained with DAPI (blue, upper panel), eGFP-H3 variants 
shown in green (middle lane) and overlay is depicted in the lower panel. Scale bar is 5 µm. 
 
Whereas eGFP-H3.1 was distributed uniformly along the chromosome, the other variants 
showed a more defined pattern, supporting the barcode hypothesis suggested by (314). 
In order to analyze the importance of the E59 residue in H3.3 for DAXX binding, I again 
isolated soluble nuclear proteins from the different eGFP-H3 variant expressing cell lines and 
immunoprecipitated them using GFP trap_M beads. As before, the samples were analyzed 
by immunoblotting with a commercially available DAXX antibody (Figure 19). 
 
 
 
Figure 19: Mutation of Q59E in H3.Y is not sufficient for DAXX binding. GFP-H3 variant cell lines and 
the H3.Y mutant H3.Y Q59E were tested regarding their DAXX binding ability. For details see Figure 7. 
 
The exchange of the single residue Q59 to the corresponding H3.3 s glutamic acid did not 
allow a stable DAXX interaction. Although this amino acid plays a crucial role in an extensive 
hydrogen bonding network with DAXX, its sole replacement was not sufficient to gain DAXX 
binding.   
 RESULTS 
 70 
3.4.2 Replacing Core Residues in H3.Y does not Enable DAXX Interaction 
Obviously, replacing glutamine at position 59 with the corresponding glutamic acid from 
H3.3 did not enable DAXX interaction. Next, I decided to further mutate H3.Y at core 
residues: a stretch from residue 77-80 is completely replaced in H3.Y. Additionally, H3.3 
glycine 102 is exchanged to glutamine in H3.Y. Both, the stretch 77-80 and G102 are flanking 
the chaperone recognition site. Thus I speculated, whether these amino acids could perturb 
the recognition or binding of H3.Y to DAXX. To test this hypothesis, I mutated the referred 
residues and finally obtained a so-called H3.Y core  mutant (Figure 20), which comprises a 
combination of the replacement of glutamine 59 to glutamic acid, the stretch from position 
77-80 and glutamine 102 to glycine.  
 
 
 
Figure 20: Alignment of H3.3, H3.Y and the H3.Y core  mutant. In the mutant H3.Y s amino acids 59, 
77-80 and 102 are replaced by the corresponding H3.3 residues. H3.3 residues are depicted in blue, 
H3.Y residues in green. The chaperone recognition site is highlighted in purple. 
 
A new stable cell line, called eGFP-H3.Y core was established. GFP expression was confirmed 
by flow cytometry analysis (Figure 21A) and chromatin incorporation was again investigated 
by immunofluorescence (Figure 21B). eGFP-H3.Y core mutant showed an exclusive nuclear 
staining. H3S10 phosphorylation was once more used for the visualization of mitotic cells 
and co-localization indicated a stable chromatin incorporation of the mutant.  
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Figure 21: H3.Y core mutant is stably expressed in HeLa Kyoto cells and localizes to chromatin. (A) 
Flow cytometry analysis of eGFP as a positive control (gray) and eGFP-H3.Y core (red) indicates a 
stable expression of the GFP-tagged construct. (B) eGFP as a control and the H3.Y mutant eGFP-H3.Y 
core were analyzed for their localization by immunofluorescence microscopy. eGFP is found in 
cytoplasm and nucleus, whereas eGFP-H3.Y core shows only nuclear staining. For details see Figure 
17.  
 
Also this new H3.Y mutant cell line was investigated for DAXX interaction. Therefore, 
chromatin-free extracts of eGFP-tagged H3 variants, including this new eGFP-H3.Y core 
mutant were prepared and subjected to immunoprecipitation, followed by immunoblotting 
(Figure 22).  
 
 
Figure 22: eGFP-H3.Y core mutant does not pull down DAXX. GFP-H3 variant cell lines, the mutant 
cell line H3.Y core and eGFP as a negative control were analyzed in respect to DAXX binding. For 
details see Figure 7. 
 
Surprisingly, also this H3.Y mutant, although being nearly identical to H3.3 in core residues, 
is not able to pull down DAXX. 
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3.4.3 H3.3 & H3.Y Tail Swap Mutant Consisting of N-terminal H3.Y & H3.3 Core/ 
C-Terminus Allows Stable DAXX Interaction 
As a next step we decided to examine larger regions of the histone variant proteins to 
identify their important sites for DAXX interaction. Therefore I designed several swap 
mutants, which are either exchanged at the N- or C-terminus with the corresponding H3.3 or 
H3.Y part (Figure 23).  
 
Figure 23: Alignment of H3.3 and H3.Y swap mutants. H3.3 residues shown in blue and H3.Y residues 
in green are either exchanged at their N-termini (N3-Y and NY-3, left) or C-termini (3-CY and Y-C3, 
right) to study DAXX interaction. The dotted line indicates sites of swaps: N-terminal at aa position 42, 
C-terminal at residue 115. 
 
The N3-Y mutant consists of the H3.3 N-terminus from aa 1 to 35 and of H3.Y from aa 36 to 
aa 135. NY-3 is composed of an H3.Y N-terminus (aa 1-35) fused to an H3.3 core (aa 36-135). 
The C-terminal swap mutants consist of either H3.3 (aa 1-114) combined with an H3.Y C-
terminus (aa 115-135) or H3.Y fused to an H3.3 C-terminal tail. These four different 
constructs were ordered at Genewiz and arrived in a pUC57 vector. To allow expression in 
HeLa Kyoto cells, the different mutants were then cloned into the pIRESneo-eGFP vector via 
gateway cloning. Subsequently, HK cells were transfected with the constructs fused to an N-
terminal GFP-tag and selected with G418-sulfate to obtain stable cell lines. The stable GFP 
expression was determined by flow cytometry analysis (Figure 24A) and nuclear localization 
was analyzed by immunofluorescence (Figure 24B). The flow cytometry profile of the eGFP-
Y-C3 cell line (Figure 24A, orange) revealed that only a fraction of approximately 20% stably 
expresses the GFP-tagged construct. Several attempts failed to stably express this construct, 
thus following experiments were performed with appropriate higher cell numbers to ensure 
the same cell number of eGFP expressing cells and thus the same amount of eGFP tagged 
protein. To determine their subcellular localization, the different H3.3/H3.Y swap mutants 
were analyzed by immunofluorescence. All four swap mutants revealed exclusive nuclear 
staining. Co-localization with H3S10 phosphorylation indicated stable chromatin 
incorporation. 
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Figure 24: N-terminal GFP-tagged H3.3 and H3.Y swap mutants are stably expressed in HeLa Kyoto 
cells and show localization to chromatin. (A) Flow cytometry analysis of four different mutant swap 
HeLa Kyoto cell lines (see Figure 23) indicates a stable GFP expression of the eGFP-N3-Y (blue), eGFP-
NY-3 (green) and eGFP-3-CY constructs (yellow), whereas only a minor fraction of the eGFP-Y-C3 cell 
line (orange) expresses the GFP-tagged construct. EGFP (gray) served as positive control. (B) For 
details see Figure 17. 
  
In order to examine the potential DAXX interaction capability of the H3.3/H3.Y swap 
mutants I isolated soluble nuclear proteins from the respective stable HeLa Kyoto cell lines 
and performed pull-down experiments, again using the GFP-trap_M. Afterwards, interaction 
with DAXX was analyzed by immunoblotting (Figure 25).  
 
 
Figure 25: eGFP NY-3 interacts with DAXX. Stable GFP-H3 variant cell lines and H3.3/H3.Y swap 
mutants were investigated regarding DAXX binding ability. For details see Figure 7.  
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The positive control eGFP-H3.3 and the swap construct eGFP-NY-3 interacted with DAXX. 
This H3.3-H3.Y chimera is composed of the N-terminal H3.Y tail and the H3.3 core. In 
contrast, all other swap mutants did not bind DAXX. Apparently, the H3.Y C-terminus 
prevented the interaction (eGFP-3-CY), whereas the N-terminal tail did not (eGFP-NY-3). 
Moreover, exchanges in the core of H3.Y were necessary for DAXX binding as eGFP-Y-C3, 
which consists of H3.Y and the H3.3 C-terminus, did not pull down DAXX. In conclusion a 
combination of residues in the core and C-terminus was necessary to determine DAXX 
interaction and only the construct eGFP-NY-3 was able to pull down DAXX. 
 
To test whether the interaction of eGFP-NY-3 with DAXX also results in its localization to 
PML bodies, our collaboration partner Erwan Delbarre transiently transfected mesenchymal 
stem cells and analyzed the potential co-localization with PML-NBs and the different swap 
chimeras (Figure 26A). To ensure a representative result, 200 cells were counted and swap 
mutants analyzed for their differential distribution in chromatin or PML structures (Figure 
26B). Since the recruitment to PML-NBs was DAXX-dependent we assumed a localization of 
eGFP-NY-3 to these structures, whereas, as already shown in Figure 9, eGFP-H3.Y is 
restricted to chromatin. As expected, eGFP-NY-3 is enriched in PML-NBs (Figure 26A and B). 
Surprisingly, also eGFP-3-CY localized there. This swap construct consists of H3.3 and an H3.Y 
C-terminus. Although this mutant did not reveal a stable DAXX interaction in 
immunoprecipitation experiments followed by western blot, it did localize to PML-NBs. 
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Figure 26: eGFP-NY-3 and -3-CY localize to PML-NBs. (A) eGFP-N3-Y, -NY-3, -3-CY, and -Y-C3 were 
transiently transfected into mesenchymal stem cells and localization to PML-NBs was analyzed by 
fluorescence microscopy. DNA was stained with DAPI (left column, blue), histones are depicted in 
green (GFP, second left panel) and PML-NBs are stained with an antibody (red, second right panel). 
Overlay image is displayed on the right; scale bar is 5 µm. (B) 200 cells were counted and the 
percentage of cells that display either a chromatin distribution (black) of the constructs or an 
enrichment in PML-NBs (gray) was depicted in a bar chart. Notably, not only eGFP-NY-3 but also 
eGFP-3-CY are found in PML-NBs. 
 
Since not only eGFP-NY-3 but also 3-CY got recruited to PML-NBs it is tempting to speculate, 
that this localization is due to a transient interaction of DAXX and 3-CY. This association, not 
stable enough to be detected in immunoblot might be sufficient for PML-NB localization. 
Hence, for a transient interaction, DAXX could tolerate both, the N-terminus (present in NY-
3) and the C-terminus (present in 3-CY) of H3.Y, meaning the replacement of H3.Y core 
residues might be sufficient for PML-NB recruitment.  
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3.5 H3.3-DAXX INTERACTION: A DEFINED COMBINATION OF AMINO 
ACIDS MATTERS 
Both NY-3 and 3-CY were localizing to PML-NBs, indicating that the sole replacement of H3.Y 
core residues might be sufficient for transient DAXX interaction. However, the C-terminus of 
H3.Y seems to prevent a stable DAXX-association and thus 3-CY could not be detected in 
immunoprecipitation experiments. Aiming for the identification of the exact residues that 
determine strong DAXX interaction, I used the H3.Y core mutant and further mutated 
several amino acids in the C-terminus to investigate which H3.Y-residues prevent stable 
DAXX interaction. Depending on the different mutants, distinct parts of the C-terminus in 
the H3.Y core mutant were exchanged with H3.3 residues (Figure 27). First, I designed the 
H3.Y core GERA mutant by replacing the last three exchanged amino acids of H3.Y with 
H3.3 s residues. Additionally, arginine at position 53 was replaced with the corresponding 
lysine from H3.3 resulting in another mutant called H3.Y K53R core GERA. R53 is in close 
proximity to lysine 56 which is known to be posttranslationally modified (95, 96, 109, 315) 
and was shown to play a role as a predeposition mark to regulate the association with 
distinct chaperone complexes in yeast (316). As arginine 53 lays close to K56 the exchanged 
residue might perturb the acetylation of K56 so I decided to further exchange this residue. 
Similarly, in H3.Y core R122K M124I amino acid 122 and 124 were exchanged in the 
background of H3.Y core. DeNizio et al. demonstrated that DAXX directly binds lysine 122, 
thus I speculated that an arginine in H3.Y might influence DAXX interaction (271). 
Furthermore, I also decided to replace amino acid 124, as it is in close proximity and might, 
therefore, perturb the binding to R122. Lastly, H3.Y K53R core C3 was generated to serve as 
a positive control since it only differs in the three residues 42, 46 and 62 from NY-3 that was 
already demonstrated to bind DAXX. 
 
 
 
Figure 27: Alignment of H3.3 and mutant H3.Y. Different H3.Y mutants were designed to further 
define the residues important for DAXX interaction. All mutants have the H3.Y core background and in 
the case of H3.Y core GERA the last four amino acids were exchanged to H3.3 residues, in H3.Y K53R 
core GERA the additional arginine 53 was exchanged. In H3.Y core R122K M124I arginine at position 
122 and methionine at position 124 were exchanged with the corresponding H3.3 lysine and 
isoleucine, respectively. Details see Figure 20. 
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As before, HeLa Kyoto cells were transfected with the different mutant H3.Y constructs and 
stable cell lines were established by selection with G418-sulfate. Stable GFP expression was 
determined by flow cytometry analysis (Figure 28A) and immunofluorescence microscopy 
revealed nuclear localization of these new mutant constructs. Co-staining with an antibody 
recognizing H3 serine 10 phosphorylation indicated again stable incorporation into 
chromatin (Figure 28B).  
 
Figure 28: GFP-tagged H3.Y mutants are stably expressed in HeLa Kyoto cells and show nuclear 
localization. (A) GFP expression of stable HeLa Kyoto cells expressing eGFP-H3.Y core GERA (light 
blue), -H3.Y K53R core GERA (dark blue), -H3.Y K53R core R122K M124I (green), and –H3.Y K53R core 
C3 (purple), was determined by flow cytometry analysis. HeLa Kyoto cells expressing eGFP were used 
as a negative control (gray). (B) For details see Figure 17. 
 
To investigate the interaction with DAXX, soluble nuclear proteins were isolated from the 
stable HeLa Kyoto cell lines and eGFP-tagged histone mutants were immunoprecipitated via 
their GFP-tag. Finally, DAXX binding was analyzed by immunoblotting (Figure 29). 
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Figure 29: New C-terminal H3.Y core mutants do not interact with DAXX. The H3.Y core mutant was 
further mutated in the C-terminus, giving rise to H3.Y core GERA, H3.Y core K53R GERA, H3.Y core 
K53R R122K M124I and H3.Y core K53R C3. These new H3.Y mutants were investigated regarding 
DAXX binding. For details see Figure 7. 
 
Surprisingly, none of the newly established mutants could stably bind DAXX. Replacement of 
the last three exchanged residues, with or without the additional K53R mutation, was not 
sufficient for DAXX binding. Likewise, neither H3.Y K53R core R122K M124I nor the putative 
positive control H3.Y K53R core C3 were able to bind DAXX.  
To test the ability of the new C-terminal mutants to weakly associate with DAXX and 
consequently localize to PML-NBs, our collaboration partner Erwan Delbarre also analyzed 
the recruitment of these mutants to PML-NBs. He again transfected mesenchymal stem cells 
and analyzed >200 cells after 24h regarding their subcellular localization (Figure 30).  
 
 
Figure 30: eGFP-H3.Y K53R core R122K M124I and -H3.Y K53R core C3 localize to PML-NBs. 
Mesenchymal stem cells were transfected with the eGFP-tagged constructs H3.Y core GERA, H3.Y 
K53R core GERA, H3.Y K53R core R122K M124I and H3.Y K53R core C3. After 24h, >200 cells per 
construct were investigated regarding their PML-NB localization (gray: found in PML-NBs, black: not in 
PML-NBs). 
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As expected, H3.Y K53R core R122K M124I and H3.Y K53R core C3 were localized in PML-
NBs. Contrary and surprisingly, neither H3.Y core GERA, nor H3.Y K53R core GERA could be 
found in PML-NBs. Although 3-CY which possesses the whole C-terminus of H3.Y localized to 
PML-NBs, the new GERA mutant with the last 4 residues identical to H3.3 could not. 
The missing stable interaction of H3.Y K53R core C3 and DAXX was surprising as this mutant 
differs only in 3 amino acids from the swap mutant construct NY-3 that was shown to bind 
DAXX (Figure 25). Therefore I further analyzed which of the remaining three residues that 
are different between H3.YK53R core C3 and NY-3 matter for the differential outcomes 
regarding DAXX interaction. To do so, I mutated the residues K42, L46 and L62 of H3.Y singly 
and in combination to the corresponding H3.3 residues, so that I ended up with six more 
constructs (Figure 31): first H3.Y K42R K53R core C3, second H3.Y L46V K53R core C3, third 
H3.Y K53R L62I core C3, fourth H3.Y K42R L46V K53R core C3, fifth H3.Y K42R K53R L62I core 
C3 and sixth H3.Y L46V K53R L62I core C3.  
 
 
Figure 31: Alignment illustrating amino acid differences between additional H3.Y core mutants. 
H3.Y R53K core C3 was further mutated in its remaining three residues that are different from NY-3 
that was shown to interact with DAXX. H3.Y s residues lysine 42, leucine 46 or leucine 62 were 
mutated singly or in combinations to the corresponding H3.3 amino acids. Details see Figure 20. 
 
Again, we established stable cell lines with eGFP-tagged constructs, determined the stable 
expression by flow cytometry analysis and checked nuclear localization by 
immunofluorescence (Figure 32).  
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Figure 32: eGFP-H3.Y K53R core C3 mutants are stably expressed in HeLa Kyoto cells and 
incorporated into chromatin. (A) eGFP-H3.Y K42R K53R core C3 (dark blue), -H3.Y L46V K53R core C3 
(green), -H3.Y K53R L62I core C3 (orange), -H3.Y K42R L46V K53R core C3 (light blue), -H3.Y K42R K53R 
L62I core C3 (fuchsia) and -H3.Y L46V K53R L62I core C3 (yellow) expression was analyzed by flow 
cytometry. eGFP cells were used as a positive control (gray). (B) For details see Figure 17. 
 
After confirming the mutant s stable chromatin incorporation I again prepared nuclear 
extracts, followed by immunoprecipitations with GFP-trap_M. Extracts and 
immunoprecipitates were analyzed for DAXX binding by immunoblotting (Figure 33).  
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Figure 33: Leucine 46 in H3.Y K53R core C3 prevents DAXX binding. For details see Figure 7. 
Exchanges of K42, L46, L62, singly or in combinations, with the corresponding H3.3 residues were 
investigated for their contribution to DAXX binding. Notably, the exchange of leucine 46 in H3.Y to 
H3.3 s valine has the biggest effect on DAXX binding, whereas the exchanges of K42R and L62I have 
only minor effects. Replacing L46V in combination with K42R or L62I could nearly fully restore DAXX 
binding.  
 
Particularly replacing leucine at position 46 with valine affected DAXX binding. Here, the 
biggest increase in DAXX binding could be detected when exchanging a single residue. 
Accordingly, exchanging L46 in combination with K42R and especially L62I re-established 
DAXX binding to nearly H3.3 binding levels. However, also H3.Y K42R K53R L62I core C3 
showed DAXX binding, although to a minor extent.  
 
 
 
3.6 DAXX BINDING TO H3.Y MUTANTS INFLUENCES CHROMATIN 
INCORPORATION SITES 
In 3.2 the difference between H3.3 and H3.Y in binding DAXX could also be observed by 
different genomic localization sites of H3.3 and H3.Y, respectively. Both variants mostly 
overlapped in their chromatin incorporation sites, however, a discrepancy was detected in 
putative DAXX-dependent, H3K9me3-positive simple repeat sites: whereas H3.3 was 
deposited to these sites, H3.Y was completely absent. Thus, we were wondering whether 
the mutants that are now able to bind DAXX could localize to these sites and thereby share 
H3.3 deposition sites. In order to investigate this, we used the eGFP-expressing H3.3 and 
H3.Y mutant cell lines N3-Y, NY-3, 3-CY, Y-C3, H3.Y L46V K53R L62I core C3 and eGFP, H3.3 
and H3.Y as controls. The procedure was done as described in 3.2. Crosslinked chromatin 
fragments were immunoprecipitated with a GFP-antibody, sequenced by the LAFUGA lab at 
the gene center Munich and results bioinformatically analyzed by Marek Bartkuhn (JLU 
Giessen).  
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Initially, the chromatin incorporation ability of all constructs was tested (Figure 34). As 
expected, peak regions of all constructs overlapped with those of H3.3, consistent with 
H3.3 s predominant localization to HIRA-dependent H3K4me3-positive sites (compare to 
Figure 10).  
 
Figure 34: H3.Y mutants incorporate into shared chromatin regions where H3.3 and H3.Y are 
present. ChIP-seq density heat maps of peaks for the mutants N3-Y, NY-3, 3-CY, Y-C3, H3.Y L46V K53R 
L62I core C3 and H3.3 and H3.Y (H3.3 and H3.Y replicate 1, compare to Figure 11). Mutants co-localize 
with the controls H3.3 and H3.Y. Color intensity represents normalized and globally scaled tag counts. 
 
Next, we were checking whether gained DAXX binding of the mutants is also reflected by 
their presence at H3.Y-reduced incorporation sites in chromatin. The tail-swap mutants N3-Y 
and Y-C3, which could neither immunoprecipitate DAXX nor localize to PML-NBs were found 
at shared sites where both H3.3 and H3.Y are present (Figure 35A). 3-CY however, which was 
not stably associated with DAXX in immunoblot but localized to PML-NBs revealed an 
intermediate phenotype regarding its incorporation sites: some H3.Y-reduced sites showed a 
slight enrichment of 3-CY, while others did not. Notably, both NY-3 and 
H3.Y L46V K53R L62I core C3 which gained stable DAXX binding, also localized to H3.Y-
reduced H3.3 deposition sites, again overlapping with H3K9me3 (Figure 35). 
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Figure 35: NY-3 and H3.Y L46V R53K L62I core C3 localize to H3.Y-reduced H3K9me3-positive sites. 
(A) Genome browser snapshot of H3.3 (blue), H3.Y (green), H3.3/H3.Y swap mutants and H3.Y L46V 
R53K L62I core C3 (different shades of turquoise), H3K4me3 (black) and H3K9me3 (ruby, (305)). 
Annotated gene features are depicted above. Blue boxes illustrate assigned peaks by MACS 2 peak 
calling method. Compare to Figure 11B. (B) Boxplot illustrating peak intensities of H3.3/H3.Y swap 
mutants and H3.Y L46V R53K L62I core C3 at all H3.3 sites versus H3.Y-reduced sites. RPK = reads per 
kilobase. Mean signal intensities for two H3.3 and H3.Y replicates are shown. Statistical significance 
was determined using Wilcoxon signed rank test. 
 
 In conclusion, we could demonstrate that DAXX binding to H3.Y mutants enabled their 
deposition at H3K9me3 sites. 
 
Summary 
All in all, I demonstrated that H3.Y in contrast to H3.3, although sharing the same chaperone 
recognition site, was not able to bind DAXX. An H3.Y mutant that is identical to H3.3 in the 
core region failed to interact with DAXX. Only the H3.3-H3.Y chimera NY-3, which consists of 
an H3.Y N-terminal tail fused to H3.3, was able to stably bind DAXX. This suggests that the 
H3.3 N-terminus alone is dispensable, whereas a combination of residues in the core and the 
C-terminus are necessary for the interaction. Aiming for the identification of exact amino 
acid residues that determine DAXX binding, I dissected NY-3 into further mutants. These 
H3.Y mutants carry H3.3 residues in the core and in addition different substitutions in the C-
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terminus. None of the new H3.Y constructs, including the supposed positive control 
H3.Y R53K core C3 was able to bind DAXX. H3.Y R53K core C3 shares all amino acids except 
three with NY-3, thus I further mutated these remaining residues singly or in combination. 
We finally identified H3.Y L46V R53K L62I core C3 as the mutant enabling strong DAXX 
binding. Apparently, for the stable interaction of H3.3 and DAXX, a defined combination of 
aa matters and only the H3.3 N-terminal tail is dispensable. The localization to PML-NBs, 
however, was achieved by several H3 variant constructs, suggesting a weak DAXX binding 
that is sufficient to for PML-NB localization. In Figure 36 DAXX binding ability and PML-NB 
localization of all mutants generated in this study are summarized. 
 
 
 
Figure 36: Alignment of H3.3, H3.Y and their mutants summarized with their binding ability towards 
DAXX and their localization to PML-NBs. Only the H3.3/H3.Y chimera NY-3 and H3.Y L46V R53K core 
C3 as well as H3.Y K42R L46V R53K core C3, H3.Y L46V L62I R53K core C3 and H3.Y K42R R53K L62I 
core C3 stably interact with DAXX. Details see Figure 20. 
 
DAXX is the chaperone needed for deposition of H3.3 into heterochromatic sites, whereas 
HIRA is responsible for deposition into euchromatic sites. The fact that H3.Y only interacts 
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with HIRA was also reflected by its chromatin incorporation sites and its nucleosomal 
interactome. We have demonstrated by ChIP-seq analysis that H3.3 and H3.Y mainly localize 
to euchromatic H3K4me3-positive sites. However, a fraction of H3.3 was incorporated into 
so-called H3.Y-reduced sites, where no H3.Y was present. Instead, these sites were 
H3K9me3-positive and enriched with simple repeats. 
In comparison to eGFP-H3.1, -H3.2 and -H3.3, eGFP-H3.Y associated with the transcription 
associated FACT complex and was depleted in heterochromatic factors like PRC1, HP1 
proteins, and SUV39H. Accordingly, H3.Y revealed reduced levels of H3K9me3, again 
confirming the ChIP-seq results where H3.Y was absent from H3K9me3 sites. 
Mutants that gained DAXX binding got incorporated into H3.Y-reduced H3K9me3-positive 
simple repeat sites, suggesting that H3 variant-DAXX interaction is necessary and sufficient 
for deposition into human heterochromatic sites. 
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4 DISCUSSION 
 
H3.Y is a novel primate-specific H3 variant expressed mainly in testis and brain but also in 
ovary, breast or lung cancer tissues (218). It shares the highest similarity with H3.3, 
especially the so-called chaperone recognition site that is thought to determine the 
interaction with distinct chaperone complexes mediating the localization of H3 variants to 
diverse genomic loci. H3.3 gets deposited by two chaperone complexes, namely the HIRA 
complex and DAXX/ATRX (190, 191, 198, 222, 266-268). The HIRA complex is responsible for 
H3.3 s localization to euchromatic sites, such as gene bodies of actively transcribed genes or 
promoters. In contrast, DAXX/ATRX promotes the deposition of H3.3 to heterochromatic 
sites, such as telomeres, periCEN or retrotransposons.  
Generally, H3.Y localizes outside of DAPI dense regions as seen in super-resolution 3D-SIM 
microscopy (218). The combination of starvation and overgrowth stress leads to an increase 
in cells expressing H3.Y. Moreover, H3.Y has been implicated in the regulation of cell cycle 
genes since its depletion results in diminished cell growth and transcriptome analysis 
revealed deregulated expression of cell cycle-associated genes (218). Aiming to unravel 
H3.Y s functions, first the chaperone complexes responsible for its deposition were analyzed. 
To do so, the interactome of H3 variants including H3.Y was identified in the chromatin-free 
fraction by SILAC-MS of immunoprecipitated H3 variants and the interacting proteins. H3.3 
and H3.Y are expected to interact with the same chaperone complexes due to their high 
sequence similarity. Surprisingly, the two variants seem to have differences in their binding 
partners. H3.Y only interacts with the HIRA complex but not DAXX/ATRX (Figure 6).  
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4.1 H3.Y ONLY INTERACTS WITH THE HIRA COMPLEX & LOCALIZES TO 
EUCHROMATIC SITES 
In order to verify whether indeed only H3.3 but not H3.Y can pull down DAXX I started to 
immunoprecipitate eGFP-H3 variants from stably expressing HeLa Kyoto cells. Instead of MS 
I now performed immunoblotting using an anti-DAXX antibody (Figure 7). Indeed, I could 
verify the results obtained by MS and only observed an interaction between H3.3 and DAXX 
but not between H3.Y and DAXX.  
Notably, DAXX exhibits a higher molecular weight when immunoprecipitated with H3.3. 
Thus, I was wondering whether DAXX modifications cause this shift and analyzed diverse 
reported DAXX PTMs. However, DAXX was neither sumoylated, ubiquitinated nor poly ADP-
ribosylated (Figure 8). Analysis of the phosphorylation status of DAXX did not reveal a clear 
result due to technical problems. Phosphorylation of DAXX was already observed to have an 
impact on H3.3 loading in neurons (296). The authors observed a correlation between DAXX-
dependent H3.3 deposition and the phosphorylation status of DAXX. However, in neurons 
H3.3 preferentially interacts with hypophosphorylated DAXX. Expressing a phosphomimetic 
version of DAXX (S669E) or a version that can not be phosphorylated in DAXX knockout cells 
(S669A) revealed that H3.3 loading is impaired in cells expressing the S669E mutant (296). 
The model suggests that upon neuronal activation, DAXX gets dephosphorylated and 
promotes H3.3 deposition and transcription of particular loci. Thus, DAXX function in H3.3 
deposition seems indeed to be regulated by its phosphorylation status. It remains to be seen 
if this is a cell type-specific phenomenon or affects only a subclass of H3.3 deposition sites. 
Nonetheless, in HeLa Kyoto cells H3.3 immunoprecipitates DAXX of higher molecular weight, 
hence potentially hyperphosphorylated instead of hypophosphorylated DAXX. Notably, the 
distinct running behavior of DAXX can only be observed in the first immunoblots (Figure 7, 
19 and 22) and is not present in further pulldowns. Although I can not exclude that DAXX is 
posttranslationally modified, my results show so far no evidence that a potential 
modification influences its function. Moreover, it could well be that technical influences like 
different charges of polyacrylamide gradient gels affect the running behavior of DAXX and 
are causing the observed shift. 
The association of H3.Y with the HIRA complex, but not DAXX/ATRX is further confirmed by 
the absence of H3.Y in PML-NBs. This localization is DAXX-dependent and therefore the 
absence of H3.Y reflects the lacking interaction of DAXX and H3.Y. PML-NBs are thought to 
serve as a triage centers for a fraction of H3.3, where H3.3 and its chaperones meet  to 
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form stable interactions before getting deposited into chromatin (272). Several chaperones, 
including ASF1A, HIRA, and ATRX are also found in PML-NBs arguing for a role as a meeting 
point for diverse chaperone complexes. Although - at least in HeLa cells - most of newly 
synthesized H3.3 associates with HIRA (191), a fraction of H3.3 might also be recruited to 
PML-NBs for further distribution to distinct chaperone complexes. Since H3.Y can interact 
with the HIRA complex, it is present in chromatin albeit absent from PML-NBs.  
 
DAXX/ATRX is responsible for the deposition of H3.3 at heterochromatic simple repeat sites, 
characterized by the presence of H3K9me3 (175, 190, 197, 198, 268). HIRA complex 
mediated deposition sites are, in contrast, characterized by open chromatin (190, 191, 266), 
a state that is often defined by the presence of H3K4me3. In order to find out whether the 
lack of DAXX in H3.Y immunoprecipitates also determines its deposition sites I performed a 
ChIP-seq analysis of H3.3 and H3.Y together with Marek Bartkuhn from the University of 
Gießen. Both H3.3 and H3.Y are highly enriched at TSS, marked by H3K4me3. Moreover, 
they are enriched at exons, sites upstream of the TSS, TES and only mildly enriched on 
introns (Figure 10A). In contrast, H3.3 and H3.Y, as well as H3K4me3, are depleted in 
intergenic regions. This result is in contrast to ChIP-seq data from mESCs and MEFs where 
H3.3 was highly enriched in intergenic regions and introns (181, 190). It might well be that 
this difference is due to different organisms, differences in differentiation states, in 
experimental procedure or bioinformatic analysis. Nonetheless, H3.3 and H3.Y share the 
majority of peaks that overlap with H3K4me3 (Figure 10B) but are depleted in H3K9me3 
(Figure 11) indicating that either the majority of H3.3 is incorporated by HIRA or our method 
reaches its technical limits at heterochromatic, often repetitive regions. All in all, our results 
are in agreement with previous data for H3.Y function. H3.Y is indeed located to 
euchromatic regions, confirming the finding obtained in high-resolution microscopy that 
depicted H3.Y outside of DAPI dense regions. Furthermore, depletion of H3.Y resulted 
overall in a higher number of downregulated genes, again supporting H3.Y s role in 
euchromatic regions like TSS, potentially promoting transcription. The unique H3.3-specific, 
H3.Y-depleted incorporation sites are characterized by the presence of H3K9me3 (Figure 11 
and Figure 12). This enrichment is typical for DAXX/ATRX-dependent deposition sites (197, 
198, 223) and further supports the absence of H3.Y from these regions. In mESCs 
DAXX/ATRX are responsible for the deposition of H3.3 into telomeres, pericentric 
heterochromatin, differentially methylated imprinted loci, and retroviral elements (198, 223, 
224). Interestingly, here DAXX/ATRX are even required for the maintenance of H3K9me3. 
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Depletion of DAXX or ATRX results in the loss of H3K9me3 at differentially methylated 
regions, endogenous retroviral elements and telomeres (197, 223, 224). Two studies 
demonstrate that H3K9me3 is indeed directly dependent on H3.3 since its loss led to 
reduced H3K9me3 levels at telomeres and retroviral elements in mESCs (197, 198, 224).  
Remarkably, our results indicate that HIRA-independent deposition of H3.3 happens 
exclusively at simple repeat sites, whereas in mouse cells H3.3 gets deposited to various 
repeat types. A recent study performing ChIP-seq with DAXX and ATRX antibodies in mESCs 
reported an enrichment of simple repeats (224). These data support our hypothesis that in 
human cells H3.3 enrichment at simple repeats is DAXX-dependent whereby H3.Y is absent 
from these sites. Generally, repeat sequences are often hypomethylated in cancer cells (317, 
318). Since our studies are carried out in the cervical cancer cell line HeLa Kyoto this might 
also be true in our experiments. Low methylation levels of some simple repeats were even 
observed in human embryonic stem cells (319). In the case of DNA hypomethylation, Su et 
al. reported high levels of DAXX/ATRX and H3K9me3 to prevent aberrant transcription of 
repeats (319). DAXX might play a central role in targeting ATRX and SUV39H since DNA 
methyltransferase triple knockout cells showed loss of H3K9me3 at these sites when DAXX is 
depleted (224). It seems that low levels of DNA methylation coincide with high levels of 
DAXX/ATRX and H3K9me3 at respective repeat sites to ensure a silent state. It is tempting to 
speculate that also in humans the low methylation levels that were observed for some 
(simple) repeat types reflect sites of high DAXX occupancy and might thus be enriched with 
H3.3 and depleted in H3.Y. 
It might well be that technical or experimental variation led to the enriched detection of 
H3.Y-depleted H3.3 deposition sites at simple repeat sites. However, it is still possible that 
this discrepancy is a biological feature stressing the difference between organisms (mouse 
and human) or their distinct development stages.  
Interestingly, in human HeLa cells, DAXX depletion does not affect global H3.3 deposition 
(191) arguing again, that DAXX deposits H3.3 only to a limited number of sites in humans, 
supporting our data showing that the majority of H3.3 is incorporated by HIRA.  
All in all, our data reveal that H3.Y is exclusively deposited by the HIRA complex. H3.3, on the 
other hand, gets deposited by both the HIRA complex and DAXX/ATRX leading to the 
localization of H3.3 but not H3.Y to simple repeat sites. If both H3.3 and H3.Y get deposited 
by the HIRA complex to the same euchromatic regions the presence of heterotypic 
nucleosomes consisting of both H3.3 and H3.Y should be observed. Indeed, 
immunoprecipitated mononucleosomes containing GFP-H3.Y also have H3.3 incorporated as 
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Figure 15D suggests. Furthermore, Kujirai et al. demonstrated that H3.3/H3.Y-containing 
heterotypic nucleosomes exist in vitro (219). These heterotypic nucleosomes also retained 
the characteristics of H3.Y nucleosomes. They were more responsive to MNase digestion 
and showed reduced H1 binding, suggesting that also these nucleosomes might be a part of 
open and relaxed chromatin.  
 
 
 
4.2 H3.Y NUCLEOSOMES ARE ENRICHED IN TRANSCRIPTION-
ASSOCIATED INTERACTION PARTNERS 
In order to analyze the interactome of the distinct H3 variant associated interaction partners 
I performed MNase-IP-qMS. The applicability of our method was confirmed by the 
enrichment of the CAF1 complex on canonical H3.1 (Figure 15C, D). The 
immunoprecipitation and/or identification of CAF1A and CAF1B but not CAF1C has already 
been observed in a study focusing on the identification of the H3.2 interactome and is 
therefore not surprising (280). Obviously the CAF1 complex is not only responsible for the 
deposition of the canonical histones but remains also stably bound to chromatin. This was 
also noticed by Latreille et al.: the authors detected the p150 subunit of the CAF1 complex 
not only in the soluble nuclear fraction but also in the chromatin fraction (280). In the course 
of this, yeast CAF1 has been demonstrated to bind DNA (320, 321). Moreover, mouse and 
human CAF1A binds to DNA in vitro and mouse CAF1A localizes to DAPI dense foci in 
fibroblast cells supporting our result that CAF1 is not only a transient interactor but stays 
stably bound to mononucleosomes (320).  
The PRC1 complex is enriched on H3.1 and H3.3 containing mononucleosomes. It comprises 
of four core subunits: polycomb group finger (PCGF), Polyhomeotic-like protein (PHC), E3 
ubiquitin-protein ligase RING1 and chromobox protein (CBX) (322, 323). In humans all of 
these subunits exist in multiple homologs, enabling the existence of various PRC1 complexes 
with distinct subunit compositions. In fact, 180 different PRC1 complexes can occur in 
humans including canonical and non-canonical complexes that do not contain CBX and PHC 
(322). Although it seems unlikely, it is so far unclear whether all of these potential 
complexes exist and what functions these distinct complexes fulfill. However, it is speculated 
that different PCGF homologs define different PRC1 complexes in humans. Gao et al. 
observed six major PRC1 complexes, all of them containing distinct PCGF homologs but with 
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only PGCF4 (BMI1) and PCGF2 (MEL18) giving rise to canonical complexes that contain CBX 
and PHC (324). These six major complexes can in turn associate with various other proteins, 
making the PRC1 composition even more complex. In our results, only BMI1 is detected 
indicating the presence of one canonical PRC1 complex (Figure 15D, E and Figure 16A). 
Indeed, the E3 ubiquitin ligases RNF2 and RING1, PHC2 and 3 and CBX8 are identified, giving 
rise to a canonical PRC1 complex consisting of all core members. Interestingly, RNF2 has only 
been shown to bind H3K27me3 whereas all other detected proteins are known to bind 
H3K27me3 as well as H3K9me3 (325). Conversely, CBX1, 3 and 5, that bind H3K9me3 (310, 
311), are enriched on eGFP-H3.1- or -H3.3-containing mononucleosomes, respectively 
(Figure 15D, E and Figure 16A). Moreover, SUV39H1 and 2 are enriched on H3.1- and H3.3-
containing mononucleosomes (Figure 15D, E and Figure 16A) connecting the presence of 
H3K9me3 and CBX proteins on H3.1 and H3.3. 
H3.Y s presence in open euchromatic regions is further confirmed by the enrichment of the 
FACT complex on H3.Y-containing mononucleosomes (Figure 15D, E and Figure 16A). The 
FACT complex is involved in nucleosome reorganization during transcription, DNA repair, 
and replication (326). As the name implies it facilitates transcription by disrupting 
nucleosomes, thereby generating an accessible DNA template for RNA polymerase II. 
Moreover, it promotes nucleosome recovery following transcription. Hence, the presence of 
FACT indicates active transcription and H3.Y s implication in transcription. Whereas the HIRA 
complex may be responsible for the deposition of newly synthesized H3.Y into euchromatic 
sites, the FACT complex might deposit H3.Y to regions of active transcription where 
nucleosomes are displaced. FACT is a rather promiscuous chaperone since it is also involved 
in the deposition of CENP-A, it binds H3-H4 tetramers and H2A-H2B dimers arguing that it 
could also bind H3.Y (233, 327).  
H3.Y s euchromatic distribution is further stressed by the absence of heterochromatin-
associated proteins SUV39H1 and 2. SUV39H is responsible for the trimethylation of H3K9 
(308, 309), a PTM that marks chromatin repression at the telomeres and periCEN. Depletion 
of both genes, Suvar39h1 and Suvar39h2, results in diminished H3K9me3 levels and 
elevated transcription (197). DAXX and ATRX were reported to interact with SUV39H, 
underlining the association of DAXX/ATRX and heterochromatin (197, 224). Thus, the 
absence of SUV39H and the reduced levels of H3K9me3 on eGFP-H3.Y-containing 
immunoprecipitated mononucleosomes (Figure 15D,E and Figure 16B) support our view on 
H3.Y as a marker for open euchromatin. Moreover, I observed H3K9me3 on the fraction of 
H3.3 that is reduced in H3.Y (Figure 11 and Figure 12).  
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Furthermore, I observed an enrichment of various subunits of distinct remodeling complexes 
on H3.Y-containing mononucleosomes (Figure 15D, E). CHD1 is a remodeler associated with 
open, transcriptionally active chromatin and has accordingly been reported to bind 
H3K4me3 (328, 329). It localizes to the 5  end of actively transcribed genes and might there 
function in the disassembly of nucleosomes (329). Moreover, CHD1 seems to be a potential 
candidate for the deposition of H3.3 at actively transcribed regions (330). Apart from CHD1 
also bromodomain plant homeodomain (PHD) finger transcription factor (BPTF) has been 
demonstrated to bind H3K4me3. BPTF is the largest and histone-binding subunit of the 
NURF complex that is generally associated with transcriptional activation (331, 332). 
Chromatin accessibility complex 1 (CHRAC1) was also enriched on H3.Y-containing 
mononucleosomes. CHRAC1 can directly bind ATP-dependent chromatin assembly factor1 
(ACF1) and builds together with CHRAC17 and the ATPase subunit SNF2H the CHRAC 
complex (333). CHRAC has been shown to enhance nucleosome sliding and assembly (333). 
Moreover, the remodeling and spacing factor 1 (RSF1) has been detected as an interaction 
partner of H3.Y-mononucleosomes. It is part of the RSF complex that consists of the ATPase 
SNF2H and the accessory protein RSF1 (334). Recent studies revealed RSF1 s function in the 
DSB repair. RSF1 is necessary for both repair pathways, in non-homologous end joining as 
well as in homologous recombination (335).  
In line with H3.Y s proposed function in euchromatin transformation/transcription 
associated protein (TRRAP) was identified on H3.Y-containing mononucleosomes (Figure 
15E). TRRAP is part of various histone acetyltransferase complexes and was suggested to be 
responsible for the recruitment of HATs to promoters by binding to the respective TF (336, 
337). As mentioned in 1.2.1 acetylation is generally associated with transcriptionally active 
chromatin, thereby the presence of TRRAP on H3.Y mononucleosomes links again H3.Y to 
transcription. Interestingly, TRRAP is also part of an SWI2/SNF2 remodeling complex the so-
called p400 complex, characterized by the E1A binding protein p400 (EP400) that harbors 
ATPase activity (338, 339). P400 is responsible for the deposition of H2A.Z and has recently 
been identified to also co-deposit H3.3 into enhancer and promoter regions of active genes 
(339). Its depletion resulted in diminished levels of H3.3 and H2A.Z deposition and reduced 
transcription levels. Since others (219) and I already speculated about the existence of 
heterotypic H3.3/H3.Y nucleosomes it could well be that TRRAP together with p400 deposits 
H3.3 to active sites where H3.Y is present. Its enrichment on H3.Y nucleosomes versus H3.3-
containing nucleosomes highlights H3.Y s sole localization to euchromatin whereas H3.3 is 
also found in heterochromatin where TRRAP does not play a role. Interestingly, albeit the 
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accessory subunits of remodeling complexes were enriched on H3.Y nucleosomes, the 
ATPase subunits SNF2H and EP400 did not appear as enriched proteins. They could actually 
be detected but are not enriched on H3.Y nucleosomes. It might be possible that the 
catalytically active subunits were more equally distributed between H3.1 or H3.3 and H3.Y. 
Indeed, the ATPase subunits are common to different complexes and solely the composition 
of different accessory subunits gives rise to distinct subcomplexes thereby enhancing or 
shaping their function (340-343). It is tempting to speculate that H3.Y s localization to 
transcriptionally active regions requires the presence of diverse chromatin remodeling 
complexes since these are sites of high nucleosome turnover.   
Noticeably, apart from remodeling complexes the SET (Su(var)3-9, Enhancer of Zeste, 
Trithorax) domain containing methyltransferases mixed-lineage leukemia 3 (MLL3) and 
SETD1A (SET domain containing 1A) are enriched on H3.Y-containing mononucleosomes. 
Both proteins are implicated in H3K4 methylation (344, 345). Whereas MLL3 is responsible 
for the monomethylation at enhancers, SETD1A promotes H3K4 di- and trimethylation at the 
TSS of active promoters (90, 346, 347). Thus, both proteins are implicated in euchromatic 
regions, supporting H3.Y s role in open H3K4me3 marked chromatin (see also Figure 10). 
The absence of HIRA complex members on mononucleosomes was surprising since HIRA has 
been shown to be able to bind free DNA. However, the data are in agreement with a 
previous study reporting that HIRA, in contrast to DAXX, is not a stable interaction partner of 
H3.3 (268). 
DAXX  presence on H3.Y-containing mononucleosomes might at first glance be surprising. 
However new ChIP-seq studies in mESCs revealed that only a fraction of DAXX associates 
with ATRX. Both proteins are co-enriched at repetitive elements, arguing for a role in H3.3 
deposition at these sites as we and others demonstrated (Figure 13 and (197, 198, 222)). 
Yet, 66% of DAXX peaks are not overlapping with ATRX, demonstrating DAXX functions apart 
from H3.3 deposition. Notably, DAXX independently localizes preferentially to promoter 
regions (224). Additionally, DAXX has been shown to bind TFs, again indicating a distinct role 
apart from H3.3 deposition for DAXX in euchromatin explaining its appearance on H3.Y 
mononucleosomes (296). 
Figure 37 summarizes the interaction partners of the different H3 variants in the chromatin-
free fraction and on chromatin as well as the chromatin features that determine the distinct 
deposition sites in the genome.  
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Figure 37: Interactome of human H3 variants and chromatin features of the respective H3 variant 
deposition sites. The canonical variants H3.1 and H3.2 get deposited by the CAF1 complex, that stays 
stably associated on chromatin. H3.3 gets deposited by two distinct chaperone complexes: 
DAXX/ATRX that determines H3.3 s localization to H3K9me3-positive and simple repeat-enriched sites 
and the HIRA complex. H3.Y gets deposited only by the HIRA complex that is responsible for its 
deposition to euchromatic, H3K4me3-positive sites. On chromatin the heterochromatic factors 
SUV39H, PRC1 and HP1 are enriched on canonical and H3.3-containing nucleosomes, whereas H3.Y-
containing nucleosomes are enriched in the transcription-associated FACT complex.   
 
 
 
4.3 A COMBINATION OF CORE & C-TERMINAL H3.3 RESIDUES 
DETERMINES DAXX INTERACTION  
Strikingly, although H3.3 and H3.Y share the same chaperone recognition site (aa 87-90) 
they show distinct associations with chaperone remodeling complexes. So far, studies 
focused on the difference between the chaperone recognition sites of canonical H3 variants 
and H3.3. Displacing single residues in the stretch ranging from aa 87 to aa 90 was sufficient 
to lose DAXX binding partially (247). Especially G90 seems to play a crucial role in DAXX 
binding. Yet, in H3.Y aa 87-90 are identical to H3.3 raising the question which residues in 
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H3.Y prevent DAXX binding. Overall, H3.Y and H3.3 differ in 26 aa. Thus, H3.Y represents an 
endogenous H3.3 mutant  allowing the analysis of DAXX interaction prerequisites. 
Noticeably, all our established mutants show stable chromatin association, arguing that 
H3.3-H3.Y hybrids form stable nucleosomes than can be incorporated into chromatin 
(Figures 17, 18, 21, 24, 28, 32). 
Although H3.3E59 participates in a hydrogen network that is crucial for DAXX interaction, I 
could show that this residue alone is not sufficient for DAXX interaction (Figure 19). Likewise, 
the replacement of the whole aa stretch from aa 77-80 and the exchange of H3.YQ102 with 
the respective glutamine in the H3.Y Q59E mutant background (H3.Y core, see Figure 20) did 
not result in H3.Y-DAXX interaction (Figure 22). The structure of the HBD of DAXX revealed 
also the importance of the αN helix for the interaction: a reported H . ΔN uta t, that 
lacks aa 1-60 abrogated DAXX binding (247). In contrast, an H3.3 mutant with a deletion 
from aa 1-43 still immunoprecipitated DAXX, arguing that aa 44-60 are critical but the H3.3 
N-terminus is dispensable for DAXX interaction (247). Accordingly, the swap mutants with 
either exchanged N- or C-termini (see Figure 23) supported this observation. Solely NY-3, a 
mutant of H3.3 that carries the H3.Y N-terminus is able to interact with DAXX (Figure 25). 
Once more the results revealed that the H3.3 tail is dispensable for DAXX binding. Moreover, 
our data are in agreement with a hydrogen/deuterium exchange mass spectrometry (H/DX-
MS) study that highlighted the importance of C-terminal residues for a stable H3.3-DAXX 
complex formation (271). H3.3D105, R116, R122 and R128 are contacting DAXX residues and 
might be crucial for DAXX binding (Figure 38).  
 
 
Figure 38: H3.3 C-terminal residues might be necessary for DAXX interaction. The HBD domain of 
DAXX is depicted together with an H3.3-H4 dimer. H3.3 D105, R116, K122 and R128 are directly 
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binding DAXX. H3.3 is shown in blue, crucial residues that are directly contacting DAXX in gray, H4 in 
beige and DAXX in magenta. Adapted and reprinted with permission from Oxford Journals (271). 
 
DeNizio et al. observed a coupled binding-folding mechanism of DAXX and its substrate 
H3.3-H4 (271). Initially, both DAXX and H3.3-H4 are in an unfolded state. After DAXX builds 
first contacts to the H3.3 chaperone recognition site, it scans the remaining part of H3.3 and 
a stable heterotrimeric complex forms. Since this new study illustrated the importance of 
the C-terminus and I could show that the H3.3 N-terminus is not necessary for DAXX binding 
I focused on H3.Y s C-terminal residues to establish new H3.Y mutants in the background of 
H3.Y core. One exchanged residue, H3.3R53, is in close proximity to H3.3K56, a residue 
shown to be posttranslationally modified (96, 109, 315). In S. cerevisiae H3K56 acetylation is 
important for the increased affinity of the H3 chaperone Rtt106 for H3 (316). Since DAXX has 
a Rtt106-like domain (267, 348) I speculated whether this modification might also be 
important for DAXX affinity. However, meanwhile it became clear that H3K56ac is only 
present on 1% of newly synthesized H3 and therefore not a predeposition mark in humans 
(349). Additionally, as mentioned earlier, H3.3K122 was demonstrated to directly contact 
DAXX and might therefore be necessary for DAXX recognition. The closeness of M124 to 
K122 prompted me to also exchange this residue. Interestingly, H3.YM124 was identified as 
the aa that contributes to H3.Y s stable association in the nucleosome (350). Replacing M124 
by isoleucine reduced the stability of the nucleosome. However, I could not detect any 
differences in nucleosome incorporation (Figure 28). Finally, as a supposed positive control, 
H3.Y K53R core C3 was established. This H3.Y mutant highly resembled NY-3, the swap 
mutant that was able to immunoprecipitate DAXX, with only 3 differences at position 42, 46 
and 62 (Figure 27). Surprisingly, none of these mutants including the putative positive 
control H3.Y K53R core C3 was able to interact with DAXX (Figure 29). Although the 
substitutions at position 42, 46 and 62 from lysine to arginine or from leucine to valine or 
isoleucine, respectively, are conserved and happen within one group of amino acids 
(charged aa in the case of lysine and arginine and hydrophobic aa in the case of leucine, 
isoleucine, and valine) they are sufficient to prevent DAXX binding to H3.Y. Figure 39 
illustrates the location of H3.3R42, V46 and I62 in the DAXX-H3.3-H4 crystal structure. 
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Figure 39: HBD of DAXX together with an H3.3-H4 dimer illustrating the position of R42, V46 and I62 
in H3.3. DAXX HBD is depicted in purple, H4 in green and H3.3 in blue. Highlighted in gray are the 
remaining H3.3 residues that distinguish NY-3 and H3.Y R53K core C3. Crystal structure downloaded 
and adapted from UCSF Chimera (PDB no. 4H9N). 
 
Two scenarios seem possible. First, one or a combination of the residues 42, 46 and 62 in 
H3.3 are necessary for H3.3 recognition by DAXX, meaning H3.Y R53K core C3 is not 
recognized as a substrate. DeNizio et al. suggested a model whereby unfolded DAXX and 
H3.3-H4 couple their own folding to the mutual binding (271). This binding happens in a 
stepwise manner with initial contacts being formed at the chaperone recognition site 
followed by DAXX sampling the remaining H3.3 residues. Thus, if the remaining H3.Y 
residues are not recognized by DAXX during the scanning  of H3.Y R53K core C3, this 
mutant is not able to bind DAXX. In a second scenario, the H3.Y residues could prevent a 
stable complex formation of DAXX-H3.Y R53K core C3-H4. It was shown that also the non-
optimal DAXX substrate H3.2-H4 can bind DAXX, however, the complex does not achieve a 
stable conformation (247, 271). It might be possible that H3.YK42, L46 and/or L62 as well 
prevent the formation of a stable complex thereby hindering DAXX immunoprecipitation. To 
investigate whether the exchange of a single aa or the combination of all three of the 
remaining ones allows DAXX binding I further mutated the remaining residues that 
distinguish H3.Y R53K core C3 from NY-3 singly or in combinations (Figure 31). Noticeably, 
H3.YL46 seems to prevent DAXX recognition and/or binding. Replacing L46 in H3.Y R53K core 
C3 is sufficient to gain back DAXX binding, albeit not to H3.3 levels (Figure 33). Lysine 42 and 
leucine 62 have only mild effects on DAXX interaction, even though H3.Y L46V R53K L62I 
core C3 reveals DAXX binding comparable to H3.3 levels. In summary, H3.Y L46V appears to 
have the biggest impact on the interaction of H3.Y and DAXX, and a combination of H3.3 C-
terminal and core residues seems to be necessary for H3.Y-DAXX interaction. 
 DISCUSSION 
 98 
Interestingly, PML-NB localization revealed other prerequisites in H3.Y sequence. Although 
PML-NB localization is dependent on DAXX interaction also the mutants 3-CY, H3.Y R53K 
core R122K M124I and H3.Y R53K core C3 that did not immunoprecipitate DAXX were 
detected in PML-NBs (Figure 36). It might be possible that the localization of these mutant 
proteins to PML-NBs happens DAXX independent or that only a transient interaction 
between DAXX and the respective mutants occurs and is sufficient to determine their 
localization to these nuclear structures. This transient binding, however, would not be 
sufficient to immunoprecipitate DAXX explaining its absence in immunoblots.  
Noticeably, it seems unlikely that DAXX is not responsible for PML-NB localization since 3-CY 
is mildly enriched at H3.Y-reduced sites in chromatin (Figure 35). This enrichment is most 
likely DAXX dependent and the transient interaction can account for the presence of 3-CY at 
some but not all H3.Y-reduced sites. Considering DeNizio et al. s model (271) it seems likely 
that 3-CY can indeed transiently bind DAXX (such as H3.2-DAXX), however a stable complex 
is not formed. This transient binding is demonstrated by the localization at some DAXX-
dependent genomic sites and at PML-NBs. In contrast, both NY-3, as well as H3.Y L46V R53K 
L62I core C3, can be found at the same genomic sites like H3.3 including H3.Y-reduced sites, 
arguing again that these mutants are able to interact with DAXX. 
 
 
In the future it would be interesting to analyze the identified residues responsible for DAXX 
interaction also in H3.3. So far all studies focused on the importance of the chaperone 
recognition site, but clearly this aa stretch is not sufficient to determine DAXX binding. Thus, 
which residues would inhibit DAXX-H3.3-H4 complex formation? Are even single residues 
sufficient to prevent H3.3-DAXX interaction? Can, therefore, a hierarchy of importance of 
H3.3 aa for DAXX recognition/binding be established? Although it seems like single aa 
substitutions of H3.Y can not establish DAXX interaction, it could well be that the binding to 
H3.3 is disrupted more easily. Knowing the responsible residues in H3.3, it could be used to 
mutate these aa in the endogenous background via CRISPR. This way an endogenous H3.3 
mutant is generated that is able to interact with the HIRA complex but not DAXX/ATRX. 
Although the H3.3 knockout mouse indicated its importance in heterochromatin formation 
and genome stability, the effect of H3.3 loss on transcription is not clear. So far only general 
H3.3 depletions could be analyzed, however, by uncoupling HIRA-mediated deposition from 
DAXX-mediated deposition the implications on different sites and functions in the genome 
can be studied. Since DAXX has additional functions apart from H3.3 deposition, effects of its 
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depletion can not only be ascribed to the loss of DAXX in H3.3 deposition. Additionally, loss 
of DAXX mediated deposition can be studied in various cell types. Whereas in mESCs DAXX is 
responsible for the deposition at various heterochromatic sites like telomeres, periCEN or 
endogenous retroviral elements, in humans we only detected DAXX-dependent H3.3 
deposition into simple repeat sites. It would be interesting to see whether loss of H3.3 in 
human simple repeat sites also affects genome stability. Thus by analyzing H3.3 s roles in 
heterochromatin of human cells like HeLa Kyoto or in mouse cells like mESCs we could gain 
further insights into H3.3 function in distinct cell types or organisms. Moreover, by further 
differentiating mESCs one could investigate the role of H3.3 in DAXX-dependent sites in 
development. 
Apart from shared H3.3/H3.Y sites H3.Y also localizes to some few H3.3-independent sites 
where only H3.Y can be detected. It is tempting to speculate that new chaperone complexes 
mediate this deposition, independent from H3.3. Although we did not detect any known 
chaperone complexes in our SILAC approach, it could be possible that proteins with other 
known functions take over this task. It could as well be that additional factors associate with 
the HIRA complex and thus mediate the deposition of H3.Y. Recently, RPA has been 
identified to be involved in HIRA-mediated H3.3 deposition to regulatory genomic sites. This 
protein has initially been implicated in DNA replication and repair and is known to bind 
ssDNA. Hence it does not seem unlikely that H3.Y binders will be identified as new members 
of chaperone complexes that regulate the deposition of H3.Y.  
I now gained some insights about H3.Y s function. However, the usage of HK cells as a model 
system has its limitations since these cells do not express endogenous H3.Y. Thus it would be 
interesting to also investigate endogenous H3.Y protein in other cell types. Recently, all 
attempts to identify in detail those cell types in the human brain that express H3.Y failed. In 
the meanwhile, new techniques developed that might be able to help to identify H3.Y 
expressing cell types or brain regions in human brain sections. Imaging MS (IMS) allows the 
identification of proteins by MS while sustaining the spatial information that a tissue section 
provides (351, 352). Potential crossreactions of the antibody are inapplicable. Moreover, the 
trigger causing enhanced H3.Y abundance after stress stimuli in U2OS cells is not known. 
Stressing U2OS cells and performing IMS might also enable the characterization of other 
proteins that increase their expression after stress and thus could be implicated in triggering 
H3.Y expression.  
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Furthermore, it would be interesting to investigate the H3.Y expression pattern in cancer 
patients. Unlike H3.3, no mutation in H3.Y is known that is associated with cancer. However, 
several cancer tissues displayed H3.Y expression in contrast to their healthy counterparts as 
analyzed by quantitative PCR (218). It is tempting to speculate that cancer patients reveal 
altered H3.Y levels in their cancer tissues that might cause alterations in the transcriptome 
and thus be implicated in cancer progression.   
 
In conclusion I could show that H3.Y interacts with the H3.3-specific chaperone HIRA and is 
deposited to euchromatic H3K4me3-positive, H3K9me3-depleted genomic regions. It can 
however not interact with the second H3.3-specific chaperone DAXX, explaining its absence 
from heterochromatic H3K9me3-enriched simple repeat sites. Accordingly, 
immunoprecipitations of mononucleosomes followed by MS revealed the association of 
mainly euchromatic factors on H3.Y and concurrently the depletion of heterochromatic 
factors like SUV39H. Furthermore, I could demonstrate that a combination of H3.Y 
C-terminal and core residues prevents stable H3.Y-DAXX complex formation. In contrast, a 
transient interaction between H3.Y mutants and DAXX is sufficient to allow localization to 
PML-NBs and some DAXX-dependent H3K9me3-positive simple repeat sites.  
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ABBREVIATIONS 
5caC     5-carboxylcytosine 
5fC      5-formylcytosine  
5hmC     5-hydroxymethylcytosine (5hmC 
5mC     5-methylcytosine 
AA      Amino acid 
ADP     Adenosine diphosphate 
ALT      Alternative lengthening of telomeres  
ASF1     Anti-silencing function 1  
ATP     Adenosine triphosphate 
ATRX      α-thalassaemia/mental retardation X-linked  
BPTF      Bromodomain PHD finger transcription factor  
BSA     Bovine serum albumin 
CABIN1     Calcineurin binding protein 1  
CAF-1     Chromatin assembly factor 1  
CBX      Chromobox protein homolog  
CHD     Chromodomain helicase DNA-binding protein 
ChIP     Chromatin immunoprecipitation 
CHRAC1     Chromatin accessibility complex 1  
CPI     Complete protease inhibitor 
CTCF      CCCTC-binding factor Culture 
DAPI     4',6-Diamidino-2-phenylindole 
DAXX     Death domain-associated protein  
DMEM     Dulbecco s modified eagle medium 
DMSO     Dimethylsulfoxide 
DSB     Double strand break 
DTT     Dithiothreitol 
EZH2     Enhancer of Zeste 2 
FACT      Facilitates chromatin transcription 
FCS     Fetal calf serum 
FSC      Forward scatter 
G2     Gap 2  
GEO      Gene expression omnibus 
GFP     Green fluorescent protein 
H/DX-MS     Hydrogen/deuterium exchange mass spectrometry 
H2A.Bbd    H2A Barr body deficient  
HAT     Histone acetyltransferase   
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HBD      Histone-binding domain  
HDAC     Histone deacteylase  
HEPES     2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
HFD     Histone fold domain 
HIRA      Histone regulatory homologue A 
HP1      Heterochromatin binding protein 1 
IF     Immunofluorescence 
IPTG     Isopropyl-β-D-thiogalactopyranoside  
KAT     Lysine acetyltransferase 
lncRNAs     Long noncoding RNAs  
MCM     Minichromosome maintenance 
MEFs      Mouse embryonic fibroblasts  
mESC     Mouse embryonic stem cell 
MLL3     Mixed-lineage leukemia 3  
MNase     Micrococcal nuclease 
MS      Mass spectrometry  
NAD      Nicotinamide adenine dinucleotide  
NAP1      Nucleosome assembly protein 1 
NASP      Nuclear autoantigenic sperm protein  
NB     Nuclear body 
Nb      Nonbound 
NCP     Nucleosome core particle 
Neo     Neomycin 
NSCs      Neural stem cell 
nt      Nucleotide 
panNET     Pancreatic neuroendocrine tumor 
PARP1     Poly (ADP-ribose) polymerase 1 
PBS     Phosphate buffered saline 
PCGF      Polycomb group finger  
PCNA      Proliferating cell nuclear antigen 
PCR     Polymerase chain reaction 
PHC     Polyhomeotic-like protein 
PHD     Plant homeodomain finger 
PML      Promyelocytic leukemia 
PRC     Polycomb Repressive Complex protein  
PTM     Posttranslational modification 
RbAp46     Retinoblastoma-associated protein 46 
RbAp48     Retinoblastoma- associated protein 48 
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RPA      Replication protein A  
RSF1     Remodeling and spacing factor 1  
RT     Room temperature 
SDS     Sodium dodecyl sulfate 
SETD1A      SET domain containing 1A 
SILAC      Stable isotope labeling of amino acids in cell culture 
Spt16      Suppressor of Ty16 
SSC      Sideward scatter 
SSRP1      Structure specific recognition protein 1 
SUMO      Small ubiquitin like modifier 
SUV39H     Suppressor of variegation 3-9 
TBE     Tris borate EDTA  
TE     Tris EDTA 
TERRA     Telomere repeat-containing RNA 
TF     Transcription factor 
TFA     Trifluoracetic acid 
TIFs      Telomere dysfunctional induced foci  
TRRAP      Transformation/transcription associated  
TSA     Trichostatin A 
TSS     Transcriptional start sites 
UBN1     Ubinuclein 1  
UTR     Untranslated region 
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Figure A.1: Identification of proteins enriched on eGFP-H3 variant-containing mononucleosomes 
obtained by label-free quantitative mass spectrometry compared to eGFP immunoprecipitations. 
Monoucleosomes of eGFP and eGFP-H3.1 (A), -H3.2 (B), -H3.3 (C) and -H3.Y (D) expressing cell lines 
were generated and subjected to immunoprecipitations with GFP-trap_M beads. Comparing 
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interactors of eGFP and H3 variants served to identify and exclude background binders. Enrichment 
differences were obtained from two-sample t-tests and are displayed by plotting p-values and t-test 
differences in volcano plots. Permutation-based FDR cutoff was utilized to identify significantly 
enriched proteins. These proteins are labeled in the plot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
